A61K6/00	7	Preparations for dentistry<br><br><u>NOTE</u><br><br> In groups A61K6/00 - A61K6/58 and A61K6/887 - A61K6/90, combination sets [C-Sets] are used, e.g. compositions for taking dental impressions containing alginates are classified as (A61K6/90, C08L5/04)	A61K6/00	A61K6/00		273
A61K6/15	8	Compositions characterised by their physical properties	A61K6/15	A61K6/15		387
A61K6/16	9	Refractive index	A61K6/16	A61K6/16		348
A61K6/17	9	Particle size	A61K6/17	A61K6/17		773
A61K6/18	9	causing dental retraction, e.g. compositions for widening the sulcus for making dental impressions or removing teeth	A61K6/18	A61K6/18		70
A61K6/19	9	Self-expanding, e.g. for filling teeth	A61K6/19	A61K6/19		32
A61K6/20	8	Protective coatings for natural or artificial teeth, e.g. sealings, dye coatings or varnish	A61K6/20	A61K6/20		1435
A61K6/25	8	Compositions for detecting or measuring, e.g. of irregularities on natural or artificial teeth	A61K6/25	A61K6/25		87
A61K6/30	8	Compositions for temporarily or permanently fixing teeth or palates, e.g. primers for dental adhesives	A61K6/30	A61K6/30		1634
A61K6/35	9	Preparations for stabilising dentures in the mouth	A61K6/35	A61K6/35		397
A61K6/40	8	Primers (for dental adhesives A61K6/30)	A61K6/40	A61K6/40		228
A61K6/50	8	Preparations specially adapted for dental root treatment	A61K6/50	A61K6/50		137
A61K6/52	9	Cleaning; Disinfecting	A61K6/52	A61K6/52		204
A61K6/54	9	Filling; Sealing	A61K6/54	A61K6/54		685
A61K6/56	9	Apical treatment	A61K6/56	A61K6/56		98
A61K6/58	9	specially adapted for dental implants	A61K6/58	A61K6/58		147
A61K6/60	8	comprising organic or organo-metallic additives	A61K6/60	A61K6/60		414
A61K6/61	9	Cationic, anionic or redox initiators	A61K6/61	A61K6/61		165
A61K6/62	9	Photochemical radical initiators	A61K6/62	A61K6/62		572
A61K6/64	9	Thermal radical initiators	A61K6/64	A61K6/64		48
A61K6/65	9	Dyes	A61K6/65	A61K6/65		152
A61K6/66	10	Photochromic dyes	A61K6/66	A61K6/66		80
A61K6/68	10	Thermochromic dyes	A61K6/68	A61K6/68		10
A61K6/69	9	Medicaments	A61K6/69	A61K6/69		739
A61K6/70	8	comprising inorganic additives	A61K6/70	A61K6/70		222
A61K6/71	9	Fillers	A61K6/71	A61K6/71		571
A61K6/72	10	comprising nitrogen-containing compounds	A61K6/72	A61K6/72		19
A61K6/73	10	comprising sulfur-containing compounds	A61K6/73	A61K6/73		30
A61K6/74	10	comprising phosphorus-containing compounds	A61K6/74	A61K6/74		102
A61K6/75	11	Apatite	A61K6/75	A61K6/75		209
A61K6/76	10	comprising silicon-containing compounds	A61K6/76	A61K6/76		690
A61K6/77	10	Glass	A61K6/77	A61K6/77		553
A61K6/78	9	Pigments	A61K6/78	A61K6/78		560
A61K6/79	9	Initiators	A61K6/79	A61K6/79		57
A61K6/80	8	Preparations for artificial teeth, for filling teeth or for capping teeth	A61K6/80	A61K6/80		433
A61K6/802	9	comprising ceramics	A61K6/802	A61K6/802		518
A61K6/804	10	comprising manganese oxide	A61K6/804	A61K6/804		36
A61K6/807	10	comprising magnesium oxide	A61K6/807	A61K6/807		289
A61K6/809	10	comprising beryllium oxide	A61K6/809	A61K6/809		5
A61K6/811	10	comprising chromium oxide	A61K6/811	A61K6/811		25
A61K6/813	10	comprising iron oxide	A61K6/813	A61K6/813		92
A61K6/816	10	comprising titanium oxide	A61K6/816	A61K6/816		304
A61K6/818	10	comprising zirconium oxide	A61K6/818	A61K6/818		939
A61K6/82	10	comprising hafnium oxide	A61K6/82	A61K6/82		47
A61K6/822	10	comprising rare earth metal oxides	A61K6/822	A61K6/822		396
A61K6/824	10	comprising transition metal oxides	A61K6/824	A61K6/824		253
A61K6/827	10	Leucite	A61K6/827	A61K6/827		85
A61K6/829	9	comprising cermet composites	A61K6/829	A61K6/829		23
A61K6/831	9	comprising non-metallic elements or compounds thereof, e.g. carbon	A61K6/831	A61K6/831		388
A61K6/833	10	Glass-ceramic composites	A61K6/833	A61K6/833		355
A61K6/836	10	Glass	A61K6/836	A61K6/836		394
A61K6/838	10	Phosphorus compounds, e.g. apatite	A61K6/838	A61K6/838		659
A61K6/84	9	comprising metals or alloys	A61K6/84	A61K6/84		634
A61K6/842	10	Rare earth metals	A61K6/842	A61K6/842		109
A61K6/844	10	Noble metals	A61K6/844	A61K6/844		600
A61K6/847	10	Amalgams	A61K6/847	A61K6/847		156
A61K6/849	9	comprising inorganic cements	A61K6/849	A61K6/849		220
A61K6/851	10	Portland cements	A61K6/851	A61K6/851		70
A61K6/853	10	Silicates	A61K6/853	A61K6/853		245
A61K6/856	10	Pozzolans	A61K6/856	A61K6/856		11
A61K6/858	10	Calcium sulfates, e.g, gypsum	A61K6/858	A61K6/858		144
A61K6/86	10	Al-cements	A61K6/86	A61K6/86		62
A61K6/862	10	Ca-Al-sulfate-cements	A61K6/862	A61K6/862		9
A61K6/864	10	Phosphate cements (apatite A61K6/838)	A61K6/864	A61K6/864		262
A61K6/867	10	Ammonium cements	A61K6/867	A61K6/867		8
A61K6/869	10	Zeolites	A61K6/869	A61K6/869		12
A61K6/871	10	Quartz; SiO2	A61K6/871	A61K6/871		67
A61K6/873	10	Carbonates	A61K6/873	A61K6/873		60
A61K6/876	10	Calcium oxide	A61K6/876	A61K6/876		162
A61K6/878	10	Zirconium oxide	A61K6/878	A61K6/878		58
A61K6/88	10	Chromium oxide	A61K6/88	A61K6/88		4
A61K6/882	10	Carbides	A61K6/882	A61K6/882		6
A61K6/884	9	comprising natural or synthetic resins	A61K6/884	A61K6/884		436
A61K6/887	10	Compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds	A61K6/887	A61K6/887		3193
A61K6/889	11	Polycarboxylate cements; Glass ionomer cements	A61K6/889	A61K6/889		602
A61K6/891	10	Compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds	A61K6/891	A61K6/891		784
A61K6/893	11	Polyurethanes	A61K6/893	A61K6/893		335
A61K6/896	11	Polyorganosilicon compounds	A61K6/896	A61K6/896		202
A61K6/898	10	Polysaccharides	A61K6/898	A61K6/898		289
A61K6/90	8	Compositions for taking dental impressions	A61K6/90	A61K6/90		830
A61K8/00	7	Cosmetics or similar toiletry preparations<br><br><u>NOTE</u><br><br> Use of cosmetics or similar toiletry preparations is further classified in subclass A61Q. <br>Use of cosmetics or similar toiletry preparations is mandatorily further classified in subclass A61Q.<br>Attention is drawn to the Notes in class C07, for example the notes following the title of subclass C07D, setting forth the rules for classifying organic compounds in that class, which rules are also applicable, if not otherwise indicated, to the classification of organic compounds in group A61K8/00.<br>Salts or complexes of organic compounds are classified according to the base compounds. If a complex is formed between two or more compounds, classification is made for each compound.	A61K8/00	A61K8/00		492
A61K8/02	8	characterised by special physical form<br><br><u>NOTE</u><br><br>In this group, the last place priority rule is applied, i.e. at each hierarchical level, in the absence of an indication to the contrary, classification is made in the last appropriate place.	A61K8/02	A61K8/02		4459
A61K8/0204	9	{Specific forms not provided for by any of groups A61K8/0208&#160;-&#160;A61K8/14}	A61K8/02	A61K8/02		890
A61K8/0208	9	{Tissues; Wipes; Patches}	A61K8/02	A61K8/02		5474
A61K8/0212	9	{Face masks}	A61K8/02	A61K8/02		5465
A61K8/0216	9	{Solid or semisolid forms}	A61K8/02	A61K8/02		2136
A61K8/022	10	{Powders; Compacted Powders}	A61K8/02	A61K8/02		2393
A61K8/0225	11	{Granulated powders}	A61K8/02	A61K8/02		430
A61K8/0229	10	{Sticks}	A61K8/02	A61K8/02		1302
A61K8/0233	10	{Distinct layers, e.g. core/shell sticks}	A61K8/02	A61K8/02		254
A61K8/0237	11	{Striped compositions}	A61K8/02	A61K8/02		197
A61K8/0241	9	{Containing particulates characterized by their shape and/or structure (see also A61K8/04, A61K8/11, and A61K8/14, further aspects are classified in A61K2800/40 and subcodes)}	A61K8/02	A61K8/02		2719
A61K8/0245	10	{Specific shapes or structures not provided for by any of the groups of A61K8/0241}	A61K8/02	A61K8/02		837
A61K8/025	10	{Explicitly spheroidal or spherical shape}	A61K8/02	A61K8/02		995
A61K8/0254	10	{Platelets; Flakes}	A61K8/02	A61K8/02		541
A61K8/0258	11	{Layered structure}	A61K8/02	A61K8/02		169
A61K8/0262	12	{Characterized by the central layer}	A61K8/02	A61K8/02		53
A61K8/0266	12	{Characterized by the sequence of layers}	A61K8/02	A61K8/02		129
A61K8/027	10	{Fibers; Fibrils}	A61K8/02	A61K8/02		666
A61K8/0275	10	{Containing agglomerated particulates}	A61K8/02	A61K8/02		209
A61K8/0279	10	{Porous; Hollow}	A61K8/02	A61K8/02		932
A61K8/0283	10	{Matrix particles}	A61K8/02	A61K8/02		316
A61K8/0287	11	{the particulate containing a solid-in-solid dispersion}	A61K8/02	A61K8/02		73
A61K8/0291	9	{Micelles}	A61K8/02	A61K8/02		307
A61K8/0295	9	{Liquid crystals}	A61K8/02	A61K8/02		870
A61K8/03	9	Liquid compositions with two or more distinct layers	A61K8/03	A61K8/03		826
A61K8/04	9	Dispersions; Emulsions	A61K8/04	A61K8/04		1361
A61K8/042	10	{Gels}	A61K8/04	A61K8/04		5712
A61K8/044	10	{Suspensions}	A61K8/04	A61K8/04		1060
A61K8/046	10	{Aerosols; Foams}	A61K8/04	A61K8/04		4881
A61K8/06	10	Emulsions	A61K8/06	A61K8/06		5830
A61K8/062	11	{Oil-in-water emulsions}	A61K8/06	A61K8/06		4000
A61K8/064	11	{Water-in-oil emulsions, e.g. Water-in-silicone emulsions}	A61K8/06	A61K8/06		2342
A61K8/066	11	{Multiple emulsions, e.g. water-in-oil-in-water}	A61K8/06	A61K8/06		510
A61K8/068	11	{Microemulsions}	A61K8/06	A61K8/06		1372
A61K8/11	9	Encapsulated compositions	A61K8/11	A61K8/11		5014
A61K8/14	9	Liposomes; Vesicles	A61K8/14	A61K8/14		3100
A61K8/18	8	characterised by the composition<br><br><u>NOTE</u><br><br>In this group, the last place priority rule is applied, i.e. at each hierarchical level, in the absence of an indication to the contrary, classification is made in the last appropriate place.	A61K8/18	A61K8/18		364
A61K8/19	9	containing inorganic ingredients	A61K8/19	A61K8/19		16966
A61K8/20	10	Halogens; Compounds thereof	A61K8/20	A61K8/20		4001
A61K8/21	11	Fluorides; Derivatives thereof	A61K8/21	A61K8/21		1919
A61K8/22	10	Peroxides; Oxygen; Ozone	A61K8/22	A61K8/22		3550
A61K8/23	10	Sulfur; Selenium; Tellurium; Compounds thereof	A61K8/23	A61K8/23		3189
A61K8/24	10	Phosphorous; Compounds thereof	A61K8/24	A61K8/24		3948
A61K8/25	10	Silicon; Compounds thereof	A61K8/25	A61K8/25		8638
A61K8/26	10	Aluminium; Compounds thereof	A61K8/26	A61K8/26		6875
A61K8/27	10	Zinc; Compounds thereof	A61K8/27	A61K8/27		5313
A61K8/28	10	Zirconium; Compounds thereof	A61K8/28	A61K8/28		1033
A61K8/29	10	Titanium; Compounds thereof	A61K8/29	A61K8/29		5231
A61K8/30	9	containing organic compounds	A61K8/30	A61K8/30		540
A61K8/31	10	Hydrocarbons	A61K8/31	A61K8/31		9726
A61K8/315	11	{Halogenated hydrocarbons}	A61K8/31	A61K8/31		273
A61K8/33	10	containing oxygen	A61K8/33	A61K8/33		2143
A61K8/34	11	Alcohols	A61K8/34	A61K8/34		12175
A61K8/342	12	{Alcohols having more than seven atoms in an unbroken chain}	A61K8/34	A61K8/34		6681
A61K8/345	12	{containing more than one hydroxy group}	A61K8/34	A61K8/34		22813
A61K8/347	12	{Phenols}	A61K8/34	A61K8/34		6149
A61K8/35	11	Ketones, e.g. benzophenone	A61K8/35	A61K8/35		6882
A61K8/355	12	{Quinones}	A61K8/35	A61K8/35		1563
A61K8/36	11	Carboxylic acids; Salts or anhydrides thereof	A61K8/36	A61K8/36		4069
A61K8/361	12	{Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof}	A61K8/36	A61K8/36		5820
A61K8/362	12	Polycarboxylic acids	A61K8/362	A61K8/362		2267
A61K8/365	12	Hydroxycarboxylic acids; Ketocarboxylic acids	A61K8/365	A61K8/365		8940
A61K8/368	12	with carboxyl groups directly bound to carbon atoms of aromatic rings	A61K8/368	A61K8/368		4065
A61K8/37	11	Esters of carboxylic acids	A61K8/37	A61K8/37		14664
A61K8/375	12	{the alcohol moiety containing more than one hydroxy group}	A61K8/37	A61K8/37		8225
A61K8/38	11	Percompounds, e.g. peracids	A61K8/38	A61K8/38		546
A61K8/39	11	Derivatives containing from 2 to 10 oxyalkylene groups	A61K8/39	A61K8/39		5629
A61K8/40	10	containing nitrogen (quinones containing nitrogen A61K8/355)	A61K8/40	A61K8/40		2075
A61K8/41	11	Amines	A61K8/41	A61K8/41		5058
A61K8/411	12	{Aromatic amines, i.e. where the amino group is directly linked to the aromatic nucleus}	A61K8/41	A61K8/41		1606
A61K8/413	12	{Indoanilines; Indophenol; Indoamines}	A61K8/41	A61K8/41		178
A61K8/415	12	{Aminophenols}	A61K8/41	A61K8/41		1155
A61K8/416	12	{Quaternary ammonium compounds (A61K8/35 takes precedence)}	A61K8/41	A61K8/41		5189
A61K8/418	12	{containing nitro groups}	A61K8/41	A61K8/41		553
A61K8/42	11	Amides	A61K8/42	A61K8/42		9331
A61K8/43	11	Guanidines	A61K8/43	A61K8/43		1407
A61K8/44	11	Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof	A61K8/44	A61K8/44		15862
A61K8/442	12	{substituted by amido group(s)}	A61K8/44	A61K8/44		3810
A61K8/445	12	{aromatic, i.e. the carboxylic acid directly linked to the aromatic ring}	A61K8/44	A61K8/44		589
A61K8/447	12	{containing sulfur}	A61K8/44	A61K8/44		1261
A61K8/45	11	Derivatives containing from 2 to 10 oxyalkylene groups	A61K8/45	A61K8/45		555
A61K8/46	10	containing sulfur (A61K8/44 takes precedence)	A61K8/46	A61K8/46		3191
A61K8/463	11	{containing sulfuric acid derivatives, e.g. sodium lauryl sulfate}	A61K8/46	A61K8/46		4613
A61K8/466	11	{containing sulfonic acid derivatives; Salts}	A61K8/46	A61K8/46		5067
A61K8/49	10	containing heterocyclic compounds	A61K8/49	A61K8/49		4488
A61K8/4906	11	{with one nitrogen as the only hetero atom}	A61K8/49	A61K8/49		439
A61K8/4913	12	{having five membered rings, e.g. pyrrolidone carboxylic acid}	A61K8/49	A61K8/49		2341
A61K8/492	13	{having condensed rings, e.g. indol}	A61K8/49	A61K8/49		1455
A61K8/4926	12	{having six membered rings}	A61K8/49	A61K8/49		4063
A61K8/4933	12	{having sulfur as an exocyclic substituent, e.g. pyridinethione}	A61K8/49	A61K8/49		751
A61K8/494	11	{with more than one nitrogen as the only hetero atom}	A61K8/49	A61K8/49		2000
A61K8/4946	12	{Imidazoles or their condensed derivatives, e.g. benzimidazoles}	A61K8/49	A61K8/49		6464
A61K8/4953	12	{containing pyrimidine ring derivatives, e.g. minoxidil}	A61K8/49	A61K8/49		2889
A61K8/496	12	{Triazoles or their condensed derivatives, e.g. benzotriazoles}	A61K8/49	A61K8/49		570
A61K8/4966	12	{Triazines or their condensed derivatives}	A61K8/49	A61K8/49		1502
A61K8/4973	11	{with oxygen as the only hetero atom}	A61K8/49	A61K8/49		3757
A61K8/498	12	{having 6-membered rings or their condensed derivatives, e.g. coumarin}	A61K8/49	A61K8/49		7640
A61K8/4986	11	{with sulfur as the only hetero atom}	A61K8/49	A61K8/49		693
A61K8/4993	11	{Derivatives containing from 2 to 10 oxyalkylene groups}	A61K8/49	A61K8/49		1563
A61K8/55	10	Phosphorus compounds	A61K8/55	A61K8/55		2829
A61K8/553	11	{Phospholipids, e.g. lecithin}	A61K8/55	A61K8/55		4471
A61K8/556	11	{Derivatives containing from 2 to 10 oxyalkylene groups}	A61K8/55	A61K8/55		311
A61K8/58	10	containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus	A61K8/58	A61K8/58		1069
A61K8/585	11	{Organosilicon compounds}	A61K8/58	A61K8/58		5034
A61K8/60	10	Sugars; Derivatives thereof	A61K8/60	A61K8/60		8520
A61K8/602	11	{Glycosides, e.g. rutin}	A61K8/60	A61K8/60		7622
A61K8/604	11	{Alkylpolyglycosides; Derivatives thereof, e.g. esters}	A61K8/60	A61K8/60		2230
A61K8/606	11	{Nucleosides; Nucleotides; Nucleic acids}	A61K8/60	A61K8/60		1660
A61K8/608	11	{Derivatives containing from 2 to 10 oxyalkylene groups}	A61K8/60	A61K8/60		183
A61K8/63	10	Steroids; Derivatives thereof<br><br><u>NOTE</u><br><br> This group covers steroids, as defined in Note (1) after the title of subclass C07J. 	A61K8/63	A61K8/63		7050
A61K8/64	10	Proteins; Peptides; Derivatives or degradation products thereof	A61K8/64	A61K8/64		17075
A61K8/645	11	{Proteins of vegetable origin; Derivatives or degradation products thereof}	A61K8/64	A61K8/64		3180
A61K8/65	11	Collagen; Gelatin; Keratin; Derivatives or degradation products thereof	A61K8/65	A61K8/65		7094
A61K8/66	11	Enzymes	A61K8/66	A61K8/66		4276
A61K8/67	10	Vitamins	A61K8/67	A61K8/67		2369
A61K8/671	11	{Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal}	A61K8/67	A61K8/67		2927
A61K8/673	11	{Vitamin B group}	A61K8/67	A61K8/67		2433
A61K8/675	12	{Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde (tocopheryl nicotinate A61K8/678)}	A61K8/67	A61K8/67		3882
A61K8/676	11	{Ascorbic acid, i.e. vitamin C}	A61K8/67	A61K8/67		6279
A61K8/678	11	{Tocopherol, i.e. vitamin E}	A61K8/67	A61K8/67		7853
A61K8/68	10	Sphingolipids, e.g. ceramides, cerebrosides, gangliosides	A61K8/68	A61K8/68		3252
A61K8/69	10	containing fluorine	A61K8/69	A61K8/69		597
A61K8/70	11	containing perfluoro groups, e.g. perfluoroethers	A61K8/70	A61K8/70		471
A61K8/72	9	containing organic macromolecular compounds	A61K8/72	A61K8/72		1095
A61K8/73	10	Polysaccharides	A61K8/73	A61K8/73		14223
A61K8/731	11	{Cellulose; Quaternized cellulose derivatives}	A61K8/73	A61K8/73		9048
A61K8/732	11	{Starch; Amylose; Amylopectin; Derivatives thereof}	A61K8/73	A61K8/73		3980
A61K8/733	11	{Alginic acid; Salts thereof}	A61K8/73	A61K8/73		2395
A61K8/735	11	{Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof}	A61K8/73	A61K8/73		11879
A61K8/736	11	{Chitin; Chitosan; Derivatives thereof}	A61K8/73	A61K8/73		3489
A61K8/737	11	{Galactomannans, e.g. guar; Derivatives thereof}	A61K8/73	A61K8/73		2360
A61K8/738	11	{Cyclodextrins}	A61K8/73	A61K8/73		1433
A61K8/81	10	obtained by reactions involving only carbon-to-carbon unsaturated bonds	A61K8/81	A61K8/81		1227
A61K8/8105	11	{Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers}	A61K8/81	A61K8/81		74
A61K8/8111	12	{Homopolymers or copolymers of aliphatic olefines, e.g. polyethylene, polyisobutene; Compositions of derivatives of such polymers}	A61K8/81	A61K8/81		2197
A61K8/8117	12	{Homopolymers or copolymers of aromatic olefines, e.g. polystyrene; Compositions of derivatives of such polymers}	A61K8/81	A61K8/81		811
A61K8/8123	11	{Compositions of homopolymers or copolymers of compounds having one carbon-to-carbon double bond, and at least one being terminated by a halogen; Compositions of derivatives of such polymers, e.g. PVC, PTFE}	A61K8/81	A61K8/81		254
A61K8/8129	11	{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers or esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers, e.g. polyvinylmethylether}	A61K8/81	A61K8/81		1392
A61K8/8135	11	{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an acyloxy radical of a saturated carboxylic acid, of carbonic acid or of a haloformic acid; Compositions of derivatives of such polymers, e.g. vinyl esters (polyvinylacetate)}	A61K8/81	A61K8/81		492
A61K8/8141	11	{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers}	A61K8/81	A61K8/81		314
A61K8/8147	12	{Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers}	A61K8/81	A61K8/81		5226
A61K8/8152	12	{Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers}	A61K8/81	A61K8/81		6842
A61K8/8158	12	{Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers}	A61K8/81	A61K8/81		2955
A61K8/8164	11	{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical, and containing at least one other carboxyl radical in the molecule, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers, e.g. poly (methyl vinyl ether-co-maleic anhydride)}	A61K8/81	A61K8/81		1021
A61K8/817	11	{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)}	A61K8/81	A61K8/81		1966
A61K8/8176	12	{Homopolymers of N-vinyl-pyrrolidones. Compositions of derivatives of such polymers}	A61K8/81	A61K8/81		1611
A61K8/8182	12	{Copolymers of vinyl-pyrrolidones. Compositions of derivatives of such polymers}	A61K8/81	A61K8/81		2097
A61K8/8188	11	{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bonds, and at least one being terminated by a bond to sulfur or by a hertocyclic ring containing sulfur; Compositions of derivatives of such polymers}	A61K8/81	A61K8/81		259
A61K8/8194	11	{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, at least one having two or more carbon-to-carbon double bonds; Compositions of derivatives of such polymers}	A61K8/81	A61K8/81		193
A61K8/84	10	obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds	A61K8/84	A61K8/84		1992
A61K8/85	11	Polyesters	A61K8/85	A61K8/85		2098
A61K8/86	11	Polyethers	A61K8/86	A61K8/86		10084
A61K8/87	11	Polyurethanes	A61K8/87	A61K8/87		2168
A61K8/88	11	Polyamides	A61K8/88	A61K8/88		2720
A61K8/89	11	Polysiloxanes	A61K8/89	A61K8/89		1739
A61K8/891	12	saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone	A61K8/891	A61K8/891		8419
A61K8/892	13	modified by a hydroxy group, e.g. dimethiconol	A61K8/892	A61K8/892		1004
A61K8/893	13	modified by an alkoxy or aryloxy group, e.g. behenoxy dimethicone or stearoxy dimethicone	A61K8/893	A61K8/893		784
A61K8/894	13	modified by a polyoxyalkylene group, e.g. cetyl dimethicone copolyol	A61K8/894	A61K8/894		2425
A61K8/895	12	containing silicon bound to unsaturated aliphatic groups, e.g. vinyl dimethicone	A61K8/895	A61K8/895		1655
A61K8/896	12	containing atoms other than silicon, carbon, oxygen and hydrogen, e.g. dimethicone copolyol phosphate	A61K8/896	A61K8/896		135
A61K8/897	13	containing halogen, e.g. fluorosilicones	A61K8/897	A61K8/897		194
A61K8/898	13	containing nitrogen, e.g. amodimethicone, trimethyl silyl amodimethicone or dimethicone propyl PG-betaine	A61K8/898	A61K8/898		2628
A61K8/899	13	containing sulfur, e.g. sodium PG-propyldimethicone thiosulfate copolyol	A61K8/899	A61K8/899		244
A61K8/90	10	Block copolymers (A61K8/89 takes precedence)	A61K8/90	A61K8/90		1695
A61K8/91	10	Graft copolymers (A61K8/89 takes precedence)	A61K8/91	A61K8/91		510
A61K8/92	9	Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof	A61K8/92	A61K8/92		4487
A61K8/922	10	{of vegetable origin}	A61K8/92	A61K8/92		26818
A61K8/925	10	{of animal origin}	A61K8/92	A61K8/92		2953
A61K8/927	10	{of insects, e.g. shellac}	A61K8/92	A61K8/92		2155
A61K8/96	9	containing materials, or derivatives thereof of undetermined constitution	A61K8/96	A61K8/96		273
A61K8/965	10	{of inanimate origin}	A61K8/96	A61K8/96		2165
A61K8/97	10	from algae, fungi, lichens or plants; from derivatives thereof	A61K8/97	A61K8/97		18069
A61K8/9706	11	Algae	A61K8/9706	A61K8/9706		1339
A61K8/9711	12	Phaeophycota or Phaeophyta [brown algae], e.g. Fucus	A61K8/9711	A61K8/9711		1863
A61K8/9717	12	Rhodophycota or Rhodophyta [red algae], e.g. Porphyra	A61K8/9717	A61K8/9717		1151
A61K8/9722	12	Chlorophycota or Chlorophyta [green algae], e.g. Chlorella	A61K8/9722	A61K8/9722		965
A61K8/9728	11	Fungi, e.g. yeasts	A61K8/9728	A61K8/9728		6671
A61K8/9733	11	Lichens	A61K8/9733	A61K8/9733		180
A61K8/9739	11	Bryophyta [mosses]	A61K8/9739	A61K8/9739		75
A61K8/9741	11	Pteridophyta [ferns]	A61K8/9741	A61K8/9741		438
A61K8/9749	12	Filicopsida or Pteridopsida	A61K8/9749	A61K8/9749		195
A61K8/9755	11	Gymnosperms [Coniferophyta]	A61K8/9755	A61K8/9755		181
A61K8/9761	12	Cupressaceae [Cypress family], e.g. juniper or cypress	A61K8/9761	A61K8/9761		1829
A61K8/9767	12	Pinaceae [Pine family], e.g. pine or cedar	A61K8/9767	A61K8/9767		1423
A61K8/9771	11	Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]	A61K8/9771	A61K8/9771		1030
A61K8/9778	11	Gnetophyta, e.g. Ephedraceae [Mormon-tea family]	A61K8/9778	A61K8/9778		53
A61K8/9783	11	Angiosperms [Magnoliophyta]	A61K8/9783	A61K8/9783		1139
A61K8/9789	12	Magnoliopsida [dicotyledons]	A61K8/9789	A61K8/9789		45123
A61K8/9794	12	Liliopsida [monocotyledons]	A61K8/9794	A61K8/9794		17118
A61K8/98	10	of animal origin	A61K8/98	A61K8/98		580
A61K8/981	11	{of mammals or bird}	A61K8/98	A61K8/98		1714
A61K8/982	12	{Reproductive organs; Embryos, Eggs}	A61K8/98	A61K8/98		1536
A61K8/983	12	{Blood, e.g. plasma}	A61K8/98	A61K8/98		284
A61K8/985	12	{Skin or skin outgrowth, e.g. hair, nails}	A61K8/98	A61K8/98		592
A61K8/986	12	{Milk; Derivatives thereof, e.g. butter}	A61K8/98	A61K8/98		1530
A61K8/987	11	{of species other than mammals or birds}	A61K8/98	A61K8/98		6307
A61K8/988	12	{Honey; Royal jelly, Propolis}	A61K8/98	A61K8/98		4338
A61K8/99	10	from microorganisms other than algae or fungi, e.g. protozoa or bacteria	A61K8/99	A61K8/99		7364
A61K9/00	7	Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations&#160;A61K49/18; preparations containing radioactive substances&#160;A61K51/12)}<br><br><u>NOTE</u><br><br> Among the one-dot groups of A61K9/00, classification is not made in the last appropriate place. <br>A61K9/00  is subdivided according to the following concepts: <br>the drug release technique ( A61K9/0002 and subgroups), <br>the site of application ( A61K9/0012 and subgroups), and <br>the physical form ( A61K9/0087&#160;-&#160;A61K9/7023 ).   Where relevant, documents are classified in more than one of these subdivisions.	A61K9/00	A61K9/00		2732
A61K9/0002	8	{Galenical forms characterised by the drug release technique; Application systems commanded by energy}	A61K9/00	A61K9/00		1428
A61K9/0004	9	{Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas}	A61K9/00	A61K9/00		3187
A61K9/0007	9	{Effervescent (A61K9/0065 takes precedence)}	A61K9/46	A61K9/00		1868
A61K9/0009	9	{involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis}	A61K9/00	A61K9/00		2617
A61K9/0012	8	{Galenical forms characterised by the site of application}	A61K9/00	A61K9/00		164
A61K9/0014	9	{Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}	A61K9/00	A61K9/00		34850
A61K9/0017	10	{Non-human animal skin, e.g. pour-on, spot-on}	A61K9/00	A61K9/00		647
A61K9/0019	9	{Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}	A61K9/00	A61K9/00		31397
A61K9/0021	10	{Intradermal administration, e.g. through microneedle arrays or needleless injectors}	A61K9/00	A61K9/00		3137
A61K9/0024	10	{Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}	A61K9/00	A61K9/00		5497
A61K9/0026	10	{Blood substitute; Oxygen transporting formulations; Plasma extender}	A61K9/00	A61K9/00		469
A61K9/0029	10	{Parenteral nutrition; Parenteral nutrition compositions as drug carriers}	A61K9/00	A61K9/00		321
A61K9/0031	9	{Rectum, anus}	A61K9/00	A61K9/00		2406
A61K9/0034	9	{Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}	A61K9/00	A61K9/00		4705
A61K9/0036	10	{Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms}	A61K9/00	A61K9/00		729
A61K9/0039	10	{Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception}	A61K9/00	A61K9/00		213
A61K9/0041	9	{Mammary glands, e.g. breasts, udder; Intramammary administration}	A61K9/00	A61K9/00		665
A61K9/0043	9	{Nose}	A61K9/00	A61K9/00		5838
A61K9/0046	9	{Ear}	A61K9/00	A61K9/00		785
A61K9/0048	9	{Eye, e.g. artificial tears}	A61K9/00	A61K9/00		8554
A61K9/0051	10	{Ocular inserts or implants}	A61K9/00	A61K9/00		1677
A61K9/0053	9	{Mouth and digestive tract, i.e. intraoral and peroral administration}	A61K9/00	A61K9/00		15082
A61K9/0056	10	{Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}	A61K9/00	A61K9/00		8305
A61K9/0058	11	{Chewing gums (non-medicinal aspects, preparing chewing gum A23G4/00; chewing gum for care of the teeth or oral cavity, e.g. with breath freshener A61Q11/00)}	A61K9/68	A61K9/00		1000
A61K9/006	10	{Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}	A61K9/00	A61K9/00		5522
A61K9/0063	10	{Periodont}	A61K9/00	A61K9/00		889
A61K9/0065	10	{Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus}	A61K9/00	A61K9/00		947
A61K9/0068	10	{Rumen, e.g. rumen bolus}	A61K9/00	A61K9/00		280
A61K9/007	9	{Pulmonary tract; Aromatherapy}	A61K9/00	A61K9/00		2206
A61K9/0073	10	{Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}	A61K9/00	A61K9/00		2368
A61K9/0075	11	{for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}	A61K9/00	A61K9/00		2223
A61K9/0078	11	{for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}	A61K9/00	A61K9/00		2471
A61K9/008	11	{comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}	A61K9/00	A61K9/00		1363
A61K9/0082	10	{Lung surfactant, artificial mucus}	A61K9/00	A61K9/00		102
A61K9/0085	9	{Brain, e.g. brain implants; Spinal cord}	A61K9/00	A61K9/00		982
A61K9/0087	8	{Galenical forms not covered by A61K9/02&#160;-&#160;A61K9/7023}	A61K9/00	A61K9/00		379
A61K9/009	9	{Sachets, pouches characterised by the material or function of the envelope (with gastric retention A61K9/0065; sachets which are not administered but function merely as a container are classified according to the content, e.g. sachets comprising powder for reconstitution of a drink A61K9/0095)}	A61K9/00	A61K9/00		950
A61K9/0092	9	{Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes}	A61K9/00	A61K9/00		741
A61K9/0095	9	{Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}	A61K9/00	A61K9/00		22760
A61K9/0097	9	{Medicinal compositions released by microdevices, e.g. microelectromechanical systems [MEMS], microdevices comprising chips or microdevices on silicon}	A61K9/00	A61K9/00		275
A61K9/02	8	Suppositories; Bougies; Bases therefor; {Ovules}(apparatus for making A61J3/08; devices for introducing into the body A61M31/00)	A61K9/02	A61K9/02		1768
A61K9/025	9	{characterised by shape or structure, e.g. hollow layered, coated}	A61K9/02	A61K9/02		173
A61K9/06	8	Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}	A61K9/06	A61K9/06		24241
A61K9/08	8	Solutions {(composition of solutions A61K47/00)}	A61K9/08	A61K9/08		19122
A61K9/10	8	Dispersions; Emulsions	A61K9/10	A61K9/10		5671
A61K9/107	9	Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}	A61K9/107	A61K9/107		4822
A61K9/1075	10	{Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}	A61K9/107	A61K9/107		6849
A61K9/113	10	Multiple emulsions, e.g. oil-in-water-in-oil {(A61K9/0026 takes precedence)}	A61K9/113	A61K9/113		495
A61K9/12	9	Aerosols; Foams {(A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015)}	A61K9/12	A61K9/12		4129
A61K9/122	10	{Foams; Dry foams (edible foams A61K9/0056)}	A61K9/12	A61K9/12		743
A61K9/124	10	{characterised by the propellant}	A61K9/12	A61K9/12		324
A61K9/127	9	Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant	A61K9/127	A61K9/127		7893
A61K9/1271	10	Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})	A61K9/1271	A61K9/1271		3580
A61K9/1272	11	comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})	A61K9/1272	A61K9/1272		2473
A61K9/1273	11	Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances	A61K9/1273	A61K9/1273		679
A61K9/1274	10	Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases	A61K9/1274	A61K9/1274		441
A61K9/1275	10	Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof	A61K9/1275	A61K9/1275		194
A61K9/1276	10	Globules of milk; Constituents thereof	A61K9/1276	A61K9/1276		44
A61K9/1277	10	Preparation processes; Proliposomes	A61K9/1277	A61K9/1277		2405
A61K9/1278	11	Post-loading, e.g. by ion or pH gradient	A61K9/1278	A61K9/1278		391
A61K9/14	8	Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}	A61K9/14	A61K9/14		8729
A61K9/141	9	{Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers ((co) spray-dried products A61K9/16, (co) lyophilised products A61K9/19; the carrier being chemically bound to the active ingredient A61K47/50)}	A61K9/14	A61K9/14		437
A61K9/143	10	{with inorganic compounds}	A61K9/14	A61K9/14		1628
A61K9/145	10	{with organic compounds}	A61K9/14	A61K9/14		3437
A61K9/146	10	{with organic macromolecular compounds}	A61K9/14	A61K9/14		5075
A61K9/148	10	{with compounds of unknown constitution, e.g. material from plants or animals (with oils, fats, waxes, shellac A61K9/145)}	A61K9/14	A61K9/14		375
A61K9/16	9	Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}	A61K9/16	A61K9/16		4006
A61K9/1605	10	{Excipients; Inactive ingredients}	A61K9/16	A61K9/16		481
A61K9/1611	11	{Inorganic compounds}	A61K9/16	A61K9/16		2319
A61K9/1617	11	{Organic compounds, e.g. phospholipids, fats}	A61K9/16	A61K9/16		3841
A61K9/1623	12	{Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}	A61K9/16	A61K9/16		4182
A61K9/1629	11	{Organic macromolecular compounds}	A61K9/16	A61K9/16		185
A61K9/1635	12	{obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}	A61K9/16	A61K9/16		3316
A61K9/1641	12	{obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}	A61K9/16	A61K9/16		1865
A61K9/1647	13	{Polyesters, e.g. poly(lactide-co-glycolide)}	A61K9/16	A61K9/16		2299
A61K9/1652	12	{Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}	A61K9/16	A61K9/16		10776
A61K9/1658	12	{Proteins, e.g. albumin, gelatin}	A61K9/16	A61K9/16		1092
A61K9/1664	11	{Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/1617)}	A61K9/16	A61K9/16		685
A61K9/167	10	{with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface (with further drug-free outer coating A61K9/5073)}	A61K9/16	A61K9/16		843
A61K9/1676	11	{having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921)}	A61K9/16	A61K9/16		1071
A61K9/1682	10	{Processes}	A61K9/16	A61K9/16		2133
A61K9/1688	11	{resulting in pure drug agglomerate optionally containing up to 5% of excipient}	A61K9/16	A61K9/16		744
A61K9/1694	11	{resulting in granules or microspheres of the matrix type containing more than 5% of excipient}	A61K9/16	A61K9/16		2236
A61K9/19	9	lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}	A61K9/19	A61K9/19		9022
A61K9/20	8	Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}	A61K9/20	A61K9/20		6748
A61K9/2004	9	{Excipients; Inactive ingredients}	A61K9/20	A61K9/20		1111
A61K9/2009	10	{Inorganic compounds}	A61K9/20	A61K9/20		5253
A61K9/2013	10	{Organic compounds, e.g. phospholipids, fats}	A61K9/20	A61K9/20		6705
A61K9/2018	11	{Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}	A61K9/20	A61K9/20		8269
A61K9/2022	10	{Organic macromolecular compounds}	A61K9/20	A61K9/20		152
A61K9/2027	11	{obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}	A61K9/20	A61K9/20		5982
A61K9/2031	11	{obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}	A61K9/20	A61K9/20		2785
A61K9/2036	12	{Silicones; Polysiloxanes}	A61K9/20	A61K9/20		128
A61K9/204	12	{Polyesters, e.g. poly(lactide-co-glycolide)}	A61K9/20	A61K9/20		418
A61K9/2045	12	{Polyamides; Polyaminoacids, e.g. polylysine}	A61K9/20	A61K9/20		56
A61K9/205	11	{Polysaccharides, e.g. alginate, gums; Cyclodextrin}	A61K9/20	A61K9/20		2366
A61K9/2054	12	{Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}	A61K9/20	A61K9/20		12680
A61K9/2059	12	{Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}	A61K9/20	A61K9/20		7922
A61K9/2063	11	{Proteins, e.g. gelatin}	A61K9/20	A61K9/20		712
A61K9/2068	10	{Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/2013)}	A61K9/20	A61K9/20		3032
A61K9/2072	9	{characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)}	A61K9/20	A61K9/20		1387
A61K9/2077	10	{Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}	A61K9/20	A61K9/20		2574
A61K9/2081	11	{with microcapsules or coated microparticles according to A61K9/50}	A61K9/20	A61K9/20		1481
A61K9/2086	10	{Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat A61K9/28)}	A61K9/20	A61K9/20		1106
A61K9/209	11	{containing drug in at least two layers or in the core and in at least one outer layer}	A61K9/24	A61K9/20		2753
A61K9/2095	9	{Tabletting processes}	A61K9/20	A61K9/20		5644
A61K9/28	9	Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}	A61K9/28	A61K9/28		2344
A61K9/2806	10	{Coating materials}	A61K9/28	A61K9/28		534
A61K9/2813	11	{Inorganic compounds}	A61K9/28	A61K9/28		685
A61K9/282	11	{Organic compounds, e.g. fats}	A61K9/28	A61K9/28		1091
A61K9/2826	12	{Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof}	A61K9/28	A61K9/28		594
A61K9/2833	11	{Organic macromolecular compounds}	A61K9/28	A61K9/28		133
A61K9/284	12	{obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone}	A61K9/28	A61K9/28		1248
A61K9/2846	13	{Poly(meth)acrylates}	A61K9/28	A61K9/28		1575
A61K9/2853	12	{obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)}	A61K9/28	A61K9/28		954
A61K9/286	12	{Polysaccharides, e.g. gums; Cyclodextrin}	A61K9/28	A61K9/28		603
A61K9/2866	13	{Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}	A61K9/28	A61K9/28		3951
A61K9/2873	12	{Proteins, e.g. gelatin}	A61K9/28	A61K9/28		209
A61K9/288	11	{Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/282)}	A61K9/28	A61K9/28		196
A61K9/2886	10	{having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer (of the type active core-drug layer-inactive layer A61K9/209)}	A61K9/28	A61K9/28		1094
A61K9/2893	10	{Tablet coating processes (mechanical aspects A61J3/06)}	A61K9/28	A61K9/28		752
A61K9/48	8	Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}	A61K9/48	A61K9/48		5029
A61K9/4808	9	{characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}	A61K9/48	A61K9/48		2745
A61K9/4816	9	{Wall or shell material}	A61K9/48	A61K9/48		1963
A61K9/4825	10	{Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}	A61K9/48	A61K9/48		1718
A61K9/4833	9	{Encapsulating processes; Filling of capsules (mechanical aspects A61J3/07)}	A61K9/48	A61K9/48		784
A61K9/4841	9	{Filling excipients; Inactive ingredients}	A61K9/48	A61K9/48		592
A61K9/485	10	{Inorganic compounds}	A61K9/48	A61K9/48		1158
A61K9/4858	10	{Organic compounds}	A61K9/48	A61K9/48		5429
A61K9/4866	10	{Organic macromolecular compounds}	A61K9/48	A61K9/48		5877
A61K9/4875	10	{Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/4858)}	A61K9/48	A61K9/48		701
A61K9/4883	9	{Capsule finishing, e.g. dyeing, aromatising, polishing}	A61K9/48	A61K9/48		154
A61K9/4891	9	{Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}	A61K9/48	A61K9/48		1330
A61K9/50	9	Microcapsules {having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals (A61K9/2081 takes precedence; particles with a single coating comprising drug A61K9/167)}	A61K9/50	A61K9/50		1315
A61K9/5005	10	{Wall or coating material}	A61K9/50	A61K9/50		111
A61K9/501	11	{Inorganic compounds}	A61K9/50	A61K9/50		916
A61K9/5015	11	{Organic compounds, e.g. fats, sugars}	A61K9/50	A61K9/50		1882
A61K9/5021	11	{Organic macromolecular compounds}	A61K9/50	A61K9/50		158
A61K9/5026	12	{obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}	A61K9/50	A61K9/50		2986
A61K9/5031	12	{obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}	A61K9/50	A61K9/50		2234
A61K9/5036	12	{Polysaccharides, e.g. gums, alginate; Cyclodextrin}	A61K9/50	A61K9/50		2590
A61K9/5042	13	{Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose}	A61K9/50	A61K9/50		1315
A61K9/5047	14	{Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose}	A61K9/50	A61K9/50		1766
A61K9/5052	12	{Proteins, e.g. albumin}	A61K9/50	A61K9/50		834
A61K9/5057	13	{Gelatin}	A61K9/50	A61K9/50		502
A61K9/5063	11	{Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/5015)}	A61K9/50	A61K9/50		363
A61K9/5068	12	{Cell membranes or bacterial membranes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}	A61K9/50	A61K9/50		1196
A61K9/5073	10	{having two or more different coatings optionally including drug-containing subcoatings}	A61K9/50	A61K9/50		1589
A61K9/5078	11	{with drug-free core}	A61K9/50	A61K9/50		1945
A61K9/5084	10	{Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K9/2077)}	A61K9/50	A61K9/50		1499
A61K9/5089	10	{Processes}	A61K9/50	A61K9/50		2528
A61K9/5094	10	{Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting}	A61K9/50	A61K9/50		404
A61K9/51	10	Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}	A61K9/51	A61K9/51		1821
A61K9/5107	11	{Excipients; Inactive ingredients}	A61K9/51	A61K9/51		74
A61K9/5115	12	{Inorganic compounds}	A61K9/51	A61K9/51		2080
A61K9/5123	12	{Organic compounds, e.g. fats, sugars}	A61K9/51	A61K9/51		4833
A61K9/513	12	{Organic macromolecular compounds; Dendrimers}	A61K9/51	A61K9/51		254
A61K9/5138	13	{obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}	A61K9/51	A61K9/51		1227
A61K9/5146	13	{obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}	A61K9/51	A61K9/51		3381
A61K9/5153	14	{Polyesters, e.g. poly(lactide-co-glycolide)}	A61K9/51	A61K9/51		1926
A61K9/5161	13	{Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}	A61K9/51	A61K9/51		2553
A61K9/5169	13	{Proteins, e.g. albumin, gelatin}	A61K9/51	A61K9/51		1933
A61K9/5176	12	{Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/5123)}	A61K9/51	A61K9/51		936
A61K9/5184	13	{Virus capsids or envelopes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}	A61K9/51	A61K9/51		358
A61K9/5192	11	{Processes}	A61K9/51	A61K9/51		3018
A61K9/70	8	Web, sheet or filament bases {; Films; Fibres of the matrix type containing drug (hollow drug-filled fibres A61K9/0092)}	A61K9/70	A61K9/70		3322
A61K9/7007	9	{Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}	A61K9/70	A61K9/70		3219
A61K9/7015	9	{Drug-containing film-forming compositions, e.g. spray-on}	A61K9/70	A61K9/70		1252
A61K9/7023	9	{Transdermal patches and similar drug-containing composite devices, e.g. cataplasms (galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006)}	A61K9/70	A61K9/70		6117
A61K9/703	10	{characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches}	A61K9/70	A61K9/70		1257
A61K9/7038	11	{Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer}	A61K9/70	A61K9/70		487
A61K9/7046	12	{the adhesive comprising macromolecular compounds}	A61K9/70	A61K9/70		239
A61K9/7053	13	{obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene}	A61K9/70	A61K9/70		1268
A61K9/7061	14	{Polyacrylates}	A61K9/70	A61K9/70		1743
A61K9/7069	13	{obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide}	A61K9/70	A61K9/70		711
A61K9/7076	12	{the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins}	A61K9/70	A61K9/70		629
A61K9/7084	11	{Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches}	A61K9/70	A61K9/70		1616
A61K9/7092	11	{Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs}	A61K9/70	A61K9/70		388
A61K31/00	7	Medicinal preparations containing organic active ingredients<br><br><u>NOTE</u><br><br>When classifying in groups A61K31/00 - A61K41/00 the symbol A61K2300/00 may be added, using Combination Sets, to indicate a mixture of active ingredients.<br>In the preparation of new organic compounds and their use in medicinal preparations, classification is only made in the relevant subclasses C07C - C07J according to the type of compound. However, the inventions dealing with medicinal preparations containing at least two active organic ingredients are always classified in this group in addition to the classification for the type of compounds in C07C - C07J.<br>Attention is drawn to the notes in class C07, particularly to the definition of steroids given in Note (1) following the title of C07J and to the definition of carbohydrates and sugars given in the notes following the title of C07H.<br>According to the last place rule, organic active compounds forming salts with heavy metals should be classified in A61K33/24 - A61K33/38 and not in subgroups A61K31/28 - A61K31/32, A61K31/555 or A61K31/714. This does not apply to complexes, as apparent from the A61K31/00 scheme, wherein the complexes hemin and hematin are classified in A61K31/555 and cyanocobalamin in A61K31/714. If a complex is formed between two or more active compounds, then they are classified according to all compounds forming the complexes followed by the symbol A61K2300/00 (i.e. as a mixture of active organic compounds).	A61K31/00	A61K31/00		10497
A61K31/01	8	Hydrocarbons	A61K31/01	A61K31/01		1341
A61K31/015	9	carbocyclic	A61K31/015	A61K31/015		2316
A61K31/02	8	Halogenated hydrocarbons	A61K31/02	A61K31/02		506
A61K31/025	9	carbocyclic	A61K31/025	A61K31/025		148
A61K31/03	10	aromatic	A61K31/03	A61K31/03		237
A61K31/035	9	having aliphatic unsaturation	A61K31/035	A61K31/035		64
A61K31/04	8	Nitro compounds	A61K31/04	A61K31/04		510
A61K31/045	8	Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates	A61K31/045	A61K31/045		14968
A61K31/047	9	having two or more hydroxy groups, e.g. sorbitol	A61K31/047	A61K31/047		3806
A61K31/05	9	Phenols {(cannabinoids A61K31/658)}<br><br><u>WARNING</u><br>Group A61K31/05 is impacted by reclassification into group A61K31/658.<br>All groups listed in this Warning should be considered in order to perform a complete search.	A61K31/05	A61K31/05		8211
A61K31/055	10	the aromatic ring being substituted by halogen	A61K31/055	A61K31/055		301
A61K31/06	10	the aromatic ring being substituted by nitro groups	A61K31/06	A61K31/06		184
A61K31/065	9	Diphenyl-substituted acyclic alcohols	A61K31/065	A61K31/065		153
A61K31/07	9	Retinol compounds, e.g. vitamin A (retinoic acids A61K31/203)	A61K31/07	A61K31/07		2875
A61K31/075	8	Ethers or acetals	A61K31/075	A61K31/075		430
A61K31/08	9	acyclic, e.g. paraformaldehyde	A61K31/08	A61K31/08		470
A61K31/085	9	having an ether linkage to aromatic ring nuclear carbon	A61K31/085	A61K31/085		1570
A61K31/09	10	having two or more such linkages	A61K31/09	A61K31/09		1260
A61K31/095	8	Sulfur, selenium, or tellurium compounds, e.g. thiols	A61K31/095	A61K31/095		711
A61K31/10	9	Sulfides; Sulfoxides; Sulfones	A61K31/10	A61K31/10		1412
A61K31/105	9	Persulfides (thiuram disulfides A61K31/145; thiosulfonic acids A61K31/185)	A61K31/105	A61K31/105		166
A61K31/11	8	Aldehydes	A61K31/11	A61K31/11		1502
A61K31/115	9	Formaldehyde	A61K31/115	A61K31/115		93
A61K31/12	8	Ketones	A61K31/12	A61K31/12		6126
A61K31/121	9	acyclic	A61K31/121	A61K31/121		593
A61K31/122	9	having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin	A61K31/122	A61K31/122		6349
A61K31/125	10	Camphor; Nuclear substituted derivatives thereof	A61K31/125	A61K31/125		2232
A61K31/13	8	Amines {(A61K31/04 takes precedence)}	A61K31/13	A61K31/13		2316
A61K31/131	9	acyclic	A61K31/131	A61K31/131		378
A61K31/132	9	having two or more amino groups, e.g. spermidine, putrescine	A61K31/132	A61K31/132		495
A61K31/133	9	having hydroxy groups, e.g. sphingosine	A61K31/133	A61K31/133		837
A61K31/135	9	having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}	A61K31/135	A61K31/135		5699
A61K31/136	10	having the amino group directly attached to the aromatic ring, e.g. benzeneamine	A61K31/136	A61K31/136		1258
A61K31/137	10	Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}	A61K31/137	A61K31/137		6796
A61K31/138	10	Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)	A61K31/138	A61K31/138		2910
A61K31/14	9	Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205)	A61K31/14	A61K31/14		2441
A61K31/145	9	having sulfur, e.g. thiurams (&gt;N&#8212;C(S)&#8212;S&#8212;C(S)&#8212;N&lt; and &gt;N&#8212;C(S)&#8212;S&#8212;S&#8212;C(S)&#8212;N&lt;), Sulfinylamines (&#8212;N=SO), Sulfonylamines (&#8212;N=SO2) (isothiourea A61K31/155)	A61K31/145	A61K31/145		1057
A61K31/15	9	Oximes (&gt;C=N&#8212;O&#8212;); Hydrazines (&gt;N&#8212;N&lt;); Hydrazones (&gt;N&#8212;N=) {; Imines (C&#8212;N=C)}	A61K31/15	A61K31/15		974
A61K31/155	9	Amidines (), e.g. guanidine (H2N&#8212;C(=NH)&#8212;NH2), isourea (N=C(OH)&#8212;NH2), isothiourea (&#8212;N=C(SH)&#8212;NH2)	A61K31/155	A61K31/155		5277
A61K31/16	8	Amides, e.g. hydroxamic acids	A61K31/16	A61K31/16		3315
A61K31/164	9	of a carboxylic acid with an aminoalcohol, e.g. ceramides	A61K31/164	A61K31/164		1234
A61K31/165	9	having aromatic rings, e.g. colchicine, atenolol, progabide	A61K31/165	A61K31/165		6125
A61K31/166	10	having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol	A61K31/166	A61K31/166		1762
A61K31/167	10	having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol	A61K31/167	A61K31/167		5998
A61K31/17	9	having the group &gt;N&#8212;C(O)&#8212;N&lt; or &gt;N&#8212;C(S)&#8212;N&lt;, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64)	A61K31/17	A61K31/17		1960
A61K31/175	10	having the group  , &gt;N&#8212;C(O)&#8212;N=N&#8212; or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof	A61K31/175	A61K31/175		425
A61K31/18	9	Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)	A61K31/18	A61K31/18		2835
A61K31/185	8	Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or&#160;hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327)<br><br><u>NOTE</u><br><br>Cyclic anhydrides are considered to be heterocyclic rings	A61K31/185	A61K31/185		3045
A61K31/19	9	Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)	A61K31/19	A61K31/19		9529
A61K31/191	10	having two or more hydroxy groups, e.g. gluconic acid	A61K31/191	A61K31/191		1068
A61K31/192	10	having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid&#160; {(cannabinoids A61K31/658)}<br><br><u>WARNING</u><br>Group A61K31/192 is impacted by reclassification into group A61K31/658.<br>All groups listed in this Warning should be considered in order to perform a complete search.	A61K31/192	A61K31/192		8696
A61K31/194	10	having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid	A61K31/194	A61K31/194		3214
A61K31/195	10	having an amino group	A61K31/195	A61K31/195		6004
A61K31/196	11	the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil	A61K31/196	A61K31/196		2997
A61K31/197	11	the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)	A61K31/197	A61K31/197		3499
A61K31/198	12	Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)	A61K31/198	A61K31/198		11103
A61K31/20	10	having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids	A61K31/20	A61K31/20		2841
A61K31/201	11	having one or two double bonds, e.g. oleic, linoleic acids	A61K31/201	A61K31/201		1702
A61K31/202	11	having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)	A61K31/202	A61K31/202		3347
A61K31/203	11	Retinoic acids {; Salts thereof}	A61K31/203	A61K31/203		1165
A61K31/205	9	Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine	A61K31/205	A61K31/205		2282
A61K31/21	8	Esters, e.g. nitroglycerine, selenocyanates	A61K31/21	A61K31/21		874
A61K31/215	9	of carboxylic acids	A61K31/215	A61K31/215		2023
A61K31/216	10	of acids having aromatic rings, e.g. benactizyne, clofibrate	A61K31/216	A61K31/216		4050
A61K31/22	10	of acyclic acids, e.g. pravastatin	A61K31/22	A61K31/22		3116
A61K31/221	11	with compounds having an amino group, e.g. acetylcholine, acetylcarnitine	A61K31/221	A61K31/221		540
A61K31/222	11	with compounds having aromatic groups, e.g. dipivefrine, ibopamine	A61K31/222	A61K31/222		925
A61K31/223	11	of alpha-aminoacids	A61K31/223	A61K31/223		422
A61K31/225	11	Polycarboxylic acids	A61K31/225	A61K31/225		1213
A61K31/23	11	of acids having a carboxyl group bound to a chain of seven or more carbon atoms	A61K31/23	A61K31/23		1778
A61K31/231	12	having one or two double bonds	A61K31/231	A61K31/231		574
A61K31/232	12	having three or more double bonds, e.g. etretinate	A61K31/232	A61K31/232		828
A61K31/235	10	having an aromatic ring attached to a carboxyl group	A61K31/235	A61K31/235		1481
A61K31/24	11	having an amino or nitro group	A61K31/24	A61K31/24		805
A61K31/245	12	Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)	A61K31/245	A61K31/245		1339
A61K31/25	10	with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol	A61K31/25	A61K31/25		207
A61K31/255	9	of sulfoxy acids or sulfur analogues thereof	A61K31/255	A61K31/255		865
A61K31/26	9	Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters	A61K31/26	A61K31/26		583
A61K31/265	9	of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid	A61K31/265	A61K31/265		303
A61K31/27	9	of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine	A61K31/27	A61K31/27		1764
A61K31/275	8	Nitriles; Isonitriles	A61K31/275	A61K31/275		1020
A61K31/277	9	having a ring, e.g. verapamil	A61K31/277	A61K31/277		1842
A61K31/28	8	Compounds containing heavy metals	A61K31/28	A61K31/28		1017
A61K31/282	9	Platinum compounds	A61K31/282	A61K31/282		1289
A61K31/285	9	Arsenic compounds	A61K31/285	A61K31/285		130
A61K31/29	9	Antimony or bismuth compounds	A61K31/29	A61K31/29		163
A61K31/295	9	Iron group metal compounds	A61K31/295	A61K31/295		792
A61K31/30	9	Copper compounds	A61K31/30	A61K31/30		287
A61K31/305	9	Mercury compounds	A61K31/305	A61K31/305		73
A61K31/31	10	containing nitrogen	A61K31/31	A61K31/31		41
A61K31/315	9	Zinc compounds	A61K31/315	A61K31/315		712
A61K31/32	9	Tin compounds	A61K31/32	A61K31/32		73
A61K31/325	8	Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof (thiurams A61K31/145)	A61K31/325	A61K31/325		507
A61K31/327	8	Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids	A61K31/327	A61K31/327		441
A61K31/33	8	Heterocyclic compounds	A61K31/33	A61K31/33		776
A61K31/335	9	having oxygen as the only ring hetero atom, e.g. fungichromin	A61K31/335	A61K31/335		1281
A61K31/336	10	having three-membered rings, e.g. oxirane, fumagillin	A61K31/336	A61K31/336		889
A61K31/337	10	having four-membered rings, e.g. taxol	A61K31/337	A61K31/337		6564
A61K31/34	10	having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide	A61K31/34	A61K31/34		1963
A61K31/341	11	not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine	A61K31/341	A61K31/341		1980
A61K31/343	11	condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone	A61K31/343	A61K31/343		3526
A61K31/345	11	Nitrofurans (nitrofurantoin A61K31/4178)	A61K31/345	A61K31/345		198
A61K31/35	10	having six-membered rings with one oxygen as the only ring hetero atom	A61K31/35	A61K31/35		2382
A61K31/351	11	not condensed with another ring	A61K31/351	A61K31/351		1883
A61K31/352	11	condensed with carbocyclic rings, e.g. methantheline&#160; {(cannabinoids A61K31/658)}<br><br><u>WARNING</u><br>Group A61K31/352 is impacted by reclassification into group A61K31/658.<br>All groups listed in this Warning should be considered in order to perform a complete search.	A61K31/352	A61K31/352		12876
A61K31/353	12	3,4-Dihydrobenzopyrans, e.g. chroman, catechin	A61K31/353	A61K31/353		5299
A61K31/355	13	Tocopherols, e.g. vitamin E	A61K31/355	A61K31/355		5651
A61K31/357	10	having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel	A61K31/357	A61K31/357		2540
A61K31/36	11	Compounds containing methylenedioxyphenyl groups, e.g. sesamin	A61K31/36	A61K31/36		1351
A61K31/365	10	Lactones	A61K31/365	A61K31/365		4895
A61K31/366	11	having six-membered rings, e.g. delta-lactones	A61K31/366	A61K31/366		3423
A61K31/37	12	Coumarins, e.g. psoralen	A61K31/37	A61K31/37		1819
A61K31/375	11	Ascorbic acid, i.e. vitamin C; Salts thereof	A61K31/375	A61K31/375		6579
A61K31/38	9	having sulfur as a ring hetero atom	A61K31/38	A61K31/38		955
A61K31/381	10	having five-membered rings	A61K31/381	A61K31/381		3335
A61K31/382	10	having six-membered rings, e.g. thioxanthenes (thiothixene A61K31/496)	A61K31/382	A61K31/382		520
A61K31/385	10	having two or more sulfur atoms in the same ring	A61K31/385	A61K31/385		1392
A61K31/39	10	having oxygen in the same ring	A61K31/39	A61K31/39		138
A61K31/395	9	having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins	A61K31/395	A61K31/395		1811
A61K31/396	10	having three-membered rings, e.g. aziridine	A61K31/396	A61K31/396		117
A61K31/397	10	having four-membered rings, e.g. azetidine	A61K31/397	A61K31/397		1311
A61K31/40	10	having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil	A61K31/40	A61K31/40		7151
A61K31/401	11	Proline; Derivatives thereof, e.g. captopril	A61K31/401	A61K31/401		1709
A61K31/4015	11	having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide	A61K31/4015	A61K31/4015		1861
A61K31/402	11	1-aryl substituted, e.g. piretanide	A61K31/402	A61K31/402		364
A61K31/4025	11	not condensed and containing further heterocyclic rings, e.g. cromakalim	A61K31/4025	A61K31/4025		1936
A61K31/403	11	condensed with carbocyclic rings, e.g. carbazole	A61K31/403	A61K31/403		1814
A61K31/4035	12	Isoindoles, e.g. phthalimide	A61K31/4035	A61K31/4035		1025
A61K31/404	12	Indoles, e.g. pindolol	A61K31/404	A61K31/404		5142
A61K31/4045	13	Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin	A61K31/4045	A61K31/4045		2897
A61K31/405	13	Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin	A61K31/405	A61K31/405		3770
A61K31/407	11	condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine	A61K31/407	A61K31/407		3060
A61K31/409	11	having four such rings, e.g. porphine derivatives, bilirubin, biliverdine (hemin, hematin A61K31/555)	A61K31/409	A61K31/409		908
A61K31/41	10	having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole	A61K31/41	A61K31/41		2799
A61K31/415	11	1,2-Diazoles	A61K31/415	A61K31/415		5427
A61K31/4152	12	having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone	A61K31/4152	A61K31/4152		691
A61K31/4155	12	non condensed and containing further heterocyclic rings	A61K31/4155	A61K31/4155		1525
A61K31/416	12	condensed with carbocyclic ring systems, e.g. indazole	A61K31/416	A61K31/416		1456
A61K31/4162	12	condensed with heterocyclic ring systems	A61K31/4162	A61K31/4162		540
A61K31/4164	11	1,3-Diazoles	A61K31/4164	A61K31/4164		3057
A61K31/4166	12	having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin	A61K31/4166	A61K31/4166		1397
A61K31/4168	12	having a nitrogen attached in position 2, e.g. clonidine	A61K31/4168	A61K31/4168		627
A61K31/417	12	Imidazole-alkylamines, e.g. histamine, phentolamine	A61K31/417	A61K31/417		518
A61K31/4172	12	Imidazole-alkanecarboxylic acids, e.g. histidine	A61K31/4172	A61K31/4172		1164
A61K31/4174	12	Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole	A61K31/4174	A61K31/4174		1438
A61K31/4178	12	not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin	A61K31/4178	A61K31/4178		3306
A61K31/4184	12	condensed with carbocyclic rings, e.g. benzimidazoles	A61K31/4184	A61K31/4184		4397
A61K31/4188	12	condensed with other heterocyclic ring systems, e.g. biotin, sorbinil	A61K31/4188	A61K31/4188		1911
A61K31/4192	11	1,2,3-Triazoles	A61K31/4192	A61K31/4192		1161
A61K31/4196	11	1,2,4-Triazoles	A61K31/4196	A61K31/4196		2594
A61K31/42	11	Oxazoles	A61K31/42	A61K31/42		2264
A61K31/421	12	1,3-Oxazoles, e.g. pemoline, trimethadione	A61K31/421	A61K31/421		1009
A61K31/422	12	not condensed and containing further heterocyclic rings	A61K31/422	A61K31/422		1655
A61K31/423	12	condensed with carbocyclic rings	A61K31/423	A61K31/423		1216
A61K31/424	12	condensed with heterocyclic ring systems, e.g. clavulanic acid	A61K31/424	A61K31/424		481
A61K31/4245	11	Oxadiazoles	A61K31/4245	A61K31/4245		1712
A61K31/425	11	Thiazoles	A61K31/425	A61K31/425		1658
A61K31/426	12	1,3-Thiazoles	A61K31/426	A61K31/426		3322
A61K31/427	12	not condensed and containing further heterocyclic rings	A61K31/427	A61K31/427		3318
A61K31/428	12	condensed with carbocyclic rings	A61K31/428	A61K31/428		1909
A61K31/429	12	condensed with heterocyclic ring systems	A61K31/429	A61K31/429		570
A61K31/43	13	Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems	A61K31/43	A61K31/43		2540
A61K31/431	14	containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin	A61K31/431	A61K31/431		501
A61K31/433	11	Thidiazoles	A61K31/433	A61K31/433		1321
A61K31/435	10	having six-membered rings with one nitrogen as the only ring hetero atom	A61K31/435	A61K31/435		1944
A61K31/4353	11	ortho- or peri-condensed with heterocyclic ring systems	A61K31/4353	A61K31/4353		409
A61K31/4355	12	the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom	A61K31/4355	A61K31/4355		511
A61K31/436	12	the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin	A61K31/436	A61K31/436		3027
A61K31/4365	12	the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine	A61K31/4365	A61K31/4365		1116
A61K31/437	12	the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline	A61K31/437	A61K31/437		6622
A61K31/4375	12	the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine	A61K31/4375	A61K31/4375		3835
A61K31/438	11	The ring being spiro-condensed with carbocyclic or heterocyclic ring systems	A61K31/438	A61K31/438		1190
A61K31/439	11	the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)	A61K31/439	A61K31/439		2469
A61K31/44	11	Non condensed pyridines; Hydrogenated derivatives thereof	A61K31/44	A61K31/44		8267
A61K31/4402	12	only substituted in position 2, e.g. pheniramine, bisacodyl	A61K31/4402	A61K31/4402		1549
A61K31/4406	12	only substituted in position 3, e.g. zimeldine (nicotinic acid A61K31/455)	A61K31/4406	A61K31/4406		985
A61K31/4409	12	only substituted in position 4, e.g. isoniazid, iproniazid	A61K31/4409	A61K31/4409		1091
A61K31/4412	12	having oxo groups directly attached to the heterocyclic ring	A61K31/4412	A61K31/4412		1292
A61K31/4415	12	Pyridoxine, i.e. Vitamin B6(pyridoxal phosphate A61K31/675)	A61K31/4415	A61K31/4415		2435
A61K31/4418	12	having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine	A61K31/4418	A61K31/4418		1417
A61K31/4422	12	1,4-Dihydropyridines, e.g. nifedipine, nicardipine	A61K31/4422	A61K31/4422		1550
A61K31/4425	12	Pyridinium derivatives, e.g. pralidoxime, pyridostigmine	A61K31/4425	A61K31/4425		535
A61K31/4427	12	containing further heterocyclic ring systems	A61K31/4427	A61K31/4427		789
A61K31/443	13	containing a five-membered ring with oxygen as a ring hetero atom	A61K31/443	A61K31/443		839
A61K31/4433	13	containing a six-membered ring with oxygen as a ring hetero atom	A61K31/4433	A61K31/4433		532
A61K31/4436	13	containing a heterocyclic ring having sulfur as a ring hetero atom	A61K31/4436	A61K31/4436		724
A61K31/4439	13	containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)	A61K31/4439	A61K31/4439		9619
A61K31/444	13	containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone	A61K31/444	A61K31/444		4500
A61K31/445	12	Non condensed piperidines, e.g. piperocaine	A61K31/445	A61K31/445		6423
A61K31/4453	13	only substituted in position 1, e.g. propipocaine, diperodon	A61K31/4453	A61K31/4453		849
A61K31/4458	13	only substituted in position 2, e.g. methylphenidate	A61K31/4458	A61K31/4458		427
A61K31/4462	13	only substituted in position 3	A61K31/4462	A61K31/4462		70
A61K31/4465	13	only substituted in position 4	A61K31/4465	A61K31/4465		227
A61K31/4468	13	having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl	A61K31/4468	A61K31/4468		977
A61K31/45	13	having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide	A61K31/45	A61K31/45		498
A61K31/451	13	having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine	A61K31/451	A61K31/451		1041
A61K31/4515	13	having a butyrophenone group in position 1, e.g. haloperidol (pipamperone A61K31/4545)	A61K31/4515	A61K31/4515		167
A61K31/452	13	Piperidinium derivatives (pancuronium A61K31/58)	A61K31/452	A61K31/452		145
A61K31/4523	13	containing further heterocyclic ring systems	A61K31/4523	A61K31/4523		469
A61K31/4525	14	containing a five-membered ring with oxygen as a ring hetero atom	A61K31/4525	A61K31/4525		1031
A61K31/453	14	containing a six-membered ring with oxygen as a ring hetero atom	A61K31/453	A61K31/453		505
A61K31/4535	14	containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen	A61K31/4535	A61K31/4535		1005
A61K31/454	14	containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone	A61K31/454	A61K31/454		5228
A61K31/4545	14	containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine	A61K31/4545	A61K31/4545		4582
A61K31/455	12	Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides	A61K31/455	A61K31/455		3470
A61K31/46	11	8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine	A61K31/46	A61K31/46		1808
A61K31/465	11	Nicotine; Derivatives thereof	A61K31/465	A61K31/465		1182
A61K31/47	11	Quinolines; Isoquinolines	A61K31/47	A61K31/47		5917
A61K31/4704	12	2-Quinolinones, e.g. carbostyril	A61K31/4704	A61K31/4704		892
A61K31/4706	12	4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine	A61K31/4706	A61K31/4706		1271
A61K31/4709	12	Non-condensed quinolines and containing further heterocyclic rings	A61K31/4709	A61K31/4709		4765
A61K31/472	12	Non-condensed isoquinolines, e.g. papaverine	A61K31/472	A61K31/472		1218
A61K31/4725	13	containing further heterocyclic rings	A61K31/4725	A61K31/4725		2174
A61K31/473	12	ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines	A61K31/473	A61K31/473		1706
A61K31/4738	12	ortho- or peri-condensed with heterocyclic ring systems	A61K31/4738	A61K31/4738		189
A61K31/4741	13	condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline	A61K31/4741	A61K31/4741		723
A61K31/4743	13	condensed with ring systems having sulfur as a ring hetero atom	A61K31/4743	A61K31/4743		110
A61K31/4745	13	condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)	A61K31/4745	A61K31/4745		5583
A61K31/4747	12	spiro-condensed	A61K31/4747	A61K31/4747		144
A61K31/4748	12	forming part of bridged ring systems (strychnine A61K31/475; morphinan derivatives A61K31/485)	A61K31/4748	A61K31/4748		529
A61K31/475	12	having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)	A61K31/475	A61K31/475		1646
A61K31/48	12	Ergoline derivatives, e.g. lysergic acid, ergotamine	A61K31/48	A61K31/48		843
A61K31/485	12	Morphinan derivatives, e.g. morphine, codeine	A61K31/485	A61K31/485		4073
A61K31/49	12	Cinchonan derivatives, e.g. quinine	A61K31/49	A61K31/49		343
A61K31/495	10	having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})	A61K31/495	A61K31/495		5562
A61K31/496	11	Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin	A61K31/496	A61K31/496		11483
A61K31/4965	11	Non-condensed pyrazines	A61K31/4965	A61K31/4965		1613
A61K31/497	12	containing further heterocyclic rings	A61K31/497	A61K31/497		3100
A61K31/498	11	Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine	A61K31/498	A61K31/498		1999
A61K31/4985	11	Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems	A61K31/4985	A61K31/4985		4058
A61K31/499	11	Spiro-condensed pyrazines or piperazines	A61K31/499	A61K31/499		165
A61K31/4995	11	Pyrazines or piperazines forming part of bridged ring systems	A61K31/4995	A61K31/4995		496
A61K31/50	11	Pyridazines; Hydrogenated pyridazines	A61K31/50	A61K31/50		1079
A61K31/501	12	not condensed and containing further heterocyclic rings	A61K31/501	A61K31/501		2034
A61K31/502	12	ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine	A61K31/502	A61K31/502		1394
A61K31/5025	12	ortho- or peri-condensed with heterocyclic ring systems	A61K31/5025	A61K31/5025		1709
A61K31/503	12	spiro-condensed	A61K31/503	A61K31/503		73
A61K31/504	12	forming part of bridged ring systems	A61K31/504	A61K31/504		80
A61K31/505	11	Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim	A61K31/505	A61K31/505		6038
A61K31/506	12	not condensed and containing further heterocyclic rings	A61K31/506	A61K31/506		11509
A61K31/51	13	Thiamines, e.g. vitamin B1	A61K31/51	A61K31/51		2081
A61K31/513	12	having oxo groups directly attached to the heterocyclic ring, e.g. cytosine	A61K31/513	A61K31/513		4551
A61K31/515	13	Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital	A61K31/515	A61K31/515		531
A61K31/517	12	ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine	A61K31/517	A61K31/517		5425
A61K31/519	12	ortho- or peri-condensed with heterocyclic rings	A61K31/519	A61K31/519		16536
A61K31/52	13	Purines, e.g. adenine	A61K31/52	A61K31/52		3523
A61K31/522	14	having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir	A61K31/522	A61K31/522		4481
A61K31/525	13	Isoalloxazines, e.g. riboflavins, vitamin B2	A61K31/525	A61K31/525		2462
A61K31/527	12	spiro-condensed	A61K31/527	A61K31/527		120
A61K31/529	12	forming part of bridged ring systems	A61K31/529	A61K31/529		219
A61K31/53	10	having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555{; with four nitrogen atoms A61K31/495})	A61K31/53	A61K31/53		3368
A61K31/535	10	having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines	A61K31/535	A61K31/535		1328
A61K31/5355	11	Non-condensed oxazines and containing further heterocyclic rings	A61K31/5355	A61K31/5355		393
A61K31/536	11	ortho- or peri-condensed with carbocyclic ring systems	A61K31/536	A61K31/536		454
A61K31/5365	11	ortho- or peri-condensed with heterocyclic ring systems	A61K31/5365	A61K31/5365		651
A61K31/537	11	spiro-condensed or forming part of bridged ring systems	A61K31/537	A61K31/537		415
A61K31/5375	11	1,4-Oxazines, e.g. morpholine	A61K31/5375	A61K31/5375		1594
A61K31/5377	12	not condensed and containing further heterocyclic rings, e.g. timolol	A61K31/5377	A61K31/5377		10462
A61K31/538	12	ortho- or peri-condensed with carbocyclic ring systems	A61K31/538	A61K31/538		983
A61K31/5383	12	ortho- or peri-condensed with heterocyclic ring systems	A61K31/5383	A61K31/5383		1506
A61K31/5386	12	spiro-condensed or forming part of bridged ring systems	A61K31/5386	A61K31/5386		632
A61K31/539	11	having two or more oxygen atoms in the same ring, e.g. dioxazines	A61K31/539	A61K31/539		23
A61K31/5395	11	having two or more nitrogen atoms in the same ring, e.g. oxadiazines	A61K31/5395	A61K31/5395		134
A61K31/54	10	having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame	A61K31/54	A61K31/54		1413
A61K31/541	11	Non-condensed thiazines containing further heterocyclic rings	A61K31/541	A61K31/541		1256
A61K31/5415	11	ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam	A61K31/5415	A61K31/5415		2006
A61K31/542	11	ortho- or peri-condensed with heterocyclic ring systems	A61K31/542	A61K31/542		429
A61K31/545	12	Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:  , e.g. cephalosporins, {cefaclor, or cephalexine}	A61K31/545	A61K31/545		1213
A61K31/546	13	containing further heterocyclic rings, e.g. cephalothin	A61K31/546	A61K31/546		1397
A61K31/547	11	spiro-condensed or forming part of bridged ring systems	A61K31/547	A61K31/547		39
A61K31/548	11	having two or more sulfur atoms in the same ring	A61K31/548	A61K31/548		42
A61K31/549	11	having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide	A61K31/549	A61K31/549		677
A61K31/55	10	having seven-membered rings, e.g. azelastine, pentylenetetrazole	A61K31/55	A61K31/55		7406
A61K31/551	11	having two nitrogen atoms, e.g. dilazep	A61K31/551	A61K31/551		3045
A61K31/5513	12	1,4-Benzodiazepines, e.g. diazepam {or clozapine}	A61K31/5513	A61K31/5513		1713
A61K31/5517	13	condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam	A61K31/5517	A61K31/5517		978
A61K31/553	11	having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine	A61K31/553	A61K31/553		1624
A61K31/554	11	having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem	A61K31/554	A61K31/554		1011
A61K31/5545	10	{having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings}<br><br><u>NOTE</u><br><br>This subgroup does not cover N-containing eight-membered rings which also contain additional condensed and non-condensed nitrogen containing 3-7 membered rings, which are covered by subgroups A61K31/396 - A61K31/554.	A61K31/395	A61K31/554		118
A61K31/555	9	containing heavy metals, e.g. hemin, hematin, melarsoprol	A61K31/555	A61K31/555		3440
A61K31/557	8	Eicosanoids, e.g. leukotrienes {or prostaglandins}	A61K31/557	A61K31/557		1146
A61K31/5575	9	having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha	A61K31/5575	A61K31/5575		1249
A61K31/5578	9	having a pentalene ring system, e.g. carbacyclin, iloprost	A61K31/5578	A61K31/5578		94
A61K31/558	9	having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes	A61K31/558	A61K31/558		89
A61K31/5585	10	having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin	A61K31/5585	A61K31/5585		172
A61K31/559	9	having heterocyclic rings containing hetero atoms other than oxygen	A61K31/559	A61K31/559		71
A61K31/56	8	Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids<br><br><u>NOTE</u><br><br> Attention is drawn to Note (1) following the title of subclass C07J which explains what is covered by the term "steroids" 	A61K31/56	A61K31/56		4922
A61K31/565	9	not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol	A61K31/565	A61K31/565		3060
A61K31/566	10	having an oxo group in position 17, e.g. estrone	A61K31/566	A61K31/566		593
A61K31/567	10	substituted in position 17 alpha, e.g. mestranol, norethandrolone	A61K31/567	A61K31/567		1167
A61K31/568	10	substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone	A61K31/568	A61K31/568		1237
A61K31/5685	11	having an oxo group in position 17, e.g. androsterone	A61K31/5685	A61K31/5685		593
A61K31/569	11	substituted in position 17 alpha, e.g. ethisterone	A61K31/569	A61K31/569		589
A61K31/57	9	substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone	A61K31/57	A61K31/57		3655
A61K31/573	10	substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone	A61K31/573	A61K31/573		6240
A61K31/575	9	substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol	A61K31/575	A61K31/575		4243
A61K31/58	9	containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})	A61K31/58	A61K31/58		4598
A61K31/585	10	containing lactone rings, e.g. oxandrolone, bufalin	A61K31/585	A61K31/585		1370
A61K31/59	8	Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems	A61K31/59	A61K31/59		2291
A61K31/592	9	9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2	A61K31/592	A61K31/592		724
A61K31/593	9	9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3	A61K31/593	A61K31/593		2494
A61K31/60	8	Salicylic acid; Derivatives thereof	A61K31/60	A61K31/60		3274
A61K31/603	9	having further aromatic rings, e.g. diflunisal	A61K31/603	A61K31/603		101
A61K31/606	9	having amino groups	A61K31/606	A61K31/606		450
A61K31/609	9	Amides, e.g. salicylamide {(labetalol, metoclopramide A61K31/166)}	A61K31/609	A61K31/609		241
A61K31/612	9	having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid (fosfosal A61K31/661)	A61K31/612	A61K31/612		15
A61K31/616	10	by carboxylic acids, e.g. acetylsalicylic acid	A61K31/616	A61K31/616		1627
A61K31/618	9	having the carboxyl group in position 1 esterified, e.g. salsalate	A61K31/618	A61K31/618		441
A61K31/621	10	having the hydroxy group in position 2 esterified, e.g. benorylate	A61K31/621	A61K31/621		252
A61K31/625	9	having heterocyclic substituents, e.g. 4-salicycloylmorpholine, (sulfasalazine A61K31/635)	A61K31/625	A61K31/625		93
A61K31/63	8	Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide	A61K31/63	A61K31/63		575
A61K31/635	9	having a heterocyclic ring, e.g.&#160;sulfadiazine	A61K31/635	A61K31/635		2172
A61K31/64	8	Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide	A61K31/64	A61K31/64		930
A61K31/65	8	Tetracyclines	A61K31/65	A61K31/65		2658
A61K31/655	8	Azo (&#8212;N=N&#8212;), diazo (=N2), azoxy (&gt;N&#8212;O&#8212;N&lt; or N(=O)&#8212;N&lt;), azido (&#8212;N3) or diazoamino (&#8212;N=N&#8212;N&lt;) compounds	A61K31/655	A61K31/655		911
A61K31/658	8	{o-phenolic cannabinoids, e.g. cannabidiol,&#160;cannabigerolic acid, cannabichromene&#160;or tetrahydrocannabinol}<br><br><u>WARNING</u><br>Group A61K31/658 is incomplete pending reclassification of documents from groups A61K31/05, A61K31/192 and A61K31/352. <br>All groups listed in this Warning should be considered in order to perform a complete search.	A61K31/00	A61K31/65		3074
A61K31/66	8	Phosphorus compounds	A61K31/66	A61K31/66		1928
A61K31/661	9	Phosphorus acids or esters thereof not having P&#8212;C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}	A61K31/661	A61K31/661		1479
A61K31/6615	10	Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid	A61K31/6615	A61K31/6615		452
A61K31/662	9	Phosphorus acids or esters thereof having P&#8212;C bonds, e.g. foscarnet, trichlorfon	A61K31/662	A61K31/662		829
A61K31/663	10	Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid	A61K31/663	A61K31/663		918
A61K31/664	9	Amides of phosphorus acids	A61K31/664	A61K31/664		338
A61K31/665	9	having oxygen as a ring hetero atom, e.g. fosfomycin	A61K31/665	A61K31/665		655
A61K31/67	9	having sulfur as a ring hetero atom	A61K31/67	A61K31/67		81
A61K31/675	9	having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate	A61K31/675	A61K31/675		5301
A61K31/683	9	Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols	A61K31/683	A61K31/683		598
A61K31/685	10	one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin	A61K31/685	A61K31/685		2529
A61K31/688	10	both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins	A61K31/688	A61K31/688		213
A61K31/69	8	Boron compounds	A61K31/69	A61K31/69		1634
A61K31/695	8	Silicon compounds	A61K31/695	A61K31/695		889
A61K31/70	8	Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)<br><br><u>NOTE</u><br><br> In this group, the expressions are used with the meanings indicated in Note (3) following the title of the subclass C07H	A61K31/70	A61K31/70		6451
A61K31/7004	9	Monosaccharides having only carbon, hydrogen and oxygen atoms	A61K31/7004	A61K31/7004		3045
A61K31/7008	9	Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine	A61K31/7008	A61K31/7008		1372
A61K31/7012	9	Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid (gluconic acid A61K31/191; ascorbic acid A61K31/375)	A61K31/7012	A61K31/7012		615
A61K31/7016	9	Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032)	A61K31/7016	A61K31/7016		3244
A61K31/702	9	Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages	A61K31/702	A61K31/702		3509
A61K31/7024	9	Esters of saccharides	A61K31/7024	A61K31/7024		1485
A61K31/7028	9	Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages	A61K31/7028	A61K31/7028		1092
A61K31/7032	10	attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides	A61K31/7032	A61K31/7032		1127
A61K31/7034	10	attached to a carbocyclic compound, e.g. phloridzin	A61K31/7034	A61K31/7034		1765
A61K31/7036	11	having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins	A61K31/7036	A61K31/7036		1804
A61K31/704	11	attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}	A61K31/704	A61K31/704		10530
A61K31/7042	9	Compounds having saccharide radicals and heterocyclic rings	A61K31/7042	A61K31/7042		373
A61K31/7048	10	having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}	A61K31/7048	A61K31/7048		11478
A61K31/7052	10	having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides	A61K31/7052	A61K31/7052		1114
A61K31/7056	11	containing five-membered rings with nitrogen as a ring hetero atom	A61K31/7056	A61K31/7056		1758
A61K31/706	11	containing six-membered rings with nitrogen as a ring hetero atom	A61K31/706	A61K31/706		2341
A61K31/7064	12	containing condensed or non-condensed pyrimidines	A61K31/7064	A61K31/7064		532
A61K31/7068	13	having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid	A61K31/7068	A61K31/7068		3672
A61K31/7072	14	having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine	A61K31/7072	A61K31/7072		1718
A61K31/7076	13	containing purines, e.g. adenosine, adenylic acid	A61K31/7076	A61K31/7076		3037
A61K31/708	14	having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid	A61K31/708	A61K31/708		631
A61K31/7084	9	Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide	A61K31/7084	A61K31/7084		843
A61K31/7088	9	Compounds having three or more nucleosides or nucleotides	A61K31/7088	A61K31/7088		8221
A61K31/7105	10	Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3&apos;-5&apos; phosphodiester links	A61K31/7105	A61K31/7105		6761
A61K31/711	10	Natural deoxyribonucleic acids, i.e. containing only 2&apos;-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3&apos;-5&apos; phosphodiester links	A61K31/711	A61K31/711		1780
A61K31/7115	10	Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine	A61K31/7115	A61K31/7115		749
A61K31/712	10	Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2&apos;-deoxyribose	A61K31/712	A61K31/712		848
A61K31/7125	10	Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3&apos;-5&apos; phosphodiesters	A61K31/7125	A61K31/7125		1093
A61K31/713	10	Double-stranded nucleic acids or oligonucleotides	A61K31/713	A61K31/713		9076
A61K31/7135	9	Compounds containing heavy metals	A61K31/7135	A61K31/7135		221
A61K31/714	10	Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12	A61K31/714	A61K31/714		2608
A61K31/715	9	Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters	A61K31/715	A61K31/715		8758
A61K31/716	10	Glucans	A61K31/716	A61K31/716		1561
A61K31/717	11	Celluloses	A61K31/717	A61K31/717		863
A61K31/718	11	Starch or degraded starch, e.g. amylose, amylopectin	A61K31/718	A61K31/718		821
A61K31/719	11	Pullulans	A61K31/719	A61K31/719		53
A61K31/721	11	Dextrans	A61K31/721	A61K31/721		384
A61K31/722	11	Chitin, chitosan	A61K31/722	A61K31/722		2566
A61K31/723	11	Xanthans	A61K31/723	A61K31/723		154
A61K31/724	11	Cyclodextrins	A61K31/724	A61K31/724		810
A61K31/726	10	Glycosaminoglycans, i.e. mucopolysaccharides (chondroitin sulfate, dermatan sulfate A61K31/737)	A61K31/726	A61K31/726		623
A61K31/727	11	Heparin; Heparan	A61K31/727	A61K31/727		1554
A61K31/728	11	Hyaluronic acid	A61K31/728	A61K31/728		3631
A61K31/729	10	Agar; Agarose; Agaropectin	A61K31/729	A61K31/729		96
A61K31/731	10	Carrageenans	A61K31/731	A61K31/731		162
A61K31/732	10	Pectin	A61K31/732	A61K31/732		471
A61K31/733	10	Fructosans, e.g. inulin	A61K31/733	A61K31/733		947
A61K31/734	10	Alginic acid	A61K31/734	A61K31/734		691
A61K31/736	10	Glucomannans or galactomannans, e.g. locust bean gum, guar gum	A61K31/736	A61K31/736		437
A61K31/737	10	Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)	A61K31/737	A61K31/737		1870
A61K31/738	10	Cross-linked polysaccharides	A61K31/738	A61K31/738		144
A61K31/739	10	Lipopolysaccharides	A61K31/739	A61K31/739		353
A61K31/74	8	Synthetic polymeric materials	A61K31/74	A61K31/74		720
A61K31/745	9	Polymers of hydrocarbons	A61K31/745	A61K31/745		106
A61K31/75	10	of ethene	A61K31/75	A61K31/75		60
A61K31/755	9	Polymers containing halogen	A61K31/755	A61K31/755		28
A61K31/76	10	of vinyl chloride	A61K31/76	A61K31/76		12
A61K31/765	9	Polymers containing oxygen	A61K31/765	A61K31/765		1287
A61K31/77	10	of oxiranes	A61K31/77	A61K31/77		506
A61K31/775	10	Phenolic resins	A61K31/775	A61K31/775		58
A61K31/78	10	of acrylic acid or derivatives thereof	A61K31/78	A61K31/78		530
A61K31/785	9	Polymers containing nitrogen	A61K31/785	A61K31/785		2185
A61K31/787	10	containing heterocyclic rings having nitrogen as a ring hetero atom	A61K31/787	A61K31/787		367
A61K31/79	11	Polymers of vinyl pyrrolidone	A61K31/79	A61K31/79		571
A61K31/795	9	Polymers containing sulfur	A61K31/795	A61K31/795		395
A61K31/80	9	Polymers containing hetero atoms not provided for in groups A61K31/755&#160;-&#160;A61K31/795	A61K31/80	A61K31/80		642
A61K33/00	7	Medicinal preparations containing inorganic active ingredients	A61K33/00	A61K33/00		8325
A61K33/02	8	Ammonia; Compounds thereof	A61K33/02	A61K33/02		333
A61K33/04	8	Sulfur, selenium or tellurium; Compounds thereof	A61K33/04	A61K33/04		5613
A61K33/06	8	Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}	A61K33/06	A61K33/06		11214
A61K33/08	9	Oxides; Hydroxides	A61K33/08	A61K33/08		1363
A61K33/10	9	Carbonates; Bicarbonates	A61K33/10	A61K33/10		1975
A61K33/12	9	Magnesium silicate	A61K33/12	A61K33/12		1736
A61K33/14	8	Alkali metal chlorides; Alkaline earth metal chlorides	A61K33/14	A61K33/14		4378
A61K33/16	8	Fluorine compounds	A61K33/16	A61K33/16		467
A61K33/18	8	Iodine; Compounds thereof	A61K33/18	A61K33/18		1529
A61K33/20	8	Elemental chlorine; Inorganic compounds releasing chlorine	A61K33/20	A61K33/20		856
A61K33/22	8	Boron compounds	A61K33/22	A61K33/22		1507
A61K33/24	8	Heavy metals; Compounds thereof	A61K33/24	A61K33/24		5427
A61K33/241	9	Lead; Compounds thereof	A61K33/241	A61K33/241		359
A61K33/242	9	Gold; Compounds thereof	A61K33/242	A61K33/242		966
A61K33/243	9	Platinum; Compounds thereof	A61K33/243	A61K33/243		3430
A61K33/244	9	Lanthanides; Compounds thereof (medicinal preparations containing radioactive lanthanides for use in therapy or testing in vivoA61K51/00)	A61K33/244	A61K33/244		619
A61K33/245	9	Bismuth; Compounds thereof	A61K33/245	A61K33/245		413
A61K33/26	9	Iron; Compounds thereof	A61K33/26	A61K33/26		7288
A61K33/28	9	Mercury; Compounds thereof	A61K33/28	A61K33/28		1521
A61K33/30	9	Zinc; Compounds thereof	A61K33/30	A61K33/30		5686
A61K33/32	9	Manganese; Compounds thereof	A61K33/32	A61K33/32		1644
A61K33/34	9	Copper; Compounds thereof	A61K33/34	A61K33/34		2830
A61K33/36	9	Arsenic; Compounds thereof	A61K33/36	A61K33/36		1532
A61K33/38	9	Silver; Compounds thereof	A61K33/38	A61K33/38		2256
A61K33/40	8	Peroxides	A61K33/40	A61K33/40		1267
A61K33/42	8	Phosphorus; Compounds thereof	A61K33/42	A61K33/42		2154
A61K33/44	8	Elemental carbon, e.g. charcoal, carbon black	A61K33/44	A61K33/44		1417
A61K35/00	7	Medicinal preparations containing materials or reaction products thereof with undetermined constitution<br><br><u>NOTE</u><br><br>In this group, classification is made for each active component or material. For each active component or material, classification is then made in the last appropriate place.<br>When classifying in this group, classification is also made in group B01D15/08 insofar as subject matter of general interest relating to chromatography is concerned.	A61K35/00	A61K35/00		949
A61K35/02	8	from inanimate materials (carbon A61K33/44)	A61K35/02	A61K35/02		3303
A61K35/04	9	Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate	A61K35/04	A61K35/04		192
A61K35/06	10	Mineral oils, e.g. paraffinic oils or aromatic oils based on aromatic hydrocarbons	A61K35/06	A61K35/06		217
A61K35/08	9	Mineral waters; Sea water	A61K35/08	A61K35/08		393
A61K35/10	9	Peat; Amber; Turf; Humus	A61K35/10	A61K35/10		1081
A61K2035/11	8	{Medicinal preparations comprising living procariotic cells}	A61K35/00	A61K35/11		362
A61K2035/115	9	{Probiotics}	A61K35/00	A61K35/11		1479
A61K35/12	8	Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)<br><br><u>NOTE</u><br><br>If the cells are characterised, classification is made in the group covering the corresponding tissue or tissue of origin.	A61K35/12	A61K35/12		4438
A61K2035/122	9	{for inducing tolerance or supression of immune responses}	A61K35/12	A61K35/12		684
A61K2035/124	9	{the cells being hematopoietic, bone marrow derived or blood cells}	A61K35/12	A61K35/12		1605
A61K2035/126	9	{Immunoprotecting barriers, e.g. jackets, diffusion chambers}	A61K35/12	A61K35/12		145
A61K2035/128	10	{capsules, e.g. microcapsules}	A61K35/12	A61K35/12		200
A61K35/13	9	Tumour cells, irrespective of tissue of origin (tumour vaccines A61K39/00)	A61K35/13	A61K35/13		575
A61K35/14	9	Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42)	A61K35/14	A61K35/14		1645
A61K35/15	10	Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00)	A61K35/15	A61K35/15		1525
A61K35/16	10	Blood plasma; Blood serum (umbilical cord blood A61K35/51)	A61K35/16	A61K35/16		1784
A61K35/17	10	Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)	A61K35/17	A61K35/17		5588
A61K35/18	10	Erythrocytes (haemoglobin A61K38/42)	A61K35/18	A61K35/18		545
A61K35/19	10	Platelets; Megacaryocytes	A61K35/19	A61K35/19		969
A61K35/20	9	Milk; Whey; Colostrum	A61K35/20	A61K35/20		1814
A61K35/22	9	Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland	A61K35/22	A61K35/22		805
A61K35/24	9	Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid (saliva A61K35/38)	A61K35/24	A61K35/24		1811
A61K35/26	9	Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes	A61K35/26	A61K35/26		420
A61K35/28	9	Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells	A61K35/28	A61K35/28		8425
A61K35/30	9	Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue	A61K35/30	A61K35/30		2143
A61K35/32	9	Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane	A61K35/32	A61K35/32		7741
A61K35/33	9	Fibroblasts	A61K35/33	A61K35/33		615
A61K35/34	9	Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)	A61K35/34	A61K35/34		1473
A61K35/35	9	Fat tissue; Adipocytes; Stromal cells; Connective tissues  (adipose-derived stem cells A61K35/28; collagen A61K38/39)	A61K35/35	A61K35/35		1094
A61K35/36	9	Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells (islets of Langerhans A61K35/39)	A61K35/36	A61K35/36		6878
A61K35/37	9	Digestive system	A61K35/37	A61K35/37		123
A61K35/38	10	Stomach; Intestine; Goblet cells; Oral mucosa; Saliva	A61K35/38	A61K35/38		687
A61K35/39	10	Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)	A61K35/39	A61K35/39		916
A61K35/407	10	Liver; Hepatocytes	A61K35/407	A61K35/407		841
A61K35/413	10	Gall bladder; Bile	A61K35/413	A61K35/413		2493
A61K35/42	9	Respiratory system, e.g. lungs, bronchi or lung cells	A61K35/42	A61K35/42		286
A61K35/44	9	Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells	A61K35/44	A61K35/44		847
A61K35/48	9	Reproductive organs	A61K35/48	A61K35/48		922
A61K35/50	10	Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells	A61K35/50	A61K35/50		2311
A61K35/51	10	Umbilical cord; Umbilical cord blood; Umbilical stem cells	A61K35/51	A61K35/51		1038
A61K35/52	10	Sperm; Prostate; Seminal fluid; Leydig cells of testes	A61K35/52	A61K35/52		359
A61K35/54	10	Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells	A61K35/54	A61K35/54		502
A61K35/545	11	Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells	A61K35/545	A61K35/545		1688
A61K35/55	9	Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands	A61K35/55	A61K35/55		2830
A61K35/56	8	Materials from animals other than mammals	A61K35/56	A61K35/56		250
A61K35/57	9	Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli	A61K35/57	A61K35/57		5723
A61K35/58	9	Reptiles (antigens from snakes A61K39/38)	A61K35/58	A61K35/58		177
A61K35/583	10	Snakes; Lizards, e.g. chameleons (therapeutic use of a snake venom protein A61K38/00)	A61K35/583	A61K35/583		4267
A61K35/586	10	Turtles; Tortoises, e.g. terrapins	A61K35/586	A61K35/586		3557
A61K35/60	9	Fish, e.g. seahorses; Fish eggs	A61K35/60	A61K35/60		3254
A61K35/612	9	Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles	A61K35/612	A61K35/612		604
A61K35/614	9	Cnidaria, e.g. sea anemones, corals, coral animals or jellyfish	A61K35/614	A61K35/614		245
A61K35/616	9	Echinodermata, e.g. starfish, sea cucumbers or sea urchins	A61K35/616	A61K35/616		648
A61K35/618	9	Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs	A61K35/618	A61K35/618		10150
A61K35/62	9	Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia	A61K35/62	A61K35/62		6322
A61K35/63	9	Arthropods (aquatic crustaceans A61K35/612)	A61K35/63	A61K35/63		8424
A61K35/64	10	Insects, e.g. bees, wasps or fleas	A61K35/64	A61K35/64		5681
A61K35/644	11	Beeswax; Propolis; Royal jelly; Honey	A61K35/644	A61K35/644		7180
A61K35/646	10	Arachnids, e.g. spiders, scorpions, ticks or mites	A61K35/646	A61K35/646		3572
A61K35/648	10	Myriapods, e.g. centipedes or millipedes	A61K35/648	A61K35/648		2940
A61K35/65	9	Amphibians, e.g. toads, frogs, salamanders or newts	A61K35/65	A61K35/65		1284
A61K35/655	9	Aquatic animals other than those covered by groups A61K35/57 - A61K35/65	A61K35/655	A61K35/655		126
A61K35/66	8	Microorganisms or materials therefrom (fungi, yeasts or candida A61K36/06)	A61K35/66	A61K35/66		294
A61K35/68	9	Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma	A61K35/68	A61K35/68		158
A61K35/74	9	Bacteria (therapeutic use of a bacterial protein A61K38/00)	A61K35/74	A61K35/74		5262
A61K35/741	10	Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)	A61K35/741	A61K35/741		3341
A61K35/742	11	Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes	A61K35/742	A61K35/742		2992
A61K35/744	11	Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs	A61K35/744	A61K35/744		4230
A61K35/745	12	Bifidobacteria	A61K35/745	A61K35/745		4302
A61K35/747	12	Lactobacilli, e.g. L. acidophilus or L. brevis	A61K35/747	A61K35/747		8728
A61K35/748	10	Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina (algae, microalgae or microphytes A61K36/02)	A61K35/748	A61K35/748		811
A61K35/76	9	Viruses; Subviral particles; Bacteriophages	A61K35/76	A61K35/76		2541
A61K35/761	10	Adenovirus	A61K35/761	A61K35/761		986
A61K35/763	10	Herpes virus	A61K35/763	A61K35/763		417
A61K35/765	10	Reovirus; Rotavirus	A61K35/765	A61K35/765		107
A61K35/766	10	Rhabdovirus, e.g. vesicular stomatitis virus	A61K35/766	A61K35/766		165
A61K35/768	10	Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766	A61K35/768	A61K35/768		782
A61K36/00	7	Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines {(antigens from pollen A61K39/36)}<br><br><u>NOTE</u><br><br>In this group, common names of plants, where given, are presented in brackets following their corresponding Latin names.	A61K36/00	A61K36/00		6231
A61K36/02	8	Algae	A61K36/02	A61K36/02		2306
A61K36/03	9	Phaeophycota or phaeophyta (brown algae), e.g. Fucus	A61K36/03	A61K36/03		3080
A61K36/04	9	Rhodophycota or rhodophyta (red algae), e.g. Porphyra	A61K36/04	A61K36/04		762
A61K36/05	9	Chlorophycota or chlorophyta (green algae), e.g. Chlorella	A61K36/05	A61K36/05		1115
A61K36/06	8	Fungi, e.g. yeasts	A61K36/06	A61K36/06		2734
A61K36/062	9	Ascomycota	A61K36/062	A61K36/062		1419
A61K36/064	10	Saccharomycetales, e.g. baker&apos;s yeast	A61K36/064	A61K36/064		2040
A61K36/066	10	Clavicipitaceae	A61K36/066	A61K36/066		183
A61K36/068	11	Cordyceps	A61K36/068	A61K36/068		3594
A61K36/07	9	Basidiomycota, e.g. Cryptococcus<br><br><u>WARNING</u><br>Group A61K36/07 is impacted by reclassification into groups A61K36/071 and A61K36/078. <br>Groups A61K36/07, A61K36/071 and A61K36/078 should be considered in order to perform a complete search.	A61K36/07	A61K36/07		6848
A61K36/071	10	{Agaricus}<br><br><u>WARNING</u><br>Group A61K36/071 is incomplete pending reclassification of documents from group A61K36/07. <br>Groups A61K36/07 and A61K36/071 should be considered in order to perform a complete search.	A61K36/07	A61K36/07		210
A61K36/074	10	Ganoderma	A61K36/074	A61K36/074		5536
A61K36/076	10	Poria	A61K36/076	A61K36/076		20896
A61K36/078	10	{Psilocybe}<br><br><u>WARNING</u><br>Group A61K36/078 is incomplete pending reclassification of documents from group A61K36/07. <br>Groups A61K36/07 and A61K36/078 should be considered in order to perform a complete search.	A61K36/07	A61K36/07		71
A61K36/09	8	Lichens	A61K36/09	A61K36/09		626
A61K36/10	8	Bryophyta (mosses)	A61K36/10	A61K36/10		527
A61K36/11	8	Pteridophyta or Filicophyta (ferns)	A61K36/11	A61K36/11		8683
A61K36/12	9	Filicopsida or Pteridopsida	A61K36/12	A61K36/12		4157
A61K36/126	10	Drynaria	A61K36/126	A61K36/126		3174
A61K36/13	8	Coniferophyta (gymnosperms)	A61K36/13	A61K36/13		1303
A61K36/14	9	Cupressaceae (Cypress family), e.g. juniper or cypress	A61K36/14	A61K36/14		4955
A61K36/15	9	Pinaceae (Pine family), e.g. pine or cedar	A61K36/15	A61K36/15		4973
A61K36/16	8	Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)	A61K36/16	A61K36/16		3760
A61K36/17	8	Gnetophyta, e.g. Ephedraceae (Mormon-tea family)	A61K36/17	A61K36/17		4671
A61K36/18	8	Magnoliophyta (angiosperms)<br><br><u>WARNING</u><br>Group A61K36/18 is impacted by reclassification into groups A61K36/348, A61K36/3482, A61K36/3486, A61K36/577, A61K36/5775, A61K36/5777 and A61K36/742. <br>All groups listed in this Warning should be considered in order to perform a complete search.	A61K36/18	A61K36/18		219
A61K36/185	9	Magnoliopsida (dicotyledons)<br><br><u>WARNING</u><br>Group A61K36/185 is impacted by reclassification into groups A61K36/348, A61K36/3482, A61K36/3486, A61K36/577, A61K36/5775, A61K36/5777 and A61K36/742. <br>All groups listed in this Warning should be considered in order to perform a complete search.	A61K36/185	A61K36/185		56524
A61K36/19	10	Acanthaceae (Acanthus family)	A61K36/19	A61K36/19		3340
A61K36/195	11	Strobilanthes	A61K36/195	A61K36/195		6617
A61K36/20	10	Aceraceae (Maple family)	A61K36/20	A61K36/20		317
A61K36/21	10	Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth	A61K36/21	A61K36/21		11660
A61K36/22	10	Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak	A61K36/22	A61K36/22		1795
A61K36/23	10	Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin	A61K36/23	A61K36/23		10422
A61K36/232	11	Angelica	A61K36/232	A61K36/232		35229
A61K36/233	11	Bupleurum	A61K36/233	A61K36/233		9466
A61K36/234	11	Cnidium (snowparsley)	A61K36/234	A61K36/234		4118
A61K36/235	11	Foeniculum (fennel)	A61K36/235	A61K36/235		1916
A61K36/236	11	Ligusticum (licorice-root)	A61K36/236	A61K36/236		17116
A61K36/237	11	Notopterygium	A61K36/237	A61K36/237		5019
A61K36/238	11	Saposhnikovia	A61K36/238	A61K36/238		8629
A61K36/24	10	Apocynaceae (Dogbane family), e.g. plumeria or periwinkle	A61K36/24	A61K36/24		3074
A61K36/25	10	Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax	A61K36/25	A61K36/25		3045
A61K36/254	11	Acanthopanax or Eleutherococcus	A61K36/254	A61K36/254		4705
A61K36/258	11	Panax (ginseng)	A61K36/258	A61K36/258		26535
A61K36/26	10	Aristolochiaceae (Birthwort family), e.g. heartleaf	A61K36/26	A61K36/26		83
A61K36/264	11	Aristolochia (Dutchman&apos;s pipe)	A61K36/264	A61K36/264		1830
A61K36/268	11	Asarum (wild ginger)	A61K36/268	A61K36/268		5701
A61K36/27	10	Asclepiadaceae (Milkweed family), e.g. hoya	A61K36/27	A61K36/27		4693
A61K36/28	10	Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea	A61K36/28	A61K36/28		29852
A61K36/282	11	Artemisia, e.g. wormwood or sagebrush	A61K36/282	A61K36/282		13112
A61K36/284	11	Atractylodes	A61K36/284	A61K36/284		19704
A61K36/285	11	Aucklandia	A61K36/285	A61K36/285		6323
A61K36/286	11	Carthamus (distaff thistle)	A61K36/286	A61K36/286		12857
A61K36/287	11	Chrysanthemum, e.g. daisy	A61K36/287	A61K36/287		9952
A61K36/288	11	Taraxacum (dandelion)	A61K36/288	A61K36/288		9302
A61K36/289	11	Vladimiria	A61K36/289	A61K36/289		110
A61K36/29	10	Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple	A61K36/29	A61K36/29		2208
A61K36/296	11	Epimedium	A61K36/296	A61K36/296		5723
A61K36/30	10	Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not	A61K36/30	A61K36/30		4152
A61K36/31	10	Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi	A61K36/31	A61K36/31		9576
A61K36/315	11	Isatis, e.g. Dyer&apos;s woad	A61K36/315	A61K36/315		6764
A61K36/32	10	Burseraceae (Frankincense family)	A61K36/32	A61K36/32		1135
A61K36/324	11	Boswellia, e.g. frankincense	A61K36/324	A61K36/324		7707
A61K36/328	11	Commiphora, e.g. mecca myrrh or balm of Gilead	A61K36/328	A61K36/328		6915
A61K36/33	10	Cactaceae (Cactus family), e.g. pricklypear or Cereus	A61K36/33	A61K36/33		1211
A61K36/34	10	Campanulaceae (Bellflower family)	A61K36/34	A61K36/34		3079
A61K36/342	11	Adenophora	A61K36/342	A61K36/342		1771
A61K36/344	11	Codonopsis	A61K36/344	A61K36/344		10715
A61K36/346	11	Platycodon	A61K36/346	A61K36/346		6054
A61K36/348	10	{Cannabaceae}<br><br><u>WARNING</u><br>Groups A61K36/348, A61K36/3482 and A61K36/3486 are incomplete pending reclassification of documents from groups A61K36/18 and A61K36/185. <br>All groups listed in this Warning should be considered in order to perform a complete search.	A61K36/185	A61K36/34		15
A61K36/3482	11	{Cannabis}	A61K36/185	A61K36/34		1913
A61K36/3486	11	{Humulus}	A61K36/185	A61K36/34		314
A61K36/35	10	Caprifoliaceae (Honeysuckle family)	A61K36/35	A61K36/35		1356
A61K36/355	11	Lonicera (honeysuckle)	A61K36/355	A61K36/355		15304
A61K36/36	10	Caryophyllaceae (Pink family), e.g. babysbreath or soapwort	A61K36/36	A61K36/36		5882
A61K36/37	10	Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree	A61K36/37	A61K36/37		2061
A61K36/38	10	Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort	A61K36/38	A61K36/38		1608
A61K36/39	10	Convolvulaceae (Morning-glory family), e.g. bindweed	A61K36/39	A61K36/39		7487
A61K36/40	10	Cornaceae (Dogwood family)	A61K36/40	A61K36/40		5551
A61K36/41	10	Crassulaceae (Stonecrop family)	A61K36/41	A61K36/41		4099
A61K36/42	10	Cucurbitaceae (Cucumber family)	A61K36/42	A61K36/42		8923
A61K36/424	11	Gynostemma	A61K36/424	A61K36/424		1926
A61K36/428	11	Trichosanthes	A61K36/428	A61K36/428		5115
A61K36/43	10	Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder	A61K36/43	A61K36/43		4030
A61K36/44	10	Ebenaceae (Ebony family), e.g. persimmon	A61K36/44	A61K36/44		932
A61K36/45	10	Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry	A61K36/45	A61K36/45		3474
A61K36/46	10	Eucommiaceae (Eucommia family), e.g. hardy rubber tree	A61K36/46	A61K36/46		8242
A61K36/47	10	Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)	A61K36/47	A61K36/47		9945
A61K36/48	10	Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae	A61K36/48	A61K36/48		24482
A61K36/481	11	Astragalus (milkvetch)	A61K36/481	A61K36/481		24504
A61K36/482	11	Cassia, e.g. golden shower tree	A61K36/482	A61K36/482		5654
A61K36/483	11	Gleditsia (locust)	A61K36/483	A61K36/483		3271
A61K36/484	11	Glycyrrhiza (licorice)	A61K36/484	A61K36/484		35558
A61K36/485	11	Gueldenstaedtia	A61K36/485	A61K36/485		30
A61K36/486	11	Millettia	A61K36/486	A61K36/486		6734
A61K36/487	11	Psoralea	A61K36/487	A61K36/487		3266
A61K36/488	11	Pueraria (kudzu)	A61K36/488	A61K36/488		10047
A61K36/489	11	Sophora, e.g. necklacepod or mamani	A61K36/489	A61K36/489		10126
A61K36/49	10	Fagaceae (Beech family), e.g. oak or chestnut	A61K36/49	A61K36/49		665
A61K36/50	10	Fumariaceae (Fumitory family), e.g. bleeding heart	A61K36/50	A61K36/50		31
A61K36/505	11	Corydalis	A61K36/505	A61K36/505		106
A61K36/51	10	Gentianaceae (Gentian family)	A61K36/51	A61K36/51		2717
A61K36/515	11	Gentiana	A61K36/515	A61K36/515		3758
A61K36/52	10	Juglandaceae (Walnut family)	A61K36/52	A61K36/52		2756
A61K36/53	10	Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender	A61K36/53	A61K36/53		14494
A61K36/532	11	Agastache, e.g. giant hyssop	A61K36/532	A61K36/532		3582
A61K36/533	11	Leonurus (motherwort)	A61K36/533	A61K36/533		4460
A61K36/534	11	Mentha (mint)	A61K36/534	A61K36/534		10485
A61K36/535	11	Perilla (beefsteak plant)	A61K36/535	A61K36/535		5341
A61K36/536	11	Prunella or Brunella (selfheal)	A61K36/536	A61K36/536		4446
A61K36/537	11	Salvia (sage)	A61K36/537	A61K36/537		15470
A61K36/538	11	Schizonepeta	A61K36/538	A61K36/538		4307
A61K36/539	11	Scutellaria (skullcap)	A61K36/539	A61K36/539		13769
A61K36/54	10	Lauraceae (Laurel family), e.g. cinnamon or sassafras	A61K36/54	A61K36/54		21008
A61K36/55	10	Linaceae (Flax family), e.g. Linum	A61K36/55	A61K36/55		995
A61K36/56	10	Loganiaceae (Logania family), e.g. trumpetflower or pinkroot	A61K36/56	A61K36/56		3201
A61K36/57	10	Magnoliaceae (Magnolia family)	A61K36/57	A61K36/57		9593
A61K36/575	11	Magnolia	A61K36/575	A61K36/575		6593
A61K36/577	10	{Malvaceae (Mallow family)}<br><br><u>WARNING</u><br>Groups A61K36/577, A61K36/5775 and A61K36/5777 are incomplete pending reclassification of documents from groups A61K36/18 and A61K36/185. <br>All groups listed in this Warning should be considered in order to perform a complete search.	A61K36/185	A61K36/57		570
A61K36/5775	11	{Hibiscus}	A61K36/185	A61K36/57		208
A61K36/5777	11	{Theobroma, e.g. cocao or cocoa}	A61K36/185	A61K36/57		371
A61K36/58	10	Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)	A61K36/58	A61K36/58		3014
A61K36/59	10	Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead	A61K36/59	A61K36/59		4171
A61K36/60	10	Moraceae (Mulberry family), e.g. breadfruit or fig	A61K36/60	A61K36/60		5687
A61K36/605	11	Morus (mulberry)	A61K36/605	A61K36/605		12901
A61K36/61	10	Myrtaceae (Myrtle family), e.g. teatree or eucalyptus	A61K36/61	A61K36/61		8943
A61K36/62	10	Nymphaeaceae (Water-lily family)	A61K36/62	A61K36/62		8113
A61K36/63	10	Oleaceae (Olive family), e.g. jasmine, lilac or ash tree	A61K36/63	A61K36/63		4205
A61K36/634	11	Forsythia	A61K36/634	A61K36/634		7219
A61K36/638	11	Ligustrum, e.g. Chinese privet	A61K36/638	A61K36/638		4674
A61K36/64	10	Orobanchaceae (Broom-rape family)	A61K36/64	A61K36/64		4650
A61K36/65	10	Paeoniaceae (Peony family), e.g. Chinese peony	A61K36/65	A61K36/65		22302
A61K36/66	10	Papaveraceae (Poppy family), e.g. bloodroot	A61K36/66	A61K36/66		7903
A61K36/67	10	Piperaceae (Pepper family), e.g. Jamaican pepper or kava	A61K36/67	A61K36/67		4143
A61K36/68	10	Plantaginaceae (Plantain Family)	A61K36/68	A61K36/68		5822
A61K36/69	10	Polygalaceae (Milkwort family)	A61K36/69	A61K36/69		4517
A61K36/70	10	Polygonaceae (Buckwheat family), e.g. spineflower or dock	A61K36/70	A61K36/70		3699
A61K36/704	11	Polygonum, e.g. knotweed	A61K36/704	A61K36/704		17269
A61K36/708	11	Rheum (rhubarb)	A61K36/708	A61K36/708		9394
A61K36/71	10	Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal	A61K36/71	A61K36/71		29125
A61K36/714	11	Aconitum (monkshood)	A61K36/714	A61K36/714		8335
A61K36/716	11	Clematis (leather flower)	A61K36/716	A61K36/716		5221
A61K36/718	11	Coptis (goldthread)	A61K36/718	A61K36/718		9082
A61K36/72	10	Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree	A61K36/72	A61K36/72		2135
A61K36/725	11	Ziziphus, e.g. jujube	A61K36/725	A61K36/725		12598
A61K36/73	10	Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn	A61K36/73	A61K36/73		13158
A61K36/732	11	Chaenomeles, e.g. flowering quince	A61K36/732	A61K36/732		3509
A61K36/734	11	Crataegus (hawthorn)	A61K36/734	A61K36/734		9684
A61K36/736	11	Prunus, e.g. plum, cherry, peach, apricot or almond	A61K36/736	A61K36/736		16342
A61K36/738	11	Rosa (rose)	A61K36/738	A61K36/738		6140
A61K36/739	11	Sanguisorba (burnet)	A61K36/739	A61K36/739		2666
A61K36/74	10	Rubiaceae (Madder family)<br><br><u>WARNING</u><br>Group A61K36/74 is impacted by reclassification into group A61K36/742. <br>Groups A61K36/74 and A61K36/742 should be considered in order to perform a complete search.	A61K36/74	A61K36/74		7472
A61K36/742	11	{Coffea, e.g. coffee}<br><br><u>WARNING</u><br>Group A61K36/742 is incomplete pending reclassification of documents from groups A61K36/18, A61K36/185 and A61K36/74. <br>All groups listed in this Warning should be considered in order to perform a complete search.	A61K36/74	A61K36/74		449
A61K36/744	11	Gardenia	A61K36/744	A61K36/744		7051
A61K36/746	11	Morinda	A61K36/746	A61K36/746		3299
A61K36/748	11	Oldenlandia or Hedyotis	A61K36/748	A61K36/748		3492
A61K36/75	10	Rutaceae (Rue family)	A61K36/75	A61K36/75		4744
A61K36/752	11	Citrus, e.g. lime, orange or lemon	A61K36/752	A61K36/752		26235
A61K36/754	11	Evodia	A61K36/754	A61K36/754		2695
A61K36/756	11	Phellodendron, e.g. corktree	A61K36/756	A61K36/756		9165
A61K36/758	11	Zanthoxylum, e.g. pricklyash	A61K36/758	A61K36/758		4830
A61K36/76	10	Salicaceae (Willow family), e.g. poplar	A61K36/76	A61K36/76		1352
A61K36/77	10	Sapindaceae (Soapberry family), e.g. lychee or soapberry	A61K36/77	A61K36/77		5151
A61K36/78	10	Saururaceae (Lizard&apos;s-tail family)	A61K36/78	A61K36/78		5174
A61K36/79	10	Schisandraceae (Schisandra family)	A61K36/79	A61K36/79		8481
A61K36/80	10	Scrophulariaceae (Figwort family)	A61K36/80	A61K36/80		3101
A61K36/804	11	Rehmannia	A61K36/804	A61K36/804		17376
A61K36/808	11	Scrophularia (figwort)	A61K36/808	A61K36/808		4398
A61K36/81	10	Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed	A61K36/81	A61K36/81		6073
A61K36/815	11	Lycium (desert-thorn)	A61K36/815	A61K36/815		17108
A61K36/82	10	Theaceae (Tea family), e.g. camellia	A61K36/82	A61K36/82		7566
A61K36/83	10	Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo	A61K36/83	A61K36/83		1261
A61K36/835	11	Aquilaria	A61K36/835	A61K36/835		2105
A61K36/84	10	Valerianaceae (Valerian family), e.g. valerian	A61K36/84	A61K36/84		2635
A61K36/85	10	Verbenaceae (Verbena family)	A61K36/85	A61K36/85		4206
A61K36/855	11	Clerodendrum, e.g. glorybower	A61K36/855	A61K36/855		2596
A61K36/86	10	Violaceae (Violet family)	A61K36/86	A61K36/86		2654
A61K36/87	10	Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine	A61K36/87	A61K36/87		5942
A61K36/88	9	Liliopsida (monocotyledons)	A61K36/88	A61K36/88		11496
A61K36/882	10	Acoraceae (Calamus family), e.g. sweetflag or Acorus calamus	A61K36/882	A61K36/882		400
A61K36/884	10	Alismataceae (Water-plantain family)	A61K36/884	A61K36/884		5408
A61K36/886	10	Aloeaceae (Aloe family), e.g. aloe vera	A61K36/886	A61K36/886		4083
A61K36/888	10	Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage	A61K36/888	A61K36/888		7528
A61K36/8884	11	Arisaema, e.g. Jack in the pulpit	A61K36/8884	A61K36/8884		2990
A61K36/8888	11	Pinellia	A61K36/8888	A61K36/8888		7281
A61K36/889	10	Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto	A61K36/889	A61K36/889		7133
A61K36/8895	11	Calamus, e.g. rattan	A61K36/8895	A61K36/8895		14
A61K36/89	10	Cyperaceae (Sedge family)	A61K36/89	A61K36/89		838
A61K36/8905	11	Cyperus (flatsedge)	A61K36/8905	A61K36/8905		5668
A61K36/894	10	Dioscoreaceae (Yam family)	A61K36/894	A61K36/894		73
A61K36/8945	11	Dioscorea, e.g. yam, Chinese yam or water yam	A61K36/8945	A61K36/8945		13013
A61K36/896	10	Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus	A61K36/896	A61K36/896		13419
A61K36/8962	11	Allium, e.g. garden onion, leek, garlic or chives	A61K36/8962	A61K36/8962		5472
A61K36/8964	11	Anemarrhena	A61K36/8964	A61K36/8964		4405
A61K36/8965	11	Asparagus, e.g. garden asparagus or asparagus fern	A61K36/8965	A61K36/8965		2298
A61K36/8966	11	Fritillaria, e.g. checker lily or mission bells	A61K36/8966	A61K36/8966		4308
A61K36/8967	11	Lilium, e.g. tiger lily or Easter lily	A61K36/8967	A61K36/8967		4263
A61K36/8968	11	Ophiopogon (Lilyturf)	A61K36/8968	A61K36/8968		7823
A61K36/8969	11	Polygonatum (Solomon&apos;s seal)	A61K36/8969	A61K36/8969		9476
A61K36/898	10	Orchidaceae (Orchid family)	A61K36/898	A61K36/898		7144
A61K36/8984	11	Dendrobium	A61K36/8984	A61K36/8984		4883
A61K36/8988	11	Gastrodia	A61K36/8988	A61K36/8988		4284
A61K36/899	10	Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane	A61K36/899	A61K36/899		20876
A61K36/8994	11	Coix (Job&apos;s tears)	A61K36/8994	A61K36/8994		7114
A61K36/8998	11	Hordeum (barley)	A61K36/8998	A61K36/8998		3938
A61K36/90	10	Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla	A61K36/90	A61K36/90		3452
A61K36/902	10	Sparganiaceae (Bur-reed family)	A61K36/902	A61K36/902		2444
A61K36/904	10	Stemonaceae (Stemona family), e.g. croomia	A61K36/904	A61K36/904		2320
A61K36/906	10	Zingiberaceae (Ginger family)	A61K36/906	A61K36/906		1283
A61K36/9062	11	Alpinia, e.g. red ginger or galangal	A61K36/9062	A61K36/9062		3936
A61K36/9064	11	Amomum, e.g. round cardamom	A61K36/9064	A61K36/9064		5476
A61K36/9066	11	Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger	A61K36/9066	A61K36/9066		12387
A61K36/9068	11	Zingiber, e.g. garden ginger	A61K36/9068	A61K36/9068		13644
A61K38/00	7	Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)<br><br><u>NOTE</u><br><br> The terms or expressions used in this group follow exactly the definitions given in Note (1) following the title of subclass C07K. <br> Preparations containing fragments of peptides or peptides modified by removal or addition of amino acids, by substitution of amino acids by others, or by combination of these modifications are classified as the preparations containing parent peptides. However, preparations containing fragments of peptides having only four or less amino acids are also classified in groups A61K38/05&#160;-&#160;A61K38/07. <br>Preparations containing peptides prepared by recombinant DNA technology are not classified according to the host, but according to the original peptide expressed, e.g. preparations containing HIV peptide expressed in E. coli are classified with the preparations containing HIV peptides.<br>This group covers also medicinal preparation containing DNA or RNA encoding for peptides as active ingredient.<br> Documents relating to new peptides, e.g. enzymes, or new DNA or RNA encoding for peptides and their use in medicinal preparations are classified in subclass C07K or in group C12N9/00 according to the peptides, with the appropriate indexing codes relating to their medical uses. 	A61K38/00	A61K38/00		66958
A61K38/005	8	{Enzyme inhibitors (protease inhibitors A61K38/55)}	A61K38/00	A61K38/00		631
A61K38/01	8	Hydrolysed proteins; Derivatives thereof	A61K38/01	A61K38/01		496
A61K38/011	9	{from plants}	A61K38/01	A61K38/01		1205
A61K38/012	9	{from animals}	A61K38/01	A61K38/01		1304
A61K38/014	10	{from connective tissue peptides, e.g. gelatin, collagen}	A61K38/01	A61K38/01		592
A61K38/015	11	{from keratin}	A61K38/01	A61K38/01		100
A61K38/017	10	{from blood}	A61K38/01	A61K38/01		86
A61K38/018	10	{from milk}	A61K38/01	A61K38/01		622
A61K38/02	8	Peptides of undefined number of amino acids; Derivatives thereof	A61K38/02	A61K38/02		1912
A61K38/03	8	Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof	A61K38/03	A61K38/03		299
A61K38/04	8	Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34{; protease inhibitors A61K38/55})	A61K38/04	A61K38/04		977
A61K38/043	9	{Kallidins; Bradykinins; Related peptides}	A61K38/04	A61K38/04		82
A61K38/046	9	{Tachykinins, e.g. eledoisins, substance P; Related peptides}	A61K38/04	A61K38/04		109
A61K38/05	9	Dipeptides	A61K38/05	A61K38/05		2456
A61K38/06	9	Tripeptides	A61K38/06	A61K38/06		2116
A61K38/063	10	{Glutathione}	A61K38/06	A61K38/06		981
A61K38/066	10	{TRH, thyroliberin, thyrotropin releasing hormone}	A61K38/06	A61K38/06		75
A61K38/07	9	Tetrapeptides	A61K38/07	A61K38/07		1817
A61K38/08	9	Peptides having 5 to 11 amino acids {(A61K38/043&#160;-&#160;A61K38/046 take precedence)}	A61K38/08	A61K38/08		4933
A61K38/085	10	{Angiotensins}	A61K38/08	A61K38/08		223
A61K38/09	10	Luteinising hormone-releasing hormone [LHRH] {, i.e. Gonadotropin-releasing hormone [GnRH]}; Related peptides	A61K38/09	A61K38/09		877
A61K38/095	10	Oxytocins; Vasopressins; Related peptides	A61K38/095	A61K38/095		622
A61K38/10	9	Peptides having 12 to 20 amino acids {(A61K38/043&#160;-&#160;A61K38/046 take precedence)}	A61K38/10	A61K38/10		3333
A61K38/105	10	{Bombesin; Related peptides}	A61K38/10	A61K38/10		42
A61K38/12	9	Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043&#160;-&#160;A61K38/046 take precedence)}	A61K38/12	A61K38/12		2756
A61K38/13	10	Cyclosporins	A61K38/13	A61K38/13		1876
A61K38/14	9	Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}	A61K38/14	A61K38/14		1326
A61K38/15	9	Depsipeptides; Derivatives thereof	A61K38/15	A61K38/15		351
A61K38/16	8	Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}	A61K38/16	A61K38/16		3779
A61K38/162	9	{from virus}	A61K38/16	A61K38/16		913
A61K38/164	9	{from bacteria}	A61K38/16	A61K38/16		1781
A61K38/166	10	{Streptokinase}	A61K38/16	A61K38/16		167
A61K38/168	9	{from plants}	A61K38/16	A61K38/16		965
A61K38/17	9	from animals; from humans {(enzyme inhibitors A61K38/005)}	A61K38/17	A61K38/17		3461
A61K38/1703	10	{from vertebrates}	A61K38/17	A61K38/17		620
A61K38/1706	11	{from fish}	A61K38/17	A61K38/17		172
A61K38/1709	11	{from mammals}	A61K38/17	A61K38/17		8271
A61K38/1716	12	{Amyloid plaque core protein}	A61K38/17	A61K38/17		105
A61K38/1719	12	{Muscle proteins, e.g. myosin or actin}	A61K38/17	A61K38/17		97
A61K38/1722	12	{Plasma globulins, lactoglobulins}	A61K38/17	A61K38/17		116
A61K38/1725	12	{Complement proteins, e.g. anaphylatoxin, C3a or C5a}	A61K38/17	A61K38/17		113
A61K38/1729	12	{Cationic antimicrobial peptides, e.g. defensins}	A61K38/17	A61K38/17		252
A61K38/1732	12	{Lectins}	A61K38/17	A61K38/17		131
A61K38/1735	12	{Mucins, e.g. human intestinal mucin}	A61K38/17	A61K38/17		84
A61K38/1738	12	{Calcium binding proteins, e.g. calmodulin}	A61K38/17	A61K38/17		86
A61K38/1741	12	{alpha-Glycoproteins}	A61K38/17	A61K38/17		74
A61K38/1745	12	{C-reactive proteins}	A61K38/17	A61K38/17		9
A61K38/1748	12	{Keratin; Cytokeratin}	A61K38/17	A61K38/17		77
A61K38/1751	12	{Bactericidal/permeability-increasing protein [BPI]}	A61K38/17	A61K38/17		69
A61K38/1754	12	{Insulin-like growth factor binding proteins}	A61K38/17	A61K38/17		87
A61K38/1758	12	{p53}	A61K38/17	A61K38/17		102
A61K38/1761	12	{Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2}	A61K38/17	A61K38/17		243
A61K38/1767	10	{from invertebrates}	A61K38/17	A61K38/17		912
A61K38/177	10	{Receptors; Cell surface antigens; Cell surface determinants}	A61K38/17	A61K38/17		1932
A61K38/1774	11	{Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}	A61K38/17	A61K38/17		1329
A61K38/1777	11	{Integrin superfamily}	A61K38/17	A61K38/17		74
A61K38/178	11	{Lectin superfamily, e.g. selectins}	A61K38/17	A61K38/17		119
A61K38/1783	11	{Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors}	A61K38/17	A61K38/17		47
A61K38/1787	11	{for neuromediators, e.g. serotonin receptor, dopamine receptor}	A61K38/17	A61K38/17		101
A61K38/179	11	{for growth factors; for growth regulators}	A61K38/17	A61K38/17		764
A61K38/1793	11	{for cytokines; for lymphokines; for interferons}	A61K38/17	A61K38/17		1037
A61K38/1796	11	{for hormones (for neuromediators A61K38/1787)}	A61K38/17	A61K38/17		227
A61K38/18	10	Growth factors; Growth regulators	A61K38/18	A61K38/18		2266
A61K38/1808	11	{Epidermal growth factor [EGF] urogastrone}	A61K38/18	A61K38/18		1031
A61K38/1816	11	{Erythropoietin [EPO]}	A61K38/18	A61K38/18		747
A61K38/1825	11	{Fibroblast growth factor [FGF]}	A61K38/18	A61K38/18		1636
A61K38/1833	11	{Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}	A61K38/18	A61K38/18		393
A61K38/1841	11	{Transforming growth factor [TGF]}	A61K38/18	A61K38/18		1153
A61K38/185	11	{Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3}	A61K38/18	A61K38/18		906
A61K38/1858	11	{Platelet-derived growth factor [PDGF]}	A61K38/18	A61K38/18		622
A61K38/1866	12	{Vascular endothelial growth factor [VEGF]}	A61K38/18	A61K38/18		1034
A61K38/1875	11	{Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor}	A61K38/18	A61K38/18		997
A61K38/1883	11	{Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor}	A61K38/18	A61K38/18		133
A61K38/1891	11	{Angiogenesic factors; Angiogenin}	A61K38/18	A61K38/18		236
A61K38/19	10	Cytokines; Lymphokines; Interferons	A61K38/19	A61K38/19		1354
A61K38/191	11	{Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}	A61K38/19	A61K38/19		1063
A61K38/193	11	{Colony stimulating factors [CSF]}	A61K38/19	A61K38/19		1541
A61K38/195	11	{Chemokines, e.g. RANTES}	A61K38/19	A61K38/19		679
A61K38/196	11	{Thrombopoietin}	A61K38/19	A61K38/19		105
A61K38/20	11	Interleukins [IL]	A61K38/20	A61K38/20		1530
A61K38/2006	12	{IL-1}	A61K38/20	A61K38/20		478
A61K38/2013	12	{IL-2}	A61K38/20	A61K38/20		1484
A61K38/202	12	{IL-3}	A61K38/20	A61K38/20		93
A61K38/2026	12	{IL-4}	A61K38/20	A61K38/20		344
A61K38/2033	12	{IL-5}	A61K38/20	A61K38/20		43
A61K38/204	12	{IL-6}	A61K38/20	A61K38/20		404
A61K38/2046	12	{IL-7}	A61K38/20	A61K38/20		222
A61K38/2053	12	{IL-8}	A61K38/20	A61K38/20		133
A61K38/206	12	{IL-9}	A61K38/20	A61K38/20		31
A61K38/2066	12	{IL-10}	A61K38/20	A61K38/20		498
A61K38/2073	12	{IL-11}	A61K38/20	A61K38/20		86
A61K38/208	12	{IL-12}	A61K38/20	A61K38/20		706
A61K38/2086	12	{IL-13 to IL-16}	A61K38/20	A61K38/20		664
A61K38/2093	12	{Leukaemia inhibitory factor [LIF]}	A61K38/20	A61K38/20		67
A61K38/21	11	Interferons {[IFN]}	A61K38/21	A61K38/21		1663
A61K38/212	12	{IFN-alpha}	A61K38/21	A61K38/21		1425
A61K38/215	12	{IFN-beta}	A61K38/21	A61K38/21		649
A61K38/217	12	{IFN-gamma}	A61K38/21	A61K38/21		860
A61K38/22	10	Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)	A61K38/22	A61K38/22		1570
A61K38/2207	11	{Gastrins; Cholecystokinins [CCK]}	A61K38/22	A61K38/22		110
A61K38/2214	11	{Motilins}	A61K38/22	A61K38/22		19
A61K38/2221	11	{Relaxins}	A61K38/22	A61K38/22		153
A61K38/2228	11	{Corticotropin releasing factor [CRF] (Urotensin)}	A61K38/22	A61K38/22		73
A61K38/2235	11	{Secretins}	A61K38/22	A61K38/22		67
A61K38/2242	11	{Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin}	A61K38/22	A61K38/22		225
A61K38/225	11	{Calcitonin gene related peptide}	A61K38/22	A61K38/22		109
A61K38/2257	11	{Prolactin}	A61K38/22	A61K38/22		87
A61K38/2264	11	{Obesity-gene products, e.g. leptin}	A61K38/22	A61K38/22		282
A61K38/2271	11	{Neuropeptide Y}	A61K38/22	A61K38/22		88
A61K38/2278	11	{Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)}	A61K38/22	A61K38/22		345
A61K38/2285	11	{Endothelin, vasoactive intestinal contractor [VIC]}	A61K38/22	A61K38/22		32
A61K38/2292	11	{Thymosin; Related peptides}	A61K38/22	A61K38/22		264
A61K38/23	11	Calcitonins	A61K38/23	A61K38/23		446
A61K38/24	11	Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]	A61K38/24	A61K38/24		796
A61K38/25	11	Growth hormone-releasing factor [GH-RF], i.e. somatoliberin	A61K38/25	A61K38/25		335
A61K38/26	11	Glucagons	A61K38/26	A61K38/26		2402
A61K38/27	11	Growth hormone [GH], i.e. somatotropin	A61K38/27	A61K38/27		1050
A61K38/28	11	Insulins	A61K38/28	A61K38/28		3352
A61K38/29	11	Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides	A61K38/29	A61K38/29		593
A61K38/30	11	Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)}	A61K38/30	A61K38/30		937
A61K38/31	11	Somatostatins	A61K38/31	A61K38/31		392
A61K38/32	11	Thymopoietins	A61K38/32	A61K38/32		27
A61K38/33	10	derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin	A61K38/33	A61K38/33		166
A61K38/34	11	Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin	A61K38/34	A61K38/34		179
A61K38/35	11	Corticotropin [ACTH]	A61K38/35	A61K38/35		232
A61K38/36	10	Blood coagulation or fibrinolysis factors	A61K38/36	A61K38/36		548
A61K38/363	11	{Fibrinogen}	A61K38/36	A61K38/36		489
A61K38/366	11	{Thrombomodulin}	A61K38/36	A61K38/36		65
A61K38/37	11	Factors VIII	A61K38/37	A61K38/37		504
A61K38/38	10	Albumins	A61K38/38	A61K38/38		963
A61K38/385	11	{Serum albumin}	A61K38/38	A61K38/38		502
A61K38/39	10	Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]	A61K38/39	A61K38/39		3327
A61K38/395	10	{Alveolar surfactant peptides; Pulmonary surfactant peptides}	A61K38/17	A61K38/39		78
A61K38/40	10	Transferrins, e.g. lactoferrins, ovotransferrins	A61K38/40	A61K38/40		977
A61K38/41	9	Porphyrin- or corrin-ring-containing peptides	A61K38/41	A61K38/41		90
A61K38/415	10	{Cytochromes}	A61K38/41	A61K38/41		54
A61K38/42	10	Haemoglobins; Myoglobins	A61K38/42	A61K38/42		564
A61K38/43	9	Enzymes; Proenzymes; Derivatives thereof<br><br><u>NOTE</u><br><br> In this group, <br>proenzymes are classified with the corresponding enzymes; <br>enzymes are generally categorised according to the "Nomenclature and Classification of Enzymes" of the International Commission of Enzymes. Where appropriate, this designation appears in the subgroups below in parenthesis. <br>the specific enzyme(s) used are additionally classified in C12Y. 	A61K38/43	A61K38/43		646
A61K38/44	10	Oxidoreductases (1)	A61K38/44	A61K38/44		1442
A61K38/443	11	{acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)}	A61K38/44	A61K38/44		720
A61K38/446	11	{Superoxide dismutase (1.15)}	A61K38/44	A61K38/44		682
A61K38/45	10	Transferases (2)	A61K38/45	A61K38/45		1800
A61K38/46	10	Hydrolases (3)	A61K38/46	A61K38/46		749
A61K38/465	11	{acting on ester bonds (3.1), e.g. lipases, ribonucleases}	A61K38/46	A61K38/46		2458
A61K38/47	11	acting on glycosyl compounds (3.2), e.g. cellulases, lactases	A61K38/47	A61K38/47		2646
A61K38/48	11	acting on peptide bonds (3.4)	A61K38/48	A61K38/48		989
A61K38/4806	12	{from animals other than mammals, e.g. snakes}	A61K38/48	A61K38/48		45
A61K38/4813	12	{Exopeptidases (3.4.11. to 3.4.19)}	A61K38/48	A61K38/48		291
A61K38/482	12	{Serine endopeptidases (3.4.21)}	A61K38/48	A61K38/48		726
A61K38/4826	13	{Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)}	A61K38/48	A61K38/48		352
A61K38/4833	13	{Thrombin (3.4.21.5)}	A61K38/48	A61K38/48		529
A61K38/484	13	{Plasmin (3.4.21.7)}	A61K38/48	A61K38/48		259
A61K38/4846	13	{Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}	A61K38/48	A61K38/48		531
A61K38/4853	13	{Kallikrein (3.4.21.34 or 3.4.21.35)}	A61K38/48	A61K38/48		95
A61K38/486	13	{Elastase (3.4.21.36 or 3.4.21.37)}	A61K38/48	A61K38/48		55
A61K38/4866	13	{Protein C (3.4.21.69)}	A61K38/48	A61K38/48		129
A61K38/4873	12	{Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H}	A61K38/48	A61K38/48		717
A61K38/488	12	{Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E}	A61K38/48	A61K38/48		174
A61K38/4886	12	{Metalloendopeptidases (3.4.24), e.g. collagenase}	A61K38/48	A61K38/48		747
A61K38/4893	13	{Botulinum neurotoxin (3.4.24.69)}	A61K38/48	A61K38/48		814
A61K38/49	12	Urokinase; Tissue plasminogen activator	A61K38/49	A61K38/49		667
A61K38/50	11	acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase	A61K38/50	A61K38/50		670
A61K38/51	10	Lyases (4)	A61K38/51	A61K38/51		590
A61K38/52	10	Isomerases (5)	A61K38/52	A61K38/52		168
A61K38/53	10	Ligases (6)	A61K38/53	A61K38/53		258
A61K38/54	10	Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44&#160;-&#160;A61K38/46 or A61K38/51&#160;-&#160;A61K38/53	A61K38/54	A61K38/54		272
A61K38/55	9	Protease inhibitors	A61K38/55	A61K38/55		802
A61K38/553	10	{Renin inhibitors}	A61K38/55	A61K38/55		50
A61K38/556	10	{Angiotensin converting enzyme inhibitors}	A61K38/55	A61K38/55		272
A61K38/56	10	from plants	A61K38/56	A61K38/56		102
A61K38/57	10	from animals; from humans {(A61K38/553, A61K38/556 take precedence)}	A61K38/57	A61K38/57		1226
A61K38/58	11	from leeches, e.g. hirudin, eglin	A61K38/58	A61K38/58		261
A61K39/00	7	Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)<br><br><u>NOTE</u><br><br> Groups A61K39/002&#160;-&#160;A61K39/295 cover preparations containing protozoa, bacteria, viruses, or subunits thereof, e.g. membrane parts. <br> Preparation of antigen or antibody compositions is also classified in subclass C12N, if the step of cultivating the microorganism is of interest. <br> Documents relating to new peptides, e.g. enzymes, or new DNA or RNA encoding for peptides and their use in medicinal preparations are classified in subclass C07K or in group C12N9/00 according to the peptides, with the appropriate indexing codes relating to their medical uses. <br> Documents relating to antibodies or DNA or RNA encoding for antibodies and their use in medicinal preparations are classified in group C07K16/00 or in group C12N9/0002 according to the antibodies, with the appropriate indexing codes relating to their medical uses. <br> Documents relating to new therapeutical uses of antibodies or DNA or RNA encoding for antibodies are classified in group C07K16/00 or in group C12N9/0002 according to the antibodies, with the appropriate indexing codes relating to their medical uses. <br> Documents relating to medicinal preparations containing different antibodies as active ingredients are classified in group C07K16/00 according to the different active antibodies, with the appropriate indexing codes relating to their medical uses. However, documents relating to medicinal preparations containing antibodies and other compounds as active ingredients are classified in groups A61K39/395&#160;-&#160;A61K39/42, in association with symbol A61K2300/00 in Combination Sets. 	A61K39/00	A61K39/00		14280
A61K39/0001	8	{Archaeal antigens}	A61K39/00	A61K39/00		19
A61K39/0002	8	{Fungal antigens, e.g. Trichophyton, Aspergillus, Candida}	A61K39/00	A61K39/00		296
A61K39/0003	8	{Invertebrate antigens}	A61K39/00	A61K39/00		379
A61K39/0005	8	{Vertebrate antigens (from snakes A61K39/38)}	A61K39/00	A61K39/00		1114
A61K39/0006	9	{Contraceptive vaccins; Vaccines against sex hormones}	A61K39/00	A61K39/00		223
A61K39/0007	9	{Nervous system antigens; Prions}	A61K39/00	A61K39/00		393
A61K39/0008	9	{Antigens related to auto-immune diseases; Preparations to induce self-tolerance}	A61K39/00	A61K39/00		1293
A61K39/001	9	{Preparations to induce tolerance to non-self, e.g. prior to transplantation}	A61K39/00	A61K39/00		482
A61K39/0011	9	{Cancer antigens}	A61K39/00	A61K39/00		4877
A61K39/001102	10	{Receptors, cell surface antigens or cell surface determinants}	A61K39/00	A61K39/00		523
A61K39/001103	11	{Receptors for growth factors}	A61K39/00	A61K39/00		59
A61K39/001104	12	{Epidermal growth factor receptors [EGFR]}	A61K39/00	A61K39/00		197
A61K39/001106	12	{Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4}	A61K39/00	A61K39/00		420
A61K39/001107	12	{Fibroblast growth factor receptors [FGFR]}	A61K39/00	A61K39/00		14
A61K39/001108	12	{Platelet-derived growth factor receptors [PDGFR]}	A61K39/00	A61K39/00		17
A61K39/001109	12	{Vascular endothelial growth factor receptors [VEGFR]}	A61K39/00	A61K39/00		74
A61K39/00111	12	{Hepatocyte growth factor receptor [HGFR or c-met]}	A61K39/00	A61K39/00		28
A61K39/001111	11	{Immunoglobulin superfamily}	A61K39/00	A61K39/00		442
A61K39/001112	12	{CD19 or B4}	A61K39/00	A61K39/00		288
A61K39/001113	12	{CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2}	A61K39/00	A61K39/00		73
A61K39/001114	12	{CD74, Ii, MHC class II invariant chain or MHC class II gamma chain}	A61K39/00	A61K39/00		69
A61K39/001116	11	{Receptors for cytokines}	A61K39/00	A61K39/00		13
A61K39/001117	12	{Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30}	A61K39/00	A61K39/00		130
A61K39/001118	12	{Receptors for colony stimulating factors [CSF]}	A61K39/00	A61K39/00		11
A61K39/001119	12	{Receptors for interleukins [IL]}	A61K39/00	A61K39/00		95
A61K39/00112	12	{Receptors for interferons [IFN]}	A61K39/00	A61K39/00		4
A61K39/001121	12	{Receptors for chemokines}	A61K39/00	A61K39/00		27
A61K39/001122	11	{Ephrin Receptors [Eph]}	A61K39/00	A61K39/00		39
A61K39/001124	11	{CD20}	A61K39/00	A61K39/00		86
A61K39/001126	11	{CD38 not IgG}	A61K39/00	A61K39/00		27
A61K39/001128	11	{CD44 not IgG}	A61K39/00	A61K39/00		32
A61K39/001129	11	{Molecules with a "CD" designation not provided for elsewhere}	A61K39/00	A61K39/00		267
A61K39/00113	10	{Growth factors}	A61K39/00	A61K39/00		34
A61K39/001131	11	{Epidermal growth factor [EGF]}	A61K39/00	A61K39/00		31
A61K39/001132	11	{Fibroblast growth factors [FGF]}	A61K39/00	A61K39/00		18
A61K39/001133	11	{Platelet-derived growth factor [PDGF]}	A61K39/00	A61K39/00		4
A61K39/001134	11	{Transforming growth factor [TGF]}	A61K39/00	A61K39/00		44
A61K39/001135	11	{Vascular endothelial growth factor [VEGF]}	A61K39/00	A61K39/00		56
A61K39/001136	10	{Cytokines}	A61K39/00	A61K39/00		32
A61K39/001138	11	{Tumor necrosis factors [TNF] or CD70}	A61K39/00	A61K39/00		47
A61K39/001139	11	{Colony stimulating factors [CSF]}	A61K39/00	A61K39/00		54
A61K39/00114	11	{Interleukins [IL]}	A61K39/00	A61K39/00		137
A61K39/001141	11	{Interferons [IFN]}	A61K39/00	A61K39/00		32
A61K39/001142	11	{Chemokines}	A61K39/00	A61K39/00		24
A61K39/001144	10	{Hormones, e.g. calcitonin}	A61K39/00	A61K39/00		45
A61K39/001148	10	{Regulators of development}	A61K39/00	A61K39/00		14
A61K39/001149	11	{Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR}	A61K39/00	A61K39/00		50
A61K39/00115	11	{Apoptosis related proteins, e.g. survivin or livin}	A61K39/00	A61K39/00		118
A61K39/001151	12	{p53}	A61K39/00	A61K39/00		155
A61K39/001152	10	{Transcription factors, e.g. SOX or c-MYC}	A61K39/00	A61K39/00		102
A61K39/001153	11	{Wilms tumor 1 [WT1]}	A61K39/00	A61K39/00		155
A61K39/001154	10	{Enzymes}	A61K39/00	A61K39/00		119
A61K39/001156	11	{Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]}	A61K39/00	A61K39/00		216
A61K39/001157	11	{Telomerase or TERT [telomerase reverse transcriptase]}	A61K39/00	A61K39/00		127
A61K39/001158	11	{Proteinases}	A61K39/00	A61K39/00		29
A61K39/001159	12	{Matrix metalloproteinases [MMP]}	A61K39/00	A61K39/00		19
A61K39/00116	12	{Serine proteases, e.g. kallikrein}	A61K39/00	A61K39/00		22
A61K39/001161	12	{Caspases}	A61K39/00	A61K39/00		15
A61K39/001162	11	{Kinases, e.g. Raf or Src}	A61K39/00	A61K39/00		126
A61K39/001163	11	{Phosphatases}	A61K39/00	A61K39/00		22
A61K39/001164	11	{GTPases, e.g. Ras or Rho}	A61K39/00	A61K39/00		163
A61K39/001166	10	{Adhesion molecules, e.g. NRCAM, EpCAM or cadherins}	A61K39/00	A61K39/00		102
A61K39/001168	11	{Mesothelin [MSLN]}	A61K39/00	A61K39/00		126
A61K39/001169	10	{Tumor associated carbohydrates}	A61K39/00	A61K39/00		71
A61K39/00117	11	{Mucins, e.g. MUC-1}	A61K39/00	A61K39/00		282
A61K39/001171	11	{Gangliosides, e.g. GM2, GD2 or GD3}	A61K39/00	A61K39/00		110
A61K39/001172	11	{Sialyl-Thomson-nouvelle antigen [sTn]}	A61K39/00	A61K39/00		36
A61K39/001173	11	{Globo-H}	A61K39/00	A61K39/00		27
A61K39/001174	10	{Proteoglycans, e.g. glypican, brevican or CSPG4}	A61K39/00	A61K39/00		64
A61K39/001176	10	{Heat shock proteins}	A61K39/00	A61K39/00		83
A61K39/001178	10	{Tumor rejection antigen precursor [TRAP]}	A61K39/00	A61K39/00		7
A61K39/00118	10	{from embryonic or fetal origin}	A61K39/00	A61K39/00		44
A61K39/001181	11	{Alpha-feto protein}	A61K39/00	A61K39/00		50
A61K39/001182	11	{Carcinoembryonic antigen [CEA]}	A61K39/00	A61K39/00		257
A61K39/001184	10	{Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE}	A61K39/00	A61K39/00		166
A61K39/001186	11	{MAGE}	A61K39/00	A61K39/00		318
A61K39/001188	11	{NY-ESO}	A61K39/00	A61K39/00		220
A61K39/001189	11	{PRAME}	A61K39/00	A61K39/00		102
A61K39/00119	10	{Melanoma antigens}	A61K39/00	A61K39/00		192
A61K39/001191	11	{Melan-A/MART}	A61K39/00	A61K39/00		169
A61K39/001192	11	{Glycoprotein 100 [Gp100]}	A61K39/00	A61K39/00		191
A61K39/001193	10	{Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR}	A61K39/00	A61K39/00		163
A61K39/001194	11	{Prostate specific antigen [PSA]}	A61K39/00	A61K39/00		172
A61K39/001195	11	{Prostate specific membrane antigen [PSMA]}	A61K39/00	A61K39/00		154
A61K39/001196	10	{Fusion proteins originating from gene translocation in cancer cells}	A61K39/00	A61K39/00		22
A61K39/001197	11	{Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]}	A61K39/00	A61K39/00		46
A61K39/001198	11	{Pml-RARalpha}	A61K39/00	A61K39/00		2
A61K39/0012	9	{Lipids; Lipoproteins}	A61K39/00	A61K39/00		90
A61K39/0013	8	{Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine}	A61K39/00	A61K39/00		114
A61K39/0015	8	{Combination vaccines based on measles-mumps-rubella}	A61K39/00	A61K39/00		34
A61K39/0016	8	{Combination vaccines based on diphtheria-tetanus-pertussis}	A61K39/00	A61K39/00		51
A61K39/0017	9	{Combination vaccines based on whole cell diphtheria-tetanus-pertussis}	A61K39/00	A61K39/00		16
A61K39/0018	9	{Combination vaccines based on acellular diphtheria-tetanus-pertussis}	A61K39/00	A61K39/00		63
A61K39/002	8	Protozoa antigens	A61K39/002	A61K39/002		380
A61K39/005	9	Trypanosoma antigens	A61K39/005	A61K39/005		90
A61K39/008	9	Leishmania antigens	A61K39/008	A61K39/008		157
A61K39/012	9	Coccidia antigens	A61K39/012	A61K39/012		233
A61K39/015	9	Hemosporidia antigens, e.g. Plasmodium antigens	A61K39/015	A61K39/015		589
A61K39/018	10	Babesia antigens, e.g. Theileria antigens	A61K39/018	A61K39/018		55
A61K39/02	8	Bacterial antigens	A61K39/02	A61K39/02		1041
A61K39/0208	9	{Specific bacteria not otherwise provided for}	A61K39/02	A61K39/02		563
A61K39/0216	9	{Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas}	A61K39/02	A61K39/02		118
A61K39/0225	9	{Spirochetes, e.g. Treponema, Leptospira, Borrelia}	A61K39/02	A61K39/02		273
A61K39/0233	9	{Rickettsiales, e.g. Anaplasma}	A61K39/02	A61K39/02		111
A61K39/0241	9	{Mollicutes, e.g. Mycoplasma, Erysipelothrix}	A61K39/02	A61K39/02		411
A61K39/025	9	{Enterobacteriales, e.g. Enterobacter}	A61K39/02	A61K39/02		192
A61K39/0258	10	{Escherichia}	A61K39/108	A61K39/02		690
A61K39/0266	10	{Klebsiella}	A61K39/108	A61K39/02		131
A61K39/0275	10	{Salmonella}	A61K39/112	A61K39/02		665
A61K39/0283	10	{Shigella}	A61K39/112	A61K39/02		148
A61K39/0291	10	{Yersinia}	A61K39/02	A61K39/02		72
A61K39/04	9	Mycobacterium, e.g. Mycobacterium tuberculosis	A61K39/04	A61K39/04		1145
A61K39/05	9	{Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella}, Corynebacterium; Propionibacterium {(Mycobacterium A61K39/04)}	A61K39/05	A61K39/05		394
A61K39/07	9	Bacillus	A61K39/07	A61K39/07		339
A61K39/08	9	Clostridium, e.g. Clostridium tetani	A61K39/08	A61K39/08		830
A61K39/085	9	Staphylococcus	A61K39/085	A61K39/085		606
A61K39/09	9	{Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus}, streptococcus	A61K39/09	A61K39/09		330
A61K39/092	10	{Streptococcus}	A61K39/09	A61K39/09		1254
A61K39/095	9	Neisseria	A61K39/095	A61K39/095		732
A61K39/098	9	{Brucella}	A61K39/02	A61K39/09		183
A61K39/099	9	{Bordetella}	A61K39/02	A61K39/09		375
A61K2039/10	9	{Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups}	A61K39/10	A61K39/10		48
A61K39/102	9	{Pasteurellales, e.g. Actinobacillus}, Pasteurella; Haemophilus	A61K39/102	A61K39/102		821
A61K39/104	9	{Pseudomonadales, e.g.} Pseudomonas	A61K39/104	A61K39/104		335
A61K39/1045	10	{Moraxella}	A61K39/104	A61K39/104		76
A61K39/105	9	{Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter}	A61K39/02	A61K39/10		278
A61K2039/106	9	{Vibrio; Campylobacter; Not used, see subgroups}	A61K39/106	A61K39/106		24
A61K39/107	9	{Vibrio}	A61K39/02	A61K39/10		299
A61K39/114	9	Fusobacterium	A61K39/114	A61K39/114		47
A61K39/116	9	Polyvalent bacterial antigens	A61K39/116	A61K39/116		138
A61K39/118	8	Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci	A61K39/118	A61K39/118		193
A61K39/12	8	Viral antigens	A61K39/12	A61K39/12		17142
A61K39/125	9	Picornaviridae, e.g. calicivirus	A61K39/125	A61K39/125		210
A61K39/13	10	Poliovirus	A61K39/13	A61K39/13		251
A61K39/135	10	Foot- and mouth-disease virus	A61K39/135	A61K39/135		240
A61K39/145	9	Orthomyxoviridae, e.g. influenza virus	A61K39/145	A61K39/145		2239
A61K39/15	9	Reoviridae, e.g. calf diarrhea virus	A61K39/15	A61K39/15		251
A61K39/155	9	Paramyxoviridae, e.g. parainfluenza virus	A61K39/155	A61K39/155		615
A61K39/165	10	Mumps or measles virus	A61K39/165	A61K39/165		196
A61K39/17	10	Newcastle disease virus	A61K39/17	A61K39/17		187
A61K39/175	10	Canine distemper virus	A61K39/175	A61K39/175		94
A61K39/187	9	Hog cholera virus	A61K39/187	A61K39/187		84
A61K39/193	9	Equine encephalomyelitis virus	A61K39/193	A61K39/193		23
A61K39/20	9	Rubella virus	A61K39/20	A61K39/20		80
A61K39/205	9	Rhabdoviridae, e.g. rabies virus	A61K39/205	A61K39/205		309
A61K39/21	9	Retroviridae, e.g. equine infectious anemia virus	A61K39/21	A61K39/21		1374
A61K39/215	9	Coronaviridae, e.g. avian infectious bronchitis virus	A61K39/215	A61K39/215		1691
A61K39/225	10	Porcine transmissible gastroenteritis virus	A61K39/225	A61K39/225		68
A61K39/23	9	Parvoviridae, e.g. feline panleukopenia virus	A61K39/23	A61K39/23		132
A61K39/235	9	Adenoviridae	A61K39/235	A61K39/235		215
A61K39/245	9	Herpetoviridae, e.g. herpes simplex virus	A61K39/245	A61K39/245		840
A61K39/25	10	Varicella-zoster virus	A61K39/25	A61K39/25		161
A61K39/255	10	Marek&apos;s disease virus	A61K39/255	A61K39/255		75
A61K39/265	10	Infectious rhinotracheitis virus	A61K39/265	A61K39/265		89
A61K39/27	10	Equine rhinopneumonitis virus	A61K39/27	A61K39/27		25
A61K39/275	9	Poxviridae, e.g. avipoxvirus	A61K39/275	A61K39/275		153
A61K39/285	10	Vaccinia virus or variola virus	A61K39/285	A61K39/285		219
A61K39/29	9	Hepatitis virus	A61K39/29	A61K39/29		617
A61K39/292	10	{Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen}	A61K39/29	A61K39/29		554
A61K39/295	9	Polyvalent viral antigens (vaccinia virus or variola virus A61K39/285); Mixtures of viral and bacterial antigens	A61K39/295	A61K39/295		305
A61K39/35	8	Allergens	A61K39/35	A61K39/35		996
A61K39/36	9	from pollen	A61K39/36	A61K39/36		339
A61K39/38	8	Antigens from snakes	A61K39/38	A61K39/38		39
A61K39/385	8	Haptens or antigens, bound to carriers	A61K39/385	A61K39/385		2381
A61K39/39	8	characterised by the immunostimulating additives, e.g. chemical adjuvants	A61K39/39	A61K39/39		9061
A61K39/395	8	Antibodies (agglutinins A61K38/36{; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum	A61K39/395	A61K39/395		9540
A61K39/39508	9	{from milk, i.e. lactoglobulins}	A61K39/395	A61K39/395		51
A61K39/39516	9	{from serum, plasma}	A61K39/395	A61K39/395		114
A61K39/39525	10	{Purification}	A61K39/395	A61K39/395		62
A61K39/39533	9	{against materials from animals}	A61K39/395	A61K39/395		589
A61K39/39541	10	{against normal tissues, cells}	A61K39/395	A61K39/395		1209
A61K39/3955	10	{against proteinaceous materials, e.g. enzymes, hormones, lymphokines}	A61K39/395	A61K39/395		8570
A61K39/39558	10	{against tumor tissues, cells, antigens}	A61K39/395	A61K39/395		4167
A61K39/39566	10	{against immunoglobulins, e.g. anti-idiotypic antibodies}	A61K39/395	A61K39/395		256
A61K39/39575	9	{against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants}	A61K39/395	A61K39/395		99
A61K39/39583	9	{against materials not provided for elsewhere, e.g. haptens, coenzymes}	A61K39/395	A61K39/395		92
A61K39/39591	9	{Stabilisation, fragmentation}	A61K39/395	A61K39/395		1492
A61K39/40	9	bacterial	A61K39/40	A61K39/40		442
A61K39/42	9	viral	A61K39/42	A61K39/42		893
A61K39/44	9	Antibodies bound to carriers	A61K39/44	A61K39/44		396
A61K2039/505	8	{comprising antibodies}	A61K39/00	A61K39/505		32202
A61K2039/507	9	{Comprising a combination of two or more separate antibodies}	A61K39/00	A61K39/507		3717
A61K2039/51	8	{comprising whole cells, viruses or DNA/RNA}	A61K39/00	A61K39/51		723
A61K2039/515	9	{Animal cells}	A61K39/00	A61K39/515		328
A61K2039/5152	10	{Tumor cells}	A61K39/00	A61K39/515		514
A61K2039/5154	10	{Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}	A61K39/00	A61K39/515		959
A61K2039/5156	10	{expressing foreign proteins}	A61K39/00	A61K39/515		1524
A61K2039/5158	10	{Antigen-pulsed cells, e.g. T-cells}	A61K39/00	A61K39/515		1308
A61K2039/517	9	{Plant cells}	A61K39/00	A61K39/517		79
A61K2039/52	9	{Bacterial cells; Fungal cells; Protozoal cells}	A61K39/00	A61K39/52		295
A61K2039/521	10	{inactivated (killed)}	A61K39/00	A61K39/52		1101
A61K2039/522	10	{avirulent or attenuated}	A61K39/00	A61K39/52		1475
A61K2039/523	10	{expressing foreign proteins}	A61K39/00	A61K39/52		1182
A61K2039/525	9	{Virus}	A61K39/00	A61K39/525		748
A61K2039/5252	10	{inactivated (killed)}	A61K39/00	A61K39/525		2518
A61K2039/5254	10	{avirulent or attenuated}	A61K39/00	A61K39/525		2751
A61K2039/5256	10	{expressing foreign proteins}	A61K39/00	A61K39/525		2738
A61K2039/5258	10	{Virus-like particles}	A61K39/00	A61K39/525		1743
A61K2039/53	9	{DNA (RNA) vaccination}	A61K39/00	A61K39/53		6703
A61K2039/54	8	{characterised by the route of administration}	A61K39/00	A61K39/54		4430
A61K2039/541	9	{Mucosal route}	A61K39/00	A61K39/54		640
A61K2039/542	10	{oral/gastrointestinal}	A61K39/00	A61K39/54		1560
A61K2039/543	10	{intranasal}	A61K39/00	A61K39/54		1612
A61K2039/544	10	{to the airways}	A61K39/00	A61K39/54		291
A61K2039/545	8	{characterised by the dose, timing or administration schedule}	A61K39/00	A61K39/545		7905
A61K2039/55	8	{characterised by the host/recipient, e.g. newborn with maternal antibodies}	A61K39/00	A61K39/55		1157
A61K2039/552	9	{Veterinary vaccine}	A61K39/00	A61K39/55		6282
A61K2039/555	8	{characterised by a specific combination antigen/adjuvant}	A61K39/00	A61K39/555		329
A61K2039/55505	9	{Inorganic adjuvants}	A61K39/00	A61K39/555		3108
A61K2039/55511	9	{Organic adjuvants}	A61K39/00	A61K39/555		2069
A61K2039/55516	10	{Proteins; Peptides}	A61K39/00	A61K39/555		1855
A61K2039/55522	10	{Cytokines; Lymphokines; Interferons}	A61K39/00	A61K39/555		927
A61K2039/55527	11	{Interleukins}	A61K39/00	A61K39/555		381
A61K2039/55533	12	{IL-2}	A61K39/00	A61K39/555		301
A61K2039/55538	12	{IL-12}	A61K39/00	A61K39/555		231
A61K2039/55544	10	{Bacterial toxins}	A61K39/00	A61K39/555		594
A61K2039/5555	10	{Muramyl dipeptides}	A61K39/00	A61K39/555		181
A61K2039/55555	10	{Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}	A61K39/00	A61K39/555		3406
A61K2039/55561	10	{CpG containing adjuvants; Oligonucleotide containing adjuvants}	A61K39/00	A61K39/555		2114
A61K2039/55566	10	{Emulsions, e.g. Freund&apos;s adjuvant, MF59}	A61K39/00	A61K39/555		2679
A61K2039/55572	10	{Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}	A61K39/00	A61K39/555		1109
A61K2039/55577	10	{Saponins; Quil A; QS21; ISCOMS}	A61K39/00	A61K39/555		994
A61K2039/55583	10	{Polysaccharides}	A61K39/00	A61K39/555		892
A61K2039/55588	9	{Adjuvants of undefined constitution}	A61K39/00	A61K39/555		410
A61K2039/55594	10	{from bacteria}	A61K39/00	A61K39/555		552
A61K2039/57	8	{characterised by the type of response, e.g. Th1, Th2}	A61K39/00	A61K39/57		2544
A61K2039/572	9	{cytotoxic response}	A61K39/00	A61K39/57		1868
A61K2039/575	9	{humoral response}	A61K39/00	A61K39/57		3092
A61K2039/577	9	{tolerising response}	A61K39/00	A61K39/57		441
A61K2039/58	8	{raising an immune response against a target which is not the antigen used for immunisation}	A61K39/00	A61K39/58		608
A61K2039/585	9	{wherein the target is cancer}	A61K39/00	A61K39/58		1355
A61K2039/60	8	{characteristics by the carrier linked to the antigen}	A61K39/00	A61K39/60		365
A61K2039/6006	9	{Cells}	A61K39/00	A61K39/60		146
A61K2039/6012	9	{Haptens, e.g. di- or trinitrophenyl (DNP, TNP)}	A61K39/00	A61K39/60		94
A61K2039/6018	9	{Lipids, e.g. in lipopeptides}	A61K39/00	A61K39/60		432
A61K2039/6025	9	{Nucleotides}	A61K39/00	A61K39/60		98
A61K2039/6031	9	{Proteins}	A61K39/00	A61K39/60		1064
A61K2039/6037	10	{Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}	A61K39/00	A61K39/60		1247
A61K2039/6043	10	{Heat shock proteins}	A61K39/00	A61K39/60		169
A61K2039/605	10	{MHC molecules or ligands thereof}	A61K39/00	A61K39/60		321
A61K2039/6056	10	{Antibodies}	A61K39/00	A61K39/60		387
A61K2039/6062	10	{Muramyl peptides}	A61K39/00	A61K39/60		15
A61K2039/6068	10	{Other bacterial proteins, e.g. OMP}	A61K39/00	A61K39/60		600
A61K2039/6075	10	{Viral proteins}	A61K39/00	A61K39/60		504
A61K2039/6081	10	{Albumin; Keyhole limpet haemocyanin [KLH]}	A61K39/00	A61K39/60		655
A61K2039/6087	9	{Polysaccharides; Lipopolysaccharides [LPS]}	A61K39/00	A61K39/60		304
A61K2039/6093	9	{Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine}	A61K39/00	A61K39/60		459
A61K2039/62	8	{characterised by the link between antigen and carrier}	A61K39/00	A61K39/62		153
A61K2039/622	9	{non-covalent binding}	A61K39/00	A61K39/62		190
A61K2039/625	9	{binding through the biotin-streptavidin system or similar}	A61K39/00	A61K39/62		89
A61K2039/627	9	{characterised by the linker}	A61K39/00	A61K39/62		632
A61K2039/64	8	{characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units}	A61K39/00	A61K39/64		373
A61K2039/645	9	{Dendrimers; Multiple antigen peptides}	A61K39/00	A61K39/64		221
A61K2039/70	8	{Multivalent vaccine}	A61K39/00	A61K39/70		4147
A61K2039/80	8	{Vaccine for a specifically defined cancer}	A61K39/00	A61K2039/80		329
A61K2039/804	9	{Blood cells [leukemia, lymphoma]}	A61K39/00	A61K2039/804		411
A61K2039/812	9	{Breast}	A61K39/00	A61K2039/812		268
A61K2039/82	9	{Colon}	A61K39/00	A61K2039/82		202
A61K2039/828	9	{Stomach}	A61K39/00	A61K2039/828		86
A61K2039/836	9	{Intestine}	A61K39/00	A61K2039/836		46
A61K2039/844	9	{Liver}	A61K39/00	A61K2039/844		129
A61K2039/852	9	{Pancreas}	A61K39/00	A61K2039/852		145
A61K2039/86	9	{Lung}	A61K39/00	A61K2039/86		224
A61K2039/868	9	{kidney}	A61K39/00	A61K2039/868		55
A61K2039/876	9	{Skin, melanoma}	A61K39/00	A61K2039/876		354
A61K2039/884	9	{prostate}	A61K39/00	A61K2039/884		139
A61K2039/892	9	{Reproductive system [uterus, ovaries, cervix, testes]}	A61K39/00	A61K2039/892		204
A61K40/00	7	Cellular immunotherapy (medicinal preparations containing antigens or antibodies A61K39/00)<br><br><u>NOTE</u><br><br>This group covers isolated cells of the immune system presenting or targeting a specific antigen or a mix of antigens for use in therapy.<br>In this main group, the last place priority rule is not applied, i.e. the common rule is applied.<br>In this group, C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of A61K40/00.	A61K40/00	A61K40/00		240
A61K40/10	8	characterised by the cell type used	A61K40/10	A61K40/10		1008
A61K40/11	9	T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells	A61K40/11	A61K40/11		9137
A61K40/13	9	B-cells	A61K40/13	A61K40/13		337
A61K40/15	9	Natural-killer [NK] cells; Natural-killer T [NKT] cells	A61K40/15	A61K40/15		1834
A61K40/17	9	Monocytes; Macrophages	A61K40/17	A61K40/17		581
A61K40/19	9	Dendritic cells	A61K40/19	A61K40/19		1649
A61K40/20	8	characterised by the effect or the function of the cells	A61K40/20	A61K40/20		54
A61K40/22	9	Immunosuppressive or immunotolerising	A61K40/22	A61K40/22		1452
A61K40/24	9	Antigen-presenting cells [APC]	A61K40/24	A61K40/24		2130
A61K40/30	8	characterised by the recombinant expression of specific molecules in the cells of the immune system	A61K40/30	A61K40/30		456
A61K40/31	9	Chimeric antigen receptors [CAR]	A61K40/31	A61K40/31		5857
A61K40/32	9	T-cell receptors [TCR]	A61K40/32	A61K40/32		1791
A61K40/33	9	Antibodies; T-cell engagers	A61K40/33	A61K40/33		212
A61K40/34	9	Antigenic peptides	A61K40/34	A61K40/34		209
A61K40/35	9	Cytokines	A61K40/35	A61K40/35		445
A61K40/36	9	Immune checkpoint inhibitors	A61K40/36	A61K40/36		177
A61K40/40	8	characterised by antigens that are targeted or presented by cells of the immune system	A61K40/40	A61K40/40		238
A61K40/405	9	{Invertebrates antigens}	A61K40/40	A61K40/40		16
A61K40/41	9	Vertebrate antigens	A61K40/41	A61K40/41		138
A61K40/412	10	{Contraceptive or sex hormones}	A61K40/41	A61K40/41		7
A61K40/414	10	{Nervous system antigens}	A61K40/41	A61K40/41		160
A61K40/416	10	{Antigens related to auto-immune diseases; Preparations to induce self-tolerance}	A61K40/41	A61K40/41		920
A61K40/418	10	{Antigens related to induction of tolerance to non-self}	A61K40/41	A61K40/41		595
A61K40/42	10	Cancer antigens	A61K40/42	A61K40/42		2833
A61K40/4201	11	{Neoantigens}	A61K40/42	A61K40/42		254
A61K40/4202	11	{Receptors, cell surface antigens or cell surface determinants}	A61K40/42	A61K40/42		966
A61K40/4203	12	{Receptors for growth factors}	A61K40/42	A61K40/42		59
A61K40/4204	13	{Epidermal growth factor receptors [EGFR]}	A61K40/42	A61K40/42		367
A61K40/4205	13	{Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}	A61K40/42	A61K40/42		598
A61K40/4206	13	{Fibroblast growth factor receptors [FGFR]}	A61K40/42	A61K40/42		12
A61K40/4207	13	{Platelet-derived growth factor receptors [PDGFR]}	A61K40/42	A61K40/42		9
A61K40/4208	13	{Vascular endothelial growth factor receptors [VEGFR]}	A61K40/42	A61K40/42		20
A61K40/4209	13	{Hepatocyte growth factor receptor [HGFR] or c-met]}	A61K40/42	A61K40/42		18
A61K40/421	12	{Immunoglobulin superfamily}	A61K40/42	A61K40/42		808
A61K40/4211	13	{CD19 or B4}	A61K40/42	A61K40/42		2256
A61K40/4212	13	{CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2}	A61K40/42	A61K40/42		224
A61K40/4213	13	{CD74, Ii, MHC class II invariant chain or MHC class II gamma chain}	A61K40/42	A61K40/42		52
A61K40/4214	12	{Receptors for cytokines}	A61K40/42	A61K40/42		40
A61K40/4215	13	{Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}	A61K40/42	A61K40/42		665
A61K40/4216	13	{Receptors for colony stimulating factors [CSF]}	A61K40/42	A61K40/42		11
A61K40/4217	13	{Receptors for interleukins [IL]}	A61K40/42	A61K40/42		260
A61K40/4218	13	{Receptors for interferons [IFN]}	A61K40/42	A61K40/42		6
A61K40/4219	13	{Receptors for chemokines}	A61K40/42	A61K40/42		76
A61K40/422	12	{Ephrin Receptors [Eph]}	A61K40/42	A61K40/42		45
A61K40/4221	12	{CD20}	A61K40/42	A61K40/42		314
A61K40/4222	12	{CD38 not IgG}	A61K40/42	A61K40/42		62
A61K40/4223	12	{CD44 not IgG}	A61K40/42	A61K40/42		25
A61K40/4224	12	{Molecules with a "CD" designation not provided for elsewhere}	A61K40/42	A61K40/42		692
A61K40/4225	11	{Growth factors}	A61K40/42	A61K40/42		15
A61K40/4226	12	{Epidermal growth factor [EGF]}	A61K40/42	A61K40/42		12
A61K40/4227	12	{Fibroblast growth factors [FGF]}	A61K40/42	A61K40/42		4
A61K40/4228	12	{Platelet-derived growth factor [PDGF]}	A61K40/42	A61K40/42		6
A61K40/4229	12	{Transforming growth factor [TGF]}	A61K40/42	A61K40/42		60
A61K40/423	12	{Vascular endothelial growth factor [VEGF]}	A61K40/42	A61K40/42		15
A61K40/4231	11	{Cytokines}	A61K40/42	A61K40/42		16
A61K40/4232	12	{Tumor necrosis factors [TNF] or CD70}	A61K40/42	A61K40/42		157
A61K40/4233	12	{Colony stimulating factors [CSF]}	A61K40/42	A61K40/42		14
A61K40/4234	12	{Interleukins [IL]}	A61K40/42	A61K40/42		160
A61K40/4235	12	{Interferons [IFN]}	A61K40/42	A61K40/42		39
A61K40/4236	12	{Chemokines}	A61K40/42	A61K40/42		32
A61K40/4237	11	{Hormones, e.g. calcitonin}	A61K40/42	A61K40/42		18
A61K40/4238	11	{Regulators of development}	A61K40/42	A61K40/42		9
A61K40/4239	12	{Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR}	A61K40/42	A61K40/42		26
A61K40/424	12	{Apoptosis related proteins, e.g. survivin or livin}	A61K40/42	A61K40/42		65
A61K40/4241	13	{p53}	A61K40/42	A61K40/42		51
A61K40/4242	11	{Transcription factors, e.g. SOX or c-MYC}	A61K40/42	A61K40/42		108
A61K40/4243	12	{Wilms tumor 1 [WT1]}	A61K40/42	A61K40/42		176
A61K40/4244	11	{Enzymes}	A61K40/42	A61K40/42		141
A61K40/4245	12	{Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]}	A61K40/42	A61K40/42		106
A61K40/4246	12	{Telomerase or [telomerase reverse transcriptase [TERT]}	A61K40/42	A61K40/42		59
A61K40/4247	12	{Proteinases}	A61K40/42	A61K40/42		22
A61K40/4248	13	{Matrix metalloproteinases [MMP]}	A61K40/42	A61K40/42		9
A61K40/4249	13	{Serine proteases, e.g. kallikrein}	A61K40/42	A61K40/42		38
A61K40/425	13	{Caspases}	A61K40/42	A61K40/42		7
A61K40/4251	12	{Kinases, e.g. Raf or Src}	A61K40/42	A61K40/42		95
A61K40/4252	12	{Phosphatases}	A61K40/42	A61K40/42		47
A61K40/4253	12	{GTPases, e.g. Ras or Rho}	A61K40/42	A61K40/42		107
A61K40/4254	11	{Adhesion molecules, e.g. NRCAM, EpCAM or cadherins}	A61K40/42	A61K40/42		183
A61K40/4255	12	{Mesothelin [MSLN]}	A61K40/42	A61K40/42		370
A61K40/4256	11	{Tumor associated carbohydrates}	A61K40/42	A61K40/42		19
A61K40/4257	12	{Mucins, e.g. MUC-1}	A61K40/42	A61K40/42		227
A61K40/4258	12	{Gangliosides, e.g. GM2, GD2 or GD3}	A61K40/42	A61K40/42		157
A61K40/4259	12	{Sialyl-Thomson-nouvelle antigen [sTn]}	A61K40/42	A61K40/42		10
A61K40/426	12	{Globo-H}	A61K40/42	A61K40/42		3
A61K40/4261	11	{Proteoglycans, e.g. glypican, brevican or CSPG4}	A61K40/42	A61K40/42		246
A61K40/4262	11	{Heat shock proteins}	A61K40/42	A61K40/42		55
A61K40/4263	11	{Tumor rejection antigen precursor [TRAP]}	A61K40/42	A61K40/42		
A61K40/4264	11	{from embryonic or fetal origin}	A61K40/42	A61K40/42		17
A61K40/4265	12	{Alpha-feto protein}	A61K40/42	A61K40/42		42
A61K40/4266	12	{Carcinoembryonic antigen [CEA]}	A61K40/42	A61K40/42		188
A61K40/4267	11	{Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE}	A61K40/42	A61K40/42		56
A61K40/4268	12	{MAGE}	A61K40/42	A61K40/42		238
A61K40/4269	12	{NY-ESO}	A61K40/42	A61K40/42		296
A61K40/427	12	{PRAME}	A61K40/42	A61K40/42		79
A61K40/4271	11	{Melanoma antigens}	A61K40/42	A61K40/42		243
A61K40/4272	12	{Melan-A/MART}	A61K40/42	A61K40/42		223
A61K40/4273	12	{Glycoprotein 100 [Gp100]}	A61K40/42	A61K40/42		226
A61K40/4274	11	{Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]}	A61K40/42	A61K40/42		101
A61K40/4275	12	{Prostate specific antigen [PSA]}	A61K40/42	A61K40/42		74
A61K40/4276	12	{Prostate specific membrane antigen [PSMA]}	A61K40/42	A61K40/42		146
A61K40/4277	11	{Fusion proteins originating from gene translocation in cancer cells}	A61K40/42	A61K40/42		16
A61K40/4278	12	{Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]}	A61K40/42	A61K40/42		1
A61K40/4279	12	{Pml-RARalpha}	A61K40/42	A61K40/42		
A61K40/428	11	{Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor}	A61K40/42	A61K40/42		565
A61K40/4285	10	{Lipids; Lipoproteins}	A61K40/41	A61K40/42		24
A61K40/429	9	{Small organic molecules e.g. cocaine or nicotine}	A61K40/40	A61K40/42		32
A61K40/43	9	Protozoan antigens	A61K40/43	A61K40/43		9
A61K40/432	10	{Trypanosoma antigens}	A61K40/43	A61K40/43		2
A61K40/434	10	{Leishmania antigens}	A61K40/43	A61K40/43		4
A61K40/436	10	{Coccidia antigens}	A61K40/43	A61K40/43		
A61K40/438	10	{Hemosporidia antigens, e.g. Plasmodium antigens}	A61K40/43	A61K40/43		14
A61K40/4385	11	{Babesia antigens, e.g. Theileria antigens}	A61K40/43	A61K40/43		1
A61K40/44	9	Fungal antigens	A61K40/44	A61K40/44		37
A61K40/45	9	Bacterial antigens	A61K40/45	A61K40/45		80
A61K40/4512	10	{Bacteriodetes, e.g. Bacteroides, Ornithobacter or Porphyromonas}	A61K40/45	A61K40/45		6
A61K40/4514	10	{Spirochetes, e.g. Treponema, Leptospira or Borrelia}	A61K40/45	A61K40/45		2
A61K40/4516	10	{Rickettsiales, e.g. Anaplasma}	A61K40/45	A61K40/45		
A61K40/4518	10	{Mollicutes, e.g. Mycoplasma or Erysipelothrix}	A61K40/45	A61K40/45		
A61K40/452	10	{Enterobacteriales, e.g. Enterobacter}	A61K40/45	A61K40/45		1
A61K40/4522	11	{Yersinia}	A61K40/45	A61K40/45		
A61K40/4524	10	{Mycobacterium, e.g. Mycobacterium tuberculosis}	A61K40/45	A61K40/45		38
A61K40/4526	10	{Corynebacterium or Propionibacterium, Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium or Gardnerella}	A61K40/45	A61K40/45		8
A61K40/4528	10	{Bacillus}	A61K40/45	A61K40/45		9
A61K40/453	10	{Clostridium, e.g. Clostridium tetani}	A61K40/45	A61K40/45		41
A61K40/4532	10	{Staphylococcus}	A61K40/45	A61K40/45		21
A61K40/4534	10	{Streptococcus}	A61K40/45	A61K40/45		5
A61K40/4536	10	{Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus or lactococcus}	A61K40/45	A61K40/45		3
A61K40/4538	10	{Neisseria}	A61K40/45	A61K40/45		2
A61K40/454	10	{Brucella; Bordetella, e.g. Bordetella pertussis}	A61K40/45	A61K40/45		
A61K40/4542	10	{Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus}	A61K40/45	A61K40/45		
A61K40/4544	10	{Pseudomonadales, e.g. Pseudomonas}	A61K40/45	A61K40/45		8
A61K40/4546	11	{Moraxella}	A61K40/45	A61K40/45		1
A61K40/4548	10	{Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales}	A61K40/45	A61K40/45		
A61K40/455	10	{Vibrio; Campylobacter}	A61K40/45	A61K40/45		1
A61K40/456	10	{Escherichia; Klebsiella}	A61K40/45	A61K40/45		5
A61K40/4562	10	{Salmonella; Shigella}	A61K40/45	A61K40/45		11
A61K40/4564	10	{Fusobacterium}	A61K40/45	A61K40/45		1
A61K40/4566	10	{Polyvalent bacterial antigens}	A61K40/45	A61K40/45		
A61K40/4568	10	{Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci}	A61K40/45	A61K40/45		11
A61K40/46	9	Viral antigens	A61K40/46	A61K40/46		1272
A61K40/48	9	Allergens	A61K40/48	A61K40/48		75
A61K40/482	10	{from pollen}	A61K40/48	A61K40/48		4
A61K40/50	8	characterised by the use of allogeneic cells	A61K40/50	A61K40/50		627
A61K41/00	7	Medicinal preparations obtained by treating materials with wave energy or particle radiation {; Therapies using these preparations}	A61K41/00	A61K41/00		1715
A61K41/0004	8	{Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood}	A61K41/00	A61K41/00		622
A61K41/0023	8	{Aggression treatment or altering}<br><br><u>NOTE</u><br><br>This group covers aggression treatment or altering <br>of a medicinal preparation prior to administration to the human/animal, e.g. altering a binding specificity of a monoclonal antibody used in a medicinal agent with an oxidizing agent or an electric potential; <br>of a tissue/organ prior to graft, e.g. destroying immunodominant epitopes; <br>the permeability of cell membranes or biological barriers in vivo, e.g. by ultrasound, prior to the administration of a medicinal preparation to the animal/human; <br>for inducing the production of stress response proteins or heat shock proteins in order to reduce subsequent response to injuries	A61K41/00	A61K41/00		203
A61K41/0028	8	{Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds}	A61K41/00	A61K41/00		987
A61K41/0033	9	{Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds (ultrasound therapy per seA61N7/00)}	A61K41/00	A61K41/00		667
A61K41/0038	8	{Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per seA61N5/10)}	A61K41/00	A61K41/00		975
A61K41/0042	8	{Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion}	A61K41/00	A61K41/00		680
A61K41/0047	8	{Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent}<br><br><u>NOTE</u><br><br> To be classified in A61K9/0009 when it is in relation to the galenic form.	A61K41/00	A61K41/00		284
A61K41/0052	8	{Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy}	A61K41/00	A61K41/00		4820
A61K41/0057	8	{Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent}	A61K41/00	A61K41/00		3760
A61K41/0061	9	{5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA}	A61K41/00	A61K41/00		283
A61K41/0066	9	{Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins}	A61K41/00	A61K41/00		81
A61K41/0071	9	{PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines}	A61K41/00	A61K41/00		1875
A61K41/0076	9	{PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines}	A61K41/00	A61K41/00		354
A61K41/008	9	{Two-Photon or Multi-Photon PDT, e.g. with upconverting dyes or photosensitisers}	A61K41/00	A61K41/00		111
A61K41/0085	8	{Mossbauer effect therapy based on mossbauer effect of a material, i.e. re-emission of gamma rays after absorption of gamma rays by the material; selective radiation therapy, i.e. involving re-emission of ionizing radiation upon exposure to a first ionizing radiation}	A61K41/00	A61K41/00		21
A61K41/009	8	{Neutron capture therapy, e.g. using uranium or non-boron material}	A61K41/00	A61K41/00		66
A61K41/0095	9	{Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins}	A61K41/00	A61K41/00		343
A61K41/10	8	Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person	A61K41/10	A61K41/10		131
A61K41/13	9	by ultrasonic waves	A61K41/13	A61K41/13		51
A61K41/17	9	by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays	A61K41/17	A61K41/17		371
A61K45/00	7	Medicinal preparations containing active ingredients not provided for in groups A61K31/00&#160;-&#160;A61K41/00	A61K45/00	A61K45/00		12046
A61K45/05	8	{Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer}	A61K45/00	A61K45/05		141
A61K45/06	8	Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca	A61K45/06	A61K45/06		67960
A61K47/00	7	Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient	A61K47/00	A61K47/00		708
A61K47/02	8	Inorganic compounds	A61K47/02	A61K47/02		15642
A61K47/06	8	Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite	A61K47/06	A61K47/06		4158
A61K47/08	9	containing oxygen, {e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides}	A61K47/08	A61K47/08		935
A61K47/10	10	Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers	A61K47/10	A61K47/10		23610
A61K47/12	10	Carboxylic acids; Salts or anhydrides thereof	A61K47/12	A61K47/12		11571
A61K47/14	10	Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters	A61K47/14	A61K47/14		9511
A61K47/16	9	containing nitrogen, {e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates}	A61K47/16	A61K47/16		366
A61K47/18	10	Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids	A61K47/18	A61K47/18		4794
A61K47/183	11	{Amino acids, e.g. glycine, EDTA or aspartame}	A61K47/18	A61K47/18		6515
A61K47/186	11	{Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide}	A61K47/18	A61K47/18		1310
A61K47/20	9	containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids	A61K47/20	A61K47/20		4135
A61K47/22	9	Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones	A61K47/22	A61K47/22		7911
A61K47/24	9	containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids	A61K47/24	A61K47/24		7118
A61K47/26	9	Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin	A61K47/26	A61K47/26		19308
A61K47/28	9	Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid	A61K47/28	A61K47/28		3012
A61K47/30	8	Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates	A61K47/30	A61K47/30		1299
A61K47/32	9	Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}	A61K47/32	A61K47/32		12323
A61K47/34	9	Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)	A61K47/34	A61K47/34		10437
A61K47/36	9	Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin	A61K47/36	A61K47/36		17828
A61K47/38	10	Cellulose; Derivatives thereof	A61K47/38	A61K47/38		10414
A61K47/40	10	Cyclodextrins; Derivatives thereof	A61K47/40	A61K47/40		2845
A61K47/42	9	Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)	A61K47/42	A61K47/42		8878
A61K47/44	8	Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)	A61K47/44	A61K47/44		10386
A61K47/46	8	Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts	A61K47/46	A61K47/46		6517
A61K47/50	8	the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates	A61K47/50	A61K47/50		1595
A61K47/51	9	the non-active ingredient being a modifying agent	A61K47/51	A61K47/51		188
A61K47/52	10	the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient	A61K47/52	A61K47/52		1035
A61K47/54	10	the modifying agent being an organic compound	A61K47/54	A61K47/54		2240
A61K47/541	11	{Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent}	A61K47/54	A61K47/54		219
A61K47/542	11	{Carboxylic acids, e.g. a fatty acid or an amino acid}	A61K47/54	A61K47/54		2181
A61K47/543	11	{Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}	A61K47/54	A61K47/54		1070
A61K47/544	12	{Phospholipids}	A61K47/54	A61K47/54		730
A61K47/545	11	{Heterocyclic compounds (A61K47/558 takes precedence)}	A61K47/54	A61K47/54		2485
A61K47/546	12	{Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine}	A61K47/54	A61K47/54		131
A61K47/547	11	{Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent}	A61K47/54	A61K47/54		322
A61K47/548	11	{Phosphates or phosphonates, e.g. bone-seeking (phospholipids A61K47/544)}	A61K47/54	A61K47/54		429
A61K47/549	11	{Sugars, nucleosides, nucleotides or nucleic acids}	A61K47/54	A61K47/54		3221
A61K47/55	11	the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug	A61K47/55	A61K47/55		2444
A61K47/551	12	{one of the codrug&apos;s components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid}	A61K47/55	A61K47/55		607
A61K47/552	12	{one of the codrug&apos;s components being an antibiotic}	A61K47/55	A61K47/55		153
A61K47/554	11	{the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid}	A61K47/54	A61K47/55		721
A61K47/555	11	{pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells}	A61K47/54	A61K47/55		313
A61K47/556	12	{enzyme catalyzed therapeutic agent [ECTA]}	A61K47/54	A61K47/55		50
A61K47/557	12	{the modifying agent being biotin}	A61K47/54	A61K47/55		167
A61K47/558	11	{the modifying agent being a chemiluminescent acceptor}	A61K47/54	A61K47/55		43
A61K47/559	11	{Redox delivery systems, e.g. dihydropyridine pyridinium salt redox systems}	A61K47/54	A61K47/55		54
A61K47/56	10	the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule	A61K47/56	A61K47/56		349
A61K47/58	11	obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin	A61K47/58	A61K47/58		1711
A61K47/585	12	{Ion exchange resins, e.g. polystyrene sulfonic acid resin}	A61K47/58	A61K47/58		441
A61K47/59	11	obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes	A61K47/59	A61K47/59		1397
A61K47/593	12	{Polyesters, e.g. PLGA or polylactide-co-glycolide}	A61K47/59	A61K47/59		655
A61K47/595	12	{Polyamides, e.g. nylon (polyamino acids A61K47/62)}	A61K47/59	A61K47/59		491
A61K47/60	12	the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol	A61K47/60	A61K47/60		6567
A61K47/605	12	{the macromolecule containing phosphorus in the main chain, e.g. poly-phosphazene}	A61K47/58	A61K47/60		91
A61K47/61	11	the organic macromolecular compound being a polysaccharide or a derivative thereof	A61K47/61	A61K47/61		3581
A61K47/62	10	the modifying agent being a protein, peptide or polyamino acid	A61K47/62	A61K47/62		2886
A61K47/64	11	Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)	A61K47/64	A61K47/64		5556
A61K47/641	12	{Branched, dendritic or hypercomb peptides}	A61K47/64	A61K47/64		137
A61K47/6415	12	{Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}	A61K47/64	A61K47/64		608
A61K47/642	12	{the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate}	A61K47/64	A61K47/64		365
A61K47/6425	12	{the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell}	A61K47/64	A61K47/64		472
A61K47/643	12	{Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}	A61K47/64	A61K47/64		1186
A61K47/6435	12	{the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin}	A61K47/64	A61K47/64		227
A61K47/644	12	{Transferrin, e.g. a lactoferrin or ovotransferrin}	A61K47/64	A61K47/64		263
A61K47/6445	12	{Haemoglobin}	A61K47/64	A61K47/64		82
A61K47/645	12	{Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}	A61K47/64	A61K47/64		1414
A61K47/6455	13	{Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids}	A61K47/64	A61K47/64		462
A61K47/646	12	{the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}	A61K47/64	A61K47/64		1084
A61K47/65	11	Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers	A61K47/65	A61K47/65		2106
A61K47/66	11	the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells	A61K47/66	A61K47/66		290
A61K47/665	12	{the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems}	A61K47/66	A61K47/66		194
A61K47/67	12	{Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT}	A61K47/66	A61K47/67		105
A61K47/68	10	the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment	A61K47/68	A61K47/68		2038
A61K47/6801	11	{Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent}	A61K47/68	A61K47/68		503
A61K47/6803	12	{Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}	A61K47/68	A61K47/68		2011
A61K47/68031	13	{the drug being an auristatin}	A61K47/68	A61K47/68		1238
A61K47/68033	13	{the drug being a maytansine}	A61K47/68	A61K47/68		613
A61K47/68035	13	{the drug being a pyrrolobenzodiazepine}	A61K47/68	A61K47/68		374
A61K47/68037	13	{the drug being a camptothecin [CPT] or derivatives}	A61K47/68	A61K47/68		803
A61K47/6805	13	{the drug being a vinca alkaloid}	A61K47/68	A61K47/68		70
A61K47/6807	13	{the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense}	A61K47/68	A61K47/68		462
A61K47/6809	14	{Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin}	A61K47/68	A61K47/68		497
A61K47/6811	13	{the drug being a protein or peptide, e.g. transferrin or bleomycin}	A61K47/68	A61K47/68		1094
A61K47/6813	14	{the drug being a peptidic cytokine, e.g. an interleukin or interferon}	A61K47/68	A61K47/68		495
A61K47/6815	14	{Enzymes}	A61K47/68	A61K47/68		250
A61K47/6817	14	{Toxins}	A61K47/68	A61K47/68		523
A61K47/6819	15	{Plant toxins}	A61K47/68	A61K47/68		54
A61K47/6821	16	{Plant heterodimeric toxins, e.g. abrin or modeccin}	A61K47/68	A61K47/68		14
A61K47/6823	17	{Double chain ricin}	A61K47/68	A61K47/68		22
A61K47/6825	16	{Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin}	A61K47/68	A61K47/68		159
A61K47/6827	17	{Ricin A}	A61K47/68	A61K47/68		78
A61K47/6829	15	{Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A}	A61K47/68	A61K47/68		307
A61K47/6831	15	{Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin}	A61K47/68	A61K47/68		127
A61K47/6833	15	{Viral toxins}	A61K47/68	A61K47/68		14
A61K47/6835	11	{the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site}	A61K47/68	A61K47/68		425
A61K47/6839	12	{the antibody targeting material from viruses}	A61K47/68	A61K47/68		89
A61K47/6841	13	{the antibody targeting a RNA virus}	A61K47/68	A61K47/68		116
A61K47/6843	12	{the antibody targeting a material from animals or humans}	A61K47/68	A61K47/68		587
A61K47/6845	12	{the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon}	A61K47/68	A61K47/68		374
A61K47/6847	12	{the antibody targeting a hormone or a hormone-releasing or -inhibiting factor}	A61K47/68	A61K47/68		50
A61K47/6849	12	{the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}	A61K47/68	A61K47/68		4416
A61K47/6851	12	{the antibody targeting a determinant of a tumour cell}	A61K47/68	A61K47/68		2416
A61K47/6853	13	{Carcino-embryonic antigens}	A61K47/68	A61K47/68		162
A61K47/6855	13	{the tumour determinant being from breast cancer cell}	A61K47/68	A61K47/68		1071
A61K47/6857	13	{the tumour determinant being from lung cancer cell}	A61K47/68	A61K47/68		216
A61K47/6859	13	{the tumour determinant being from liver or pancreas cancer cell}	A61K47/68	A61K47/68		179
A61K47/6861	13	{the tumour determinant being from kidney or bladder cancer cell}	A61K47/68	A61K47/68		85
A61K47/6863	13	{the tumour determinant being from stomach or intestines cancer cell}	A61K47/68	A61K47/68		258
A61K47/6865	13	{the tumour determinant being from skin, nerves or brain cancer cell}	A61K47/68	A61K47/68		157
A61K47/6867	13	{the tumour determinant being from a cell of a blood cancer}	A61K47/68	A61K47/68		345
A61K47/6869	13	{the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}	A61K47/68	A61K47/68		372
A61K47/6871	12	{the antibody targeting an enzyme}	A61K47/68	A61K47/68		281
A61K47/6873	12	{the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody}	A61K47/68	A61K47/68		114
A61K47/6875	12	{the antibody being a hybrid immunoglobulin}	A61K47/68	A61K47/68		34
A61K47/6877	13	{the antibody being an immunoglobulin containing regions, domains or residues from different species}	A61K47/68	A61K47/68		103
A61K47/6879	13	{the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin}	A61K47/68	A61K47/68		351
A61K47/6881	12	{Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other}	A61K47/68	A61K47/68		74
A61K47/6883	12	{Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy}	A61K47/68	A61K47/68		273
A61K47/6885	13	{the conjugate or the polymer being a starburst, a dendrimer, a cascade}	A61K47/68	A61K47/68		53
A61K47/6887	12	{Antibody-chelate conjugates using chelates for therapeutic purposes (radioactive substances, e.g. for use in radio diagnosis or radiotherapy, A61K51/10; antibody-chelates for use in MRI A61K49/14)}	A61K47/68	A61K47/68		77
A61K47/6889	11	{Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}	A61K47/68	A61K47/68		2085
A61K47/6891	11	{Pre-targeting systems involving an antibody for targeting specific cells}	A61K47/68	A61K47/68		128
A61K47/6893	12	{clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M}	A61K47/68	A61K47/68		64
A61K47/6895	12	{Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies}	A61K47/68	A61K47/68		30
A61K47/6897	12	{Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies}	A61K47/68	A61K47/68		165
A61K47/6898	13	{using avidin- or biotin-conjugated antibodies}	A61K47/68	A61K47/68		166
A61K47/6899	12	{Antibody-Directed Enzyme Prodrug Therapy [ADEPT]}	A61K47/68	A61K47/68		117
A61K47/69	9	the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit	A61K47/69	A61K47/69		404
A61K47/6901	10	{Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}	A61K47/69	A61K47/69		1442
A61K47/6903	10	{the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel}	A61K47/69	A61K47/69		808
A61K47/6905	10	{the form being a colloid or an emulsion}	A61K47/69	A61K47/69		80
A61K47/6907	11	{the form being a microemulsion, nanoemulsion or micelle}	A61K47/69	A61K47/69		787
A61K47/6909	12	{Micelles formed by phospholipids}	A61K47/69	A61K47/69		96
A61K47/6911	11	{the form being a liposome}	A61K47/69	A61K47/69		1649
A61K47/6913	12	{the liposome being modified on its surface by an antibody}	A61K47/69	A61K47/69		399
A61K47/6915	12	{the form being a liposome with polymerisable or polymerized bilayer-forming substances, e.g. polymersomes}	A61K47/69	A61K47/69		120
A61K47/6917	11	{the form being a lipoprotein vesicle, e.g. HDL or LDL proteins}	A61K47/69	A61K47/69		89
A61K47/6919	11	{the form being a ribbon or a tubule cochleate}	A61K47/69	A61K47/69		41
A61K47/6921	10	{the form being a particulate, a powder, an adsorbate, a bead or a sphere}	A61K47/69	A61K47/69		310
A61K47/6923	11	{the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}	A61K47/69	A61K47/69		1936
A61K47/6925	11	{the form being a microcapsule, nanocapsule, microbubble or nanobubble}	A61K47/69	A61K47/69		889
A61K47/6927	11	{the form being a solid microparticle having no hollow or gas-filled cores}	A61K47/69	A61K47/69		323
A61K47/6929	12	{the form being a nanoparticle, e.g. an immuno-nanoparticle}	A61K47/69	A61K47/69		2470
A61K47/6931	13	{the material constituting the nanoparticle being a polymer}	A61K47/69	A61K47/69		304
A61K47/6933	14	{the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol}	A61K47/69	A61K47/69		290
A61K47/6935	14	{the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol}	A61K47/69	A61K47/69		1076
A61K47/6937	15	{the polymer being PLGA, PLA or polyglycolic acid}	A61K47/69	A61K47/69		549
A61K47/6939	14	{the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin}	A61K47/69	A61K47/69		530
A61K47/6941	11	{the form being a granulate or an agglomerate}	A61K47/69	A61K47/69		67
A61K47/6943	10	{the form being a pill, a tablet, a lozenge or a capsule}	A61K47/69	A61K47/69		35
A61K47/6949	10	{inclusion complexes, e.g. clathrates, cavitates or fullerenes}	A61K47/69	A61K47/69		2297
A61K47/6951	11	{using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}	A61K47/69	A61K47/69		3377
A61K47/6953	10	{the form being a fibre, a textile, a slab or a sheet}	A61K47/69	A61K47/69		115
A61K47/6955	10	{the form being a plaster, a bandage, a dressing or a patch}	A61K47/69	A61K47/69		30
A61K47/6957	10	{the form being a device or a kit, e.g. stents or microdevices}	A61K47/69	A61K47/69		266
A61K48/00	7	Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy	A61K48/00	A61K48/00		15706
A61K48/0008	8	{characterised by an aspect of the &apos;non-active&apos; part of the composition delivered, e.g. wherein such &apos;non-active&apos; part is not delivered simultaneously with the &apos;active&apos; part of the composition}	A61K48/00	A61K48/00		2181
A61K48/0016	9	{wherein the nucleic acid is delivered as a &apos;naked&apos; nucleic acid, i.e. not combined with an entity such as a cationic lipid}	A61K48/00	A61K48/00		243
A61K48/0025	9	{wherein the non-active part clearly interacts with the delivered nucleic acid}	A61K48/00	A61K48/00		888
A61K48/0033	10	{the non-active part being non-polymeric}	A61K48/00	A61K48/00		826
A61K48/0041	10	{the non-active part being polymeric}	A61K48/00	A61K48/00		1857
A61K48/005	8	{characterised by an aspect of the &apos;active&apos; part of the composition delivered, i.e. the nucleic acid delivered}	A61K48/00	A61K48/00		8667
A61K48/0058	9	{Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}	A61K48/00	A61K48/00		2132
A61K48/0066	9	{Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}	A61K48/00	A61K48/00		1075
A61K48/0075	8	{characterised by an aspect of the delivery route, e.g. oral, subcutaneous}	A61K48/00	A61K48/00		1916
A61K48/0083	8	{characterised by an aspect of the administration regime}	A61K48/00	A61K48/00		525
A61K48/0091	8	{Purification or manufacturing processes for gene therapy compositions}	A61K48/00	A61K48/00		437
A61K49/00	7	Preparations for testing in vivo	A61K49/00	A61K49/00		1246
A61K49/0002	8	{General or multifunctional contrast agents, e.g. chelated agents}	A61K49/00	A61K49/00		1937
A61K49/0004	8	{Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions}	A61K49/00	A61K49/00		1211
A61K49/0006	9	{Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity}	A61K49/00	A61K49/00		293
A61K49/0008	9	{Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}	A61K49/00	A61K49/00		3469
A61K49/001	8	{Preparation for luminescence or biological staining}	A61K49/00	A61K49/00		78
A61K49/0013	9	{Luminescence}	A61K49/00	A61K49/00		233
A61K49/0015	10	{Phosphorescence}	A61K49/00	A61K49/00		77
A61K49/0017	10	{Fluorescence in vivo}	A61K49/00	A61K49/00		375
A61K49/0019	11	{characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules}<br><br><u>NOTE</u><br><br>If this fluorescent group is complexed or covalently linked to a carrier, classification is also made according to the nature of the carrier in the appropriate A61K49/005 subgroup.	A61K49/00	A61K49/00		759
A61K49/0021	12	{the fluorescent group being a small organic molecule}	A61K49/00	A61K49/00		2078
A61K49/0023	13	{Di-or triarylmethane dye (xanthene dyes A61K49/0041)}	A61K49/00	A61K49/00		47
A61K49/0026	13	{Acridine dyes}	A61K49/00	A61K49/00		44
A61K49/0028	13	{Oxazine dyes}	A61K49/00	A61K49/00		79
A61K49/003	13	{Thiazine dyes}	A61K49/00	A61K49/00		85
A61K49/0032	13	{Methine dyes, e.g. cyanine dyes}	A61K49/00	A61K49/00		1560
A61K49/0034	14	{Indocyanine green, i.e. ICG, cardiogreen}	A61K49/00	A61K49/00		708
A61K49/0036	13	{Porphyrins (used in photodynamic therapy A61K41/0071 or A61K41/0076; used as targeting group or modifying agent for targeting a therapeutic compound A61K47/546)}	A61K49/00	A61K49/00		357
A61K49/0039	13	{Coumarin dyes}	A61K49/00	A61K49/00		170
A61K49/0041	13	{Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal (in vivoG01N)}	A61K49/00	A61K49/00		539
A61K49/0043	14	{Fluorescein, used in vivo}	A61K49/00	A61K49/00		666
A61K49/0045	12	{the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo}	A61K49/00	A61K49/00		198
A61K49/0047	13	{Green fluorescent protein [GFP]}	A61K49/00	A61K49/00		149
A61K49/005	11	{characterised by the carrier molecule carrying the fluorescent agent}<br><br><u>NOTE</u><br><br>Classification is also made according to the nature of the fluorescent group in the appropriate subgroup of A61K49/0019.	A61K49/00	A61K49/00		326
A61K49/0052	12	{Small organic molecules (oligomers, polymers, dendrimers A61K49/0054)}	A61K49/00	A61K49/00		1131
A61K49/0054	12	{Macromolecular compounds, i.e. oligomers, polymers, dendrimers}	A61K49/00	A61K49/00		1356
A61K49/0056	12	{Peptides, proteins, polyamino acids}	A61K49/00	A61K49/00		1615
A61K49/0058	12	{Antibodies}	A61K49/00	A61K49/00		666
A61K49/006	9	{Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery}<br><br><u>NOTE</u><br><br>If the dye used for staining is fluorescent, classification is also given for the appropriate subgroup of A61K49/0019.	A61K49/00	A61K49/00		470
A61K49/0063	9	{characterised by a special physical or galenical form, e.g. emulsions, microspheres}<br><br><u>NOTE</u><br><br>Note Classification is also made according to the nature of the luminescent or fluorescent agent and/or the carrier carrying the fluorescent agent.	A61K49/00	A61K49/00		40
A61K49/0065	10	{the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle}	A61K49/00	A61K49/00		288
A61K49/0067	11	{quantum dots, fluorescent nanocrystals}<br><br><u>NOTE</u><br><br>Quantum dots modified on their surface by an antibody are also classified in A61K49/0058.	A61K49/00	A61K49/00		540
A61K49/0069	10	{the agent being in a particular physical galenical form}<br><br><u>NOTE</u><br><br>If the physical or galenical form containing a fluorescent agent is modified by a particular agent, classification is also made according to the nature of this agent in the appropriate A61K49/005 subgroup.	A61K49/00	A61K49/00		70
A61K49/0071	11	{solution, solute}	A61K49/00	A61K49/00		74
A61K49/0073	11	{semi-solid, gel, hydrogel, ointment}	A61K49/00	A61K49/00		143
A61K49/0076	11	{dispersion, suspension, e.g. particles in a liquid, colloid, emulsion}	A61K49/00	A61K49/00		46
A61K49/0078	12	{microemulsion, nanoemulsion}<br><br><u>NOTE</u><br><br>Microemulsion means that the dispersed phase is in the form of globules having a diameter above or equal to 1 micrometer. Nanoemulsion means that the dispersed phase is in the form of globules having a diameter below 1 micrometer.	A61K49/00	A61K49/00		43
A61K49/008	12	{lipoprotein vesicle, e.g. HDL or LDL proteins}	A61K49/00	A61K49/00		25
A61K49/0082	12	{micelle, e.g. phospholipidic micelle and polymeric micelle}<br><br><u>NOTE</u><br><br>Micelles comprise a monolayer of surfactant molecules that are aggregated head-to-head and tail-to-tail, thus forming a small spherical particle; micelles can be normal, i.e., the surfactant heads are hydrophilic, or inverse.	A61K49/00	A61K49/00		183
A61K49/0084	12	{liposome, i.e. bilayered vesicular structure}<br><br><u>NOTE</u><br><br>When the surface of the liposome encapsulating a fluorescent agent and used in vivo is functionalised by a modifying agent, classification is also made according to the nature of this modifying agent: e.g. a liposome modified on its surface by a peptide is classified in A61K49/0084 and A61K49/0056. Liposomes encapsulating a fluorescent agent, used in vivo and modified on their surface by a polymer because they incorporate a polymer-lipid conjugate, are only additionally classified in A61K49/0054 if the polymer modifying the lipid is unusual. Liposomes encapsulating a fluorescent agent which are pegylated because they incorporate a pegylated lipid are only classified in A61K49/0084, not in A61K49/0054.	A61K49/00	A61K49/00		274
A61K49/0086	13	{Polymersome, i.e. liposome with polymerisable or polymerized bilayered-forming substances}	A61K49/00	A61K49/00		35
A61K49/0089	11	{Particulate, powder, adsorbate, bead, sphere}	A61K49/00	A61K49/00		63
A61K49/0091	12	{Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer}<br><br><u>NOTE</u><br><br>When the surface of the microparticle encapsulating a fluorescent agent and used in vivo is functionalised by a modifying agent, classification is also made according to the nature of this modifying agent, e.g. a microparticle modified on its surface by a peptide is classified in A61K49/0091 and A61K49/0056.	A61K49/00	A61K49/00		165
A61K49/0093	13	{Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle}	A61K49/00	A61K49/00		1385
A61K49/0095	14	{Nanotubes}	A61K49/00	A61K49/00		22
A61K49/0097	11	{Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis in vivo}	A61K49/00	A61K49/00		192
A61K49/04	8	X-ray contrast preparations<br><br><u>NOTE</u><br><br> In the preparation of new organic compounds and their use in X-ray contrast preparations, classification is only made in the relevant subclasses C07C&#160;-&#160;C07J according to the type of compound 	A61K49/04	A61K49/04		1079
A61K49/0404	9	{containing barium sulfate}	A61K49/04	A61K49/04		262
A61K49/0409	9	{Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound}	A61K49/04	A61K49/04		193
A61K49/0414	10	{Particles, beads, capsules or spheres}	A61K49/04	A61K49/04		53
A61K49/0419	11	{Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer}	A61K49/04	A61K49/04		69
A61K49/0423	11	{Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer}	A61K49/04	A61K49/04		129
A61K49/0428	12	{Surface-modified nanoparticles, e.g. immuno-nanoparticles}	A61K49/04	A61K49/04		128
A61K49/0433	9	{containing an organic halogenated X-ray contrast-enhancing agent}	A61K49/04	A61K49/04		431
A61K49/0438	10	{Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol}	A61K49/04	A61K49/04		427
A61K49/0442	10	{Polymeric X-ray contrast-enhancing agent comprising a halogenated group}	A61K49/04	A61K49/04		180
A61K49/0447	10	{Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound}	A61K49/04	A61K49/04		96
A61K49/0452	11	{Solutions, e.g. for injection}	A61K49/04	A61K49/04		155
A61K49/0457	11	{Semi-solid forms, ointments, gels, hydrogels}	A61K49/04	A61K49/04		82
A61K49/0461	11	{Dispersions, colloids, emulsions or suspensions}	A61K49/04	A61K49/04		136
A61K49/0466	12	{Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles}	A61K49/04	A61K49/04		68
A61K49/0471	12	{Perflubron, i.e. perfluoroctylbromide, C8F17Br emulsions}	A61K49/04	A61K49/04		17
A61K49/0476	11	{Particles, beads, capsules, spheres}	A61K49/04	A61K49/04		22
A61K49/048	12	{Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer}	A61K49/04	A61K49/04		52
A61K49/0485	12	{Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer}	A61K49/04	A61K49/04		70
A61K49/049	13	{Surface-modified nanoparticles, e.g. immune-nanoparticles}	A61K49/04	A61K49/04		47
A61K49/0495	11	{intended for oral administration}	A61K49/04	A61K49/04		87
A61K49/06	8	Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations<br><br><u>NOTE</u><br><br>characterised only by the (inorganic) MRI-active nucleus, e.g. 129Xe	A61K49/06	A61K49/06		906
A61K49/08	9	characterised by the carrier<br><br><u>NOTE</u><br><br>characterised by the carrier carrying the MRI-active nucleus, e.g. inorganic carrier	A61K49/08	A61K49/08		394
A61K49/085	10	{conjugated systems}<br><br><u>NOTE</u><br><br>The MRI-active nucleus being complexed to a complex-forming compound (e.g. chelating group) or being covalently linked to a molecule, which being further covalently linked or conjugated to a carrier, e.g. polymer. Classification being also made according to the nature of the carrier, e.g. [Gd3+]DOTA-polymer to be classified in A61K49/085 and in the appropriate A61K49/12 adequate subgroup.	A61K49/08	A61K49/08		752
A61K49/10	10	Organic compounds<br><br><u>NOTE</u><br><br>the carrier being an organic compound, e.g. 13C-labelled molecule or perfluorinated alkane, used as MRI in vivo probe, or a small organic molecule, e.g. a sugar, linked to a Gd-chelate	A61K49/10	A61K49/10		832
A61K49/101	11	{the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals}<br><br><u>NOTE</u><br><br>In the A61K49/101 subgroups, the MRI-active nucleus being complexed to a complex-forming compound, e.g. chelating group. Classification being made according to the nature of this complex-forming agent, if it being either an uncommon or new complexing agent (not the usual DTPA, DOTA, DOTP, etc...groups) that forms the real contribution to the claimed MRI invention, or if it being not conjugated to any further molecule, e.g. which being not conjugated to a polymer, peptide, protein or antibody. In that latter case, the MRI probe being e.g. a paramagnetic metal chelate.	A61K49/10	A61K49/10		93
A61K49/103	12	{the complex-forming compound being acyclic, e.g. DTPA}	A61K49/10	A61K49/10		237
A61K49/105	13	{the metal complex being Gd-DTPA}	A61K49/10	A61K49/10		135
A61K49/106	12	{the complex-forming compound being cyclic, e.g. DOTA}	A61K49/10	A61K49/10		412
A61K49/108	13	{the metal complex being Gd-DOTA}	A61K49/10	A61K49/10		228
A61K49/12	11	Macromolecular compounds<br><br><u>NOTE</u><br><br> the carrier being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule (not being a peptide, protein, polyamino acid (seeA61K49/00) or an antibody (seeA61K49/00 or A61K49/16 ) 	A61K49/12	A61K49/12		285
A61K49/122	12	{dimers of complexes or complex-forming compounds}	A61K49/12	A61K49/12		57
A61K49/124	12	{dendrimers, dendrons, hyperbranched compounds}<br><br><u>NOTE</u><br><br>Said compounds are either complexes or complex-forming compounds, or they form a backbone to which MRI active nuclei are complexed or covalently linked through chelating groups. In that latter case, the subgroup A61K49/085 being also given. Dendrimeric, dendronised or hyperbranched polyamino acids used as carriers are also classified in A61K49/146.	A61K49/12	A61K49/12		155
A61K49/126	12	{Linear polymers, e.g. dextran, inulin, PEG}	A61K49/12	A61K49/12		575
A61K49/128	13	{comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone}<br><br><u>NOTE</u><br><br>In that latter case, classification is also made in A61K49/085.	A61K49/12	A61K49/12		126
A61K49/14	11	Peptides, e.g. proteins<br><br><u>NOTE</u><br><br> the carrier being a peptide (polyamino acid, A61K49/146 ) or protein (not an antibody, seeA61K49/16 ). If the MRI-active nucleus being linked to the peptide or protein or polyamino acid via a complexing or chelating group, the subgroup A61K49/085 should also be given. If the peptide or protein or polyamino acid being a dendrimer, a dendron, or hyperbranched, then the A61K49/124 being also given 	A61K49/14	A61K49/14		758
A61K49/143	12	{the protein being an albumin, e.g. HSA, BSA, ovalbumin}	A61K49/14	A61K49/14		150
A61K49/146	12	{the peptide being a polyamino acid, e.g. poly-lysine}	A61K49/14	A61K49/14		107
A61K49/16	12	Antibodies; Immunoglobulins; Fragments thereof<br><br><u>NOTE</u><br><br> the protein being an antibody, an immunoglobulin or a fragment thereof. If the MRI-active nucleus being linked to the antibody via a complexing or chelating group, the subgroup A61K49/085 should also be given 	A61K49/16	A61K49/16		371
A61K49/18	9	characterised by a special physical form, e.g. emulsions, microcapsules, liposomes<br><br><u>NOTE</u><br><br>Classification being also made according to the molecule complexing or bearing the MRI-active nucleus	A61K49/18	A61K49/18		324
A61K49/1803	10	{Semi-solid preparations, e.g. ointments, gels, hydrogels}	A61K49/18	A61K49/18		85
A61K49/1806	10	{Suspensions, emulsions, colloids, dispersions}	A61K49/18	A61K49/18		215
A61K49/1809	11	{Micelles, e.g. phospholipidic or polymeric micelles}	A61K49/18	A61K49/18		126
A61K49/1812	11	{liposomes, polymersomes, e.g. immunoliposomes}<br><br><u>NOTE</u><br><br>If the paramagnetic metal complexes are covalently linked to the bilayered membrane, then the A61K49/085 subgroup being also given. Liposomes modified on their external surface by a targeting agent, e.g. an antibody are classified in A61K49/1812 without further indication for the targeting agent .	A61K49/18	A61K49/18		272
A61K49/1815	11	{compo-inhalant, e.g. breath tests}	A61K49/18	A61K49/18		119
A61K49/1818	10	{particles, e.g. uncoated or non-functionalised microparticles or nanoparticles}<br><br><u>NOTE</u><br><br> For nanoparticles, i.e. having a size or diameter smaller than 1 micrometer, the subgroups B82Y5/00 and B82Y15/00 are also given. 	A61K49/18	A61K49/18		467
A61K49/1821	11	{coated or functionalised microparticles or nanoparticles}	A61K49/18	A61K49/18		102
A61K49/1824	12	{coated or functionalised nanoparticles (liposomes A61K49/1812; nanoemulsions A61K49/1806; micelles A61K49/1809)}	A61K49/18	A61K49/18		259
A61K49/1827	13	{having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle}	A61K49/18	A61K49/18		90
A61K49/183	14	{having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus}	A61K49/18	A61K49/18		198
A61K49/1833	14	{having a (super)(para)magnetic core coated or functionalised with a small organic molecule (oligomeric, polymeric, dendrimeric A61K49/1851)}	A61K49/18	A61K49/18		184
A61K49/1836	15	{the small organic molecule being a carboxylic acid having less than 8 carbon atoms in the main chain}	A61K49/18	A61K49/18		69
A61K49/1839	15	{the small organic molecule being a lipid, a fatty acid having 8 or more carbon atoms in the main chain, or a phospholipid}	A61K49/18	A61K49/18		100
A61K49/1842	15	{the small organic molecule being a phosphate or a phosphonate, not being a phospholipid}	A61K49/18	A61K49/18		38
A61K49/1845	15	{the small organic molecule being a carbohydrate (monosaccharides, discacharides)}	A61K49/18	A61K49/18		50
A61K49/1848	15	{the small organic molecule being a silane}	A61K49/18	A61K49/18		52
A61K49/1851	14	{having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule (peptide or protein A61K49/1866; polyamino acid A61K49/1872; antibody A61K49/1875)}	A61K49/18	A61K49/18		52
A61K49/1854	15	{the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol}	A61K49/18	A61K49/18		149
A61K49/1857	15	{the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA}	A61K49/18	A61K49/18		206
A61K49/186	16	{the organic macromolecular compound being polyethyleneglycol [PEG]}	A61K49/18	A61K49/18		296
A61K49/1863	15	{the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch}	A61K49/18	A61K49/18		307
A61K49/1866	14	{the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid}	A61K49/18	A61K49/18		261
A61K49/1869	15	{coated or functionalised with a protein being an albumin, e.g. HSA, BSA, ovalbumin}	A61K49/18	A61K49/18		96
A61K49/1872	15	{coated or functionalised with a polyamino acid, e.g. polylysine, polyglutamic acid}	A61K49/18	A61K49/18		26
A61K49/1875	14	{coated or functionalised with an antibody}	A61K49/18	A61K49/18		131
A61K49/1878	13	{the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating}	A61K49/18	A61K49/18		59
A61K49/1881	14	{wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface}	A61K49/18	A61K49/18		76
A61K49/1884	11	{Nanotubes, nanorods or nanowires}	A61K49/18	A61K49/18		22
A61K49/1887	11	{Agglomerates, clusters, i.e. more than one (super)(para)magnetic microparticle or nanoparticle are aggregated or entrapped in the same maxtrix}	A61K49/18	A61K49/18		102
A61K49/189	10	{Host-guest complexes, e.g. cyclodextrins}	A61K49/18	A61K49/18		63
A61K49/1893	11	{Molecular sieves}	A61K49/18	A61K49/18		7
A61K49/1896	10	{not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsides}	A61K49/18	A61K49/18		189
A61K49/20	9	containing free radicals {, e.g. trityl radical for overhauser}	A61K49/20	A61K49/20		100
A61K49/22	8	Echographic preparations; Ultrasonic imaging preparations	A61K49/22	A61K49/22		557
A61K49/221	9	{characterised by the targeting agent or modifying agent linked to the acoustically-active agent}	A61K49/22	A61K49/22		495
A61K49/222	9	{characterised by a special physical form, e.g. emulsions, liposomes}	A61K49/22	A61K49/22		216
A61K49/223	10	{Microbubbles, hollow microspheres, free gas bubbles, gas microspheres}	A61K49/22	A61K49/22		965
A61K49/225	10	{Microparticles, microcapsules (gas-filled to be classified in A61K49/223)}	A61K49/22	A61K49/22		567
A61K49/226	10	{Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels}	A61K49/22	A61K49/22		306
A61K49/227	10	{Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric}	A61K49/22	A61K49/22		230
A61K49/228	10	{Host-guest complexes, clathrates, chelates}	A61K49/22	A61K49/22		36
A61K51/00	7	Preparations containing radioactive substances for use in therapy or testing in vivo	A61K51/00	A61K51/00		552
A61K51/02	8	characterised by the carrier {, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus}	A61K51/02	A61K51/02		341
A61K51/025	9	{inorganic Tc complexes or compounds}	A61K51/02	A61K51/02		128
A61K51/04	9	Organic compounds<br><br><u>NOTE</u><br><br>Organic compounds used as carriers	A61K51/04	A61K51/04		879
A61K51/0402	10	{carboxylic acid carriers, fatty acids (amino acids A61K51/0406)}	A61K51/04	A61K51/04		513
A61K51/0404	10	{Lipids, e.g. triglycerides; Polycationic carriers (polycationic carriers being oligomers, polymers, dendrimers A61K47/56; fatty acids A61K51/0402; cholesterol A61K51/0493)}	A61K51/04	A61K51/04		22
A61K51/0406	11	{Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines}	A61K51/04	A61K51/04		364
A61K51/0408	11	{Phospholipids (liposomes encapsulating the radioactive probe or having no radiolabelled phospholipids A61K51/1231)}	A61K51/04	A61K51/04		44
A61K51/041	10	{Heterocyclic compounds}<br><br><u>NOTE</u><br><br>Under this group, the last place rule is followed.	A61K51/04	A61K51/04		43
A61K51/0412	11	{having oxygen as the only ring hetero atom, e.g. fungichromin}	A61K51/04	A61K51/04		7
A61K51/0414	12	{having three-membered rings, e.g. oxirane, fumagillin}	A61K51/04	A61K51/04		1
A61K51/0417	12	{having four-membered rings, e.g. taxol}	A61K51/04	A61K51/04		2
A61K51/0419	12	{having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide}	A61K51/04	A61K51/04		38
A61K51/0421	12	{having six-membered rings with one oxygen as the only ring hetero atom}	A61K51/04	A61K51/04		61
A61K51/0423	12	{having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel}	A61K51/04	A61K51/04		18
A61K51/0425	12	{compounds containing methylenedioxyphenol groups, e.g. sesamin}	A61K51/04	A61K51/04		5
A61K51/0427	12	{Lactones}	A61K51/04	A61K51/04		23
A61K51/0429	11	{having sulfur as a ring hetero atom}	A61K51/04	A61K51/04		2
A61K51/0431	12	{having five-membered rings}	A61K51/04	A61K51/04		37
A61K51/0434	12	{having six-membered rings, e.g. thioxanthenes&#160; (thiothixene&#160;A61K51/0459)}	A61K51/04	A61K51/04		2
A61K51/0436	12	{having two or more sulfur atoms in the same ring}	A61K51/04	A61K51/04		2
A61K51/0438	12	{having oxygen in the same ring}	A61K51/04	A61K51/04		5
A61K51/044	11	{having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins (rifampin A61K51/0459)}	A61K51/04	A61K51/04		82
A61K51/0442	12	{having three-membered rings, e.g. aziridine}	A61K51/04	A61K51/04		3
A61K51/0444	12	{having four-membered rings, e.g. azetidine}	A61K51/04	A61K51/04		6
A61K51/0446	12	{having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil}	A61K51/04	A61K51/04		203
A61K51/0448	13	{tropane or nortropane groups, e.g. cocaine}	A61K51/04	A61K51/04		56
A61K51/0451	13	{having four such rings, e.g. phorphine derivatives, bilirubin, biliverdine (hemin, hematin A61K51/0472)}<br><br><u>NOTE</u><br><br>Porphyrins or texaphyrins used as complex-forming compounds, i.e. wherein the nitrogen atoms forming the central ring system complex the radioactive metal, are classified in A61K51/0485.	A61K51/04	A61K51/04		16
A61K51/0453	12	{having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole}	A61K51/04	A61K51/04		351
A61K51/0455	12	{having six-membered rings with one nitrogen as the only ring hetero atom}	A61K51/04	A61K51/04		699
A61K51/0457	13	{Vesamicol}	A61K51/04	A61K51/04		6
A61K51/0459	12	{having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine}	A61K51/04	A61K51/04		506
A61K51/0461	12	{having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K51/0472)}	A61K51/04	A61K51/04		27
A61K51/0463	12	{having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines}	A61K51/04	A61K51/04		80
A61K51/0465	12	{having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame}	A61K51/04	A61K51/04		25
A61K51/0468	12	{having seven-membered rings, e.g. azelastine, pentylenetetrazole}	A61K51/04	A61K51/04		59
A61K51/047	13	{Benzodiazepines}	A61K51/04	A61K51/04		30
A61K51/0472	11	{containing heavy metals, e.g. hemin, hematin, melarsoprol}	A61K51/04	A61K51/04		34
A61K51/0474	10	{complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group}<br><br><u>NOTE</u><br><br>Classification is made according to the nature of this complex-forming agent, if it is either an uncommon or new complexing agent (not the usual DTPA, DOTA, DOTP, MAG3 etc...groups) that forms the real contribution to the claimed invention (radioimaging or radiotherapeutic agent), or if it is not conjugated to any further molecule, e.g. which is not conjugated to a polymer, peptide, protein or antibody. In that latter case, the radioactive agent is e.g. a radioactive metal chelate.	A61K51/04	A61K51/04		127
A61K51/0476	11	{complexes from monodendate ligands, e.g. sestamibi}	A61K51/04	A61K51/04		93
A61K51/0478	11	{complexes from non-cyclic ligands, e.g. EDTA, MAG3}	A61K51/04	A61K51/04		543
A61K51/048	12	{DTPA (diethylenetriamine tetraacetic acid)}	A61K51/04	A61K51/04		122
A61K51/0482	11	{chelates from cyclic ligands, e.g. DOTA}	A61K51/04	A61K51/04		902
A61K51/0485	11	{Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal}<br><br><u>NOTE</u><br><br>Porphyrins used as simple heterocyclic carriers containing a radioactive nucleus (e.g. 11C) or substituted with a radioactive nucleus (e.g. 18F), are classified in A61K51/0451.	A61K51/04	A61K51/04		102
A61K51/0487	11	{Metallocenes, i.e. complexes based on a radioactive metal complexed by two cyclopentadienyl anions}	A61K51/04	A61K51/04		27
A61K51/0489	10	{Phosphates or phosphonates, e.g. bone-seeking phosphonates; (phospholipids: A61K51/0408; nucleotides or nucleic acids: A61K51/0491)}	A61K51/04	A61K51/04		201
A61K51/0491	10	{Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers}	A61K51/04	A61K51/04		635
A61K51/0493	10	{Steroids, e.g. cholesterol, testosterone}	A61K51/04	A61K51/04		96
A61K51/0495	10	{Pretargeting}<br><br><u>NOTE</u><br><br>Pretargeting is the administration of an agent X bearing the radioisotope or radioactive nucleus and of an agent Y capable of binding X and a cell Y in several steps, e.g. the radiolabelled agent is a radiolabelled biotin and the agent Y is a (strept)avidin molecule targeting specific cells. Classification is also made according to the nature of the carrier bearing/linked to the radioactive nucleus, e.g. an antibody.	A61K51/04	A61K51/04		103
A61K51/0497	10	{conjugates with a carrier being an organic compounds}<br><br><u>NOTE</u><br><br>The compound which bears, complexes or chelates the radioactive nucleus, is covalently linked or complexed to the carrier being another (small) organic molecule, i.e. not oligomeric, polymeric, dendrimeric. Classification is also made according to the nature of this small organic molecule. In case of a conjugate comprising a complex-forming compound (chelating group) complexing a radioactive metal linked to the carrier (organic compound in A61K51/0497 ), the nature of this complex-forming compound is not classified except if the complexing/chelating group is the subject of the invention and is uncommon, e.g. 111In-DTPA-glucose is classified in A61K51/0497 (not in A61K51/048 ) and in A61K51/0491.	A61K51/04	A61K51/04		878
A61K51/06	10	Macromolecular compounds {, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules (peptides, proteins, polyamino acids A61K51/08; antibodies A61K51/10)}	A61K51/06	A61K51/06		319
A61K51/065	11	{conjugates with carriers being macromolecules}<br><br><u>NOTE</u><br><br>The compound which bears, complexes or chelates the radioactive nucleus, is covalently linked or complexed to the carrier being a macromolecule (not being a peptide, polyamino acid, protein, antibody). In case of a conjugate comprising a complex-forming compound (chelating group) complexing a radioactive metal linked to the carrier (organic macromolecular compound in A61K51/065 ), the nature of this complex-forming compound is not classified except if it is the real contribution of the claimed invention and it is an uncommon complexing/chelating group, e.g. 111In-DTPA-PEG is classified in A61K51/065 and new DTPA-like derivatives conjugated to PEG and complexing 111In for use in vivo is classified in A61K51/0478 and A61K51/065.	A61K51/06	A61K51/06		308
A61K51/08	10	Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}	A61K51/08	A61K51/08		1205
A61K51/081	11	{the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin}	A61K51/08	A61K51/08		153
A61K51/082	11	{the peptide being a RGD-containing peptide}	A61K51/08	A61K51/08		208
A61K51/083	11	{the peptide being octreotide or a somatostatin-receptor-binding peptide}	A61K51/08	A61K51/08		240
A61K51/084	11	{the peptide being oxytocin}	A61K51/08	A61K51/08		5
A61K51/085	11	{the peptide being neurotensin}	A61K51/08	A61K51/08		17
A61K51/086	11	{the peptide being alphaMSH, alpha melanocyte stimulating hormone}	A61K51/08	A61K51/08		19
A61K51/087	11	{the peptide being an annexin, e.g. annexin V}	A61K51/08	A61K51/08		41
A61K51/088	11	{conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}<br><br><u>NOTE</u><br><br>The compound which bears, complexes or chelates the radioactive nucleus, is covalently linked/complexed to the carrier being a peptide, polyamino acid or protein (not being an antibody). Classification is also made according to the nature of the peptide or protein (e.g. if it is BSA, then A61K51/081 is also indicated). In case of a conjugate comprising a complex-forming compound (chelating group) complexing a radioactive metal linked to the carrier (peptide, protein or polyamino acid in A61K51/088), the nature of this complex-forming compound is not classified except if it is the real contribution of the claimed invention and it is an uncommon complexing or chelating group, e.g. 111In-DTPA-interleukin 2 is classified in A61K51/088; new DTPA-like derivatives conjugated to interleukin 2 and complexing 111In for use in vivo is classified in A61K51/0478 and A61K51/088.	A61K51/08	A61K51/08		1495
A61K51/10	11	Antibodies or immunoglobulins; Fragments thereof {, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody}	A61K51/10	A61K51/10		315
A61K51/1006	12	{the antibody being against or targeting material from viruses}	A61K51/10	A61K51/10		30
A61K51/1009	12	{against material from bacteria}	A61K51/10	A61K51/10		16
A61K51/1012	12	{against material from fungi, lichens or algae}	A61K51/10	A61K51/10		
A61K51/1015	12	{against material from plants}	A61K51/10	A61K51/10		6
A61K51/1018	12	{against material from animals or humans}	A61K51/10	A61K51/10		208
A61K51/1021	12	{against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons}	A61K51/10	A61K51/10		63
A61K51/1024	12	{against hormones, hormone-releasing or hormone-inhibiting factors}	A61K51/10	A61K51/10		15
A61K51/1027	12	{against receptors, cell-surface antigens or cell-surface determinants}	A61K51/10	A61K51/10		501
A61K51/103	13	{against receptors for growth factors or receptors for growth regulators}	A61K51/10	A61K51/10		105
A61K51/1033	13	{against receptors for cytokines, lymphokines or interferons}	A61K51/10	A61K51/10		35
A61K51/1036	13	{against hormone receptors}	A61K51/10	A61K51/10		15
A61K51/1039	13	{against T-cell receptors}	A61K51/10	A61K51/10		24
A61K51/1042	14	{against T-cell receptor (TcR)-CD3 complex}	A61K51/10	A61K51/10		17
A61K51/1045	12	{against animal or human tumor cells or tumor cell determinants}	A61K51/10	A61K51/10		489
A61K51/1048	13	{the tumor cell determinant being a carcino embryonic antigen}	A61K51/10	A61K51/10		85
A61K51/1051	13	{the tumor cell being from breast, e.g. the antibody being herceptin}	A61K51/10	A61K51/10		169
A61K51/1054	13	{the tumor cell being from lung}	A61K51/10	A61K51/10		50
A61K51/1057	13	{the tumor cell being from liver or pancreas}	A61K51/10	A61K51/10		71
A61K51/106	13	{the tumor cell being from kidney or bladder}	A61K51/10	A61K51/10		36
A61K51/1063	13	{the tumor cell being from stomach or intestines}	A61K51/10	A61K51/10		76
A61K51/1066	13	{the tumor cell being from skin}	A61K51/10	A61K51/10		34
A61K51/1069	13	{the tumor cell being from blood cells, e.g. the cancer being a myeloma}	A61K51/10	A61K51/10		73
A61K51/1072	13	{the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate}	A61K51/10	A61K51/10		148
A61K51/1075	12	{the antibody being against an enzyme}	A61K51/10	A61K51/10		67
A61K51/1078	12	{the antibody being against an immunoglobulin, i.e. being an (anti)-anti-idiotypic antibody}	A61K51/10	A61K51/10		34
A61K51/1084	12	{the antibody being a hybrid immunoglobulin}	A61K51/10	A61K51/10		10
A61K51/1087	13	{the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins}	A61K51/10	A61K51/10		45
A61K51/109	13	{immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies}	A61K51/10	A61K51/10		68
A61K51/1093	12	{conjugates with carriers being antibodies}<br><br><u>NOTE</u><br><br>The compound which bears, complexes or chelates the radioactive nucleus, being covalently linked or complexed to the carrier being an antibody. Classification being also made according to the appropriate A61K51/10 subgroup. In case of a conjugate comprising a complex-forming compound (chelating group) complexing a radioactive metal linked to the carrier (antibody in A61K51/1093 ), the nature of this complex-forming compound being not classified except if it being the real contribution of the claimed invention and it being an uncommon complexing/chelating group, e.g. 111In-DTPA-herceptin being classified in A61K51/1093 and A61K51/1051, new DTPA-like derivatives conjugated to herceptin and complexing 111In for use in vivo being classified in A61K51/0478, A61K51/1093 and A61K51/1051.	A61K51/10	A61K51/10		785
A61K51/1096	13	{radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications}	A61K51/10	A61K51/10		313
A61K51/12	8	characterised by a special physical form, e.g. emulsion, microcapsules, liposomes {, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules (liposomes A61K51/1234)}	A61K51/12	A61K51/12		235
A61K51/1203	9	{in a form not provided for by groups A61K51/1206&#160;-&#160;A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors}	A61K51/12	A61K51/12		156
A61K51/1206	9	{Administration of radioactive gases, aerosols or breath tests}	A61K51/12	A61K51/12		106
A61K51/121	9	{Solutions, i.e. homogeneous liquid formulation}	A61K51/12	A61K51/12		170
A61K51/1213	9	{Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature}	A61K51/12	A61K51/12		132
A61K51/1217	9	{Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols}	A61K51/12	A61K51/12		164
A61K51/122	10	{Microemulsions, nanoemulsions}	A61K51/12	A61K51/12		15
A61K51/1224	10	{Lipoprotein vesicles, e.g. HDL and LDL proteins}	A61K51/12	A61K51/12		15
A61K51/1227	10	{Micelles, e.g. phospholipidic or polymeric micelles}	A61K51/12	A61K51/12		50
A61K51/1231	10	{Aerosols or breath tests, e.g. administration of gasses, emanators}	A61K51/12	A61K51/12		9
A61K51/1234	10	{Liposomes}<br><br><u>NOTE</u><br><br>Liposomes modified on their external surface by a targeting agent, e.g. an antibody, are not additionally classified with the symbol of the targeting agent.	A61K51/12	A61K51/12		168
A61K51/1237	11	{Polymersomes, i.e. liposomes with polymerisable or polymerized bilayer-forming substances}	A61K51/12	A61K51/12		23
A61K51/1241	9	{particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins}	A61K51/12	A61K51/12		127
A61K51/1244	10	{microparticles or nanoparticles, e.g. polymeric nanoparticles}	A61K51/12	A61K51/12		411
A61K51/1248	11	{nanotubes}	A61K51/12	A61K51/12		11
A61K51/1251	11	{micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules}	A61K51/12	A61K51/12		269
A61K51/1255	10	{Granulates, agglomerates, microspheres}	A61K51/12	A61K51/12		152
A61K51/1258	9	{Pills, tablets, lozenges}	A61K51/12	A61K51/12		33
A61K51/1262	9	{Capsules}	A61K51/12	A61K51/12		26
A61K51/1265	10	{Microcapsules}	A61K51/12	A61K51/12		14
A61K51/1268	9	{host-guest, closed hollow molecules, inclusion complexes, e.g. with cyclodextrins, clathrates, cavitates, fullerenes}	A61K51/12	A61K51/12		71
A61K51/1272	9	{Sponges}	A61K51/12	A61K51/12		18
A61K51/1275	9	{Fibers, textiles, slabbs, or sheets}	A61K51/12	A61K51/12		35
A61K51/1279	9	{Plasters, bandages, dressings, patches or adhesives}	A61K51/12	A61K51/12		48
A61K51/1282	9	{Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents}	A61K51/12	A61K51/12		337
A61K51/1286	10	{Ampoules, glass carriers carrying the therapeutic or in vivo diagnostic agent}	A61K51/12	A61K51/12		19
A61K51/1289	10	{Devices or containers for impregnation, for emanation, e.g. bottles or jars for radioactive water for use in radiotherapy}	A61K51/12	A61K51/12		136
A61K51/1293	9	{Radioactive cosmetics, e.g. radioactive bathsalts, soaps}	A61K51/12	A61K51/12		10
A61K51/1296	9	{Radioactive food, e.g. chocolates, drinks}	A61K51/12	A61K51/12		24
A61K2121/00	7	Preparations for use in therapy	CPCONLY	A61K2121/00		4185
A61K2123/00	7	Preparations for testing in vivo	CPCONLY	A61K2123/00		2088
A61K2236/00	7	Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine<br><br><u>NOTE</u><br><br> If the isolation or extraction method is considered relevant, at least one symbol of A61K36/30 should always be given. The method can be further characterized by additional A61K36/10 and/or A61K36/50 symbols. The last place priority rule does not apply in this part of the scheme 	CPCONLY	A61K2236/00		1793
A61K2236/10	8	Preparation or pretreatment of starting material	CPCONLY	A61K2236/10		2101
A61K2236/11	9	involving culturing conditions, e.g. cultivation in the dark or under defined water stress	CPCONLY	A61K2236/11		274
A61K2236/13	9	involving cleaning, e.g. washing or peeling	CPCONLY	A61K2236/13		3148
A61K2236/15	9	involving mechanical treatment, e.g. chopping up, cutting or grinding	CPCONLY	A61K2236/15		8502
A61K2236/17	9	involving drying, e.g. sun-drying or wilting	CPCONLY	A61K2236/17		4564
A61K2236/19	9	involving fermentation using yeast, bacteria or both; enzymatic treatment	CPCONLY	A61K2236/19		9503
A61K2236/30	8	Extraction of the material	CPCONLY	A61K2236/30		1004
A61K2236/31	9	involving untreated material, e.g. fruit juice or sap obtained from fresh plants	CPCONLY	A61K2236/31		2064
A61K2236/33	9	involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones	CPCONLY	A61K2236/33		5592
A61K2236/331	10	using water, e.g. cold water, infusion, tea, steam distillation or decoction	CPCONLY	A61K2236/331		47349
A61K2236/333	10	using mixed solvents, e.g. 70% EtOH	CPCONLY	A61K2236/333		27060
A61K2236/35	9	Extraction with lipophilic solvents, e.g. Hexane or petrol ether	CPCONLY	A61K2236/35		3285
A61K2236/37	9	Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction	CPCONLY	A61K2236/37		4513
A61K2236/39	9	Complex extraction schemes, e.g. fractionation or repeated extraction steps	CPCONLY	A61K2236/39		34707
A61K2236/50	8	Methods involving additional extraction steps	CPCONLY	A61K2236/50		248
A61K2236/51	9	Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying	CPCONLY	A61K2236/51		27808
A61K2236/53	9	Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization	CPCONLY	A61K2236/53		19165
A61K2236/55	9	Liquid-liquid separation; Phase separation	CPCONLY	A61K2236/55		6819
A61K2239/00	7	Indexing codes associated with cellular immunotherapy of group A61K40/00	CPCONLY	A61K2239/00		9
A61K2239/10	8	characterized by the structure of the chimeric antigen receptor [CAR]	CPCONLY	A61K2239/10		131
A61K2239/11	9	Antigen recognition domain	CPCONLY	A61K2239/11		64
A61K2239/13	10	Antibody-based	CPCONLY	A61K2239/13		885
A61K2239/15	10	Non-antibody based	CPCONLY	A61K2239/15		155
A61K2239/17	9	Hinge-spacer domain	CPCONLY	A61K2239/17		308
A61K2239/21	9	Transmembrane domain	CPCONLY	A61K2239/21		516
A61K2239/22	9	Intracellular domain	CPCONLY	A61K2239/22		548
A61K2239/23	9	On/off switch	CPCONLY	A61K2239/23		99
A61K2239/24	10	Dimerizable CARs; CARs with adapter	CPCONLY	A61K2239/24		71
A61K2239/25	10	Suicide switch	CPCONLY	A61K2239/25		56
A61K2239/27	8	characterized by targeting or presenting multiple antigens	CPCONLY	A61K2239/27		45
A61K2239/28	9	Expressing multiple CARs, TCRs or antigens	CPCONLY	A61K2239/28		360
A61K2239/29	9	Multispecific CARs	CPCONLY	A61K2239/29		350
A61K2239/30	9	Mixture of cells	CPCONLY	A61K2239/30		43
A61K2239/31	8	characterized by the route of administration	CPCONLY	A61K2239/31		3352
A61K2239/38	8	characterised by the dose, timing or administration schedule	CPCONLY	A61K2239/38		3733
A61K2239/39	8	characterised by a specific adjuvant, e.g. cytokines or CpG	CPCONLY	A61K2239/39		152
A61K2239/46	8	characterised by the cancer treated	CPCONLY	A61K2239/46		358
A61K2239/47	9	Brain; Nervous system	CPCONLY	A61K2239/47		349
A61K2239/48	9	Blood cells, e.g. leukemia or lymphoma	CPCONLY	A61K2239/48		2162
A61K2239/49	9	Breast	CPCONLY	A61K2239/49		460
A61K2239/50	9	Colon	CPCONLY	A61K2239/50		344
A61K2239/51	9	Stomach	CPCONLY	A61K2239/51		85
A61K2239/52	9	Intestine	CPCONLY	A61K2239/52		32
A61K2239/53	9	Liver	CPCONLY	A61K2239/53		224
A61K2239/54	9	Pancreas	CPCONLY	A61K2239/54		274
A61K2239/55	9	Lung	CPCONLY	A61K2239/55		433
A61K2239/56	9	Kidney	CPCONLY	A61K2239/56		96
A61K2239/57	9	Skin; melanoma	CPCONLY	A61K2239/57		821
A61K2239/58	9	Prostate	CPCONLY	A61K2239/58		200
A61K2239/59	9	Reproductive system, e.g. uterus, ovaries, cervix or testes	CPCONLY	A61K2239/59		428
A61K2300/00	7	Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00&#160;-&#160;A61K41/00<br><br><u>NOTE</u><br><br>Orthogonal Indexing Code A61K2300/00 shall only be used as a subsequent symbol of a C-Set, but not be used as a single symbol for classification.	CPCONLY	A61K2300/00		257826
A61K2800/00	7	Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects<br><br><u>NOTE</u><br><br>The indexing symbols of this group are for obligatory secondary classification of subject-matter already classified in group A61K8/00 or subclass A61Q.	CPCONLY	A61K2800/00		44
A61K2800/10	8	General cosmetic use	CPCONLY	A61K2800/10		5583
A61K2800/20	8	Chemical, physico-chemical or functional or structural properties of the composition as a whole	CPCONLY	A61K2800/20		194
A61K2800/21	9	Emulsions characterized by droplet sizes below 1 micron	CPCONLY	A61K2800/21		566
A61K2800/22	9	Gas releasing	CPCONLY	A61K2800/22		257
A61K2800/222	10	Effervescent	CPCONLY	A61K2800/222		674
A61K2800/24	9	Thermal properties	CPCONLY	A61K2800/24		249
A61K2800/242	10	Exothermic; Self-heating; Heating sensation	CPCONLY	A61K2800/242		512
A61K2800/244	10	Endothermic; Cooling; Cooling sensation	CPCONLY	A61K2800/244		758
A61K2800/26	9	Optical properties	CPCONLY	A61K2800/26		288
A61K2800/262	10	Transparent; Translucent	CPCONLY	A61K2800/262		2046
A61K2800/28	9	Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants	CPCONLY	A61K2800/28		3297
A61K2800/30	9	Characterized by the absence of a particular group of ingredients	CPCONLY	A61K2800/30		3717
A61K2800/31	10	Anhydrous	CPCONLY	A61K2800/31		2181
A61K2800/33	10	Free of surfactant	CPCONLY	A61K2800/33		511
A61K2800/34	10	Free of silicones	CPCONLY	A61K2800/34		785
A61K2800/40	8	Chemical, physico-chemical or functional or structural properties of particular ingredients	CPCONLY	A61K2800/40		180
A61K2800/41	9	Particular ingredients further characterized by their size	CPCONLY	A61K2800/41		404
A61K2800/412	10	Microsized, i.e. having sizes between 0.1 and 100 microns	CPCONLY	A61K2800/412		6653
A61K2800/413	10	Nanosized, i.e. having sizes below 100 nm	CPCONLY	A61K2800/413		3958
A61K2800/42	9	Colour properties	CPCONLY	A61K2800/42		422
A61K2800/43	10	Pigments; Dyes	CPCONLY	A61K2800/43		3128
A61K2800/432	11	Direct dyes	CPCONLY	A61K2800/432		570
A61K2800/4322	12	in preparations for temporarily coloring the hair further containing an oxidizing agent	CPCONLY	A61K2800/4322		380
A61K2800/4324	12	in preparations for permanently dyeing the hair	CPCONLY	A61K2800/4324		614
A61K2800/434	11	Luminescent, Fluorescent; Optical brighteners; Photosensitizers	CPCONLY	A61K2800/434		575
A61K2800/436	11	Interference pigments, e.g. Iridescent, Pearlescent	CPCONLY	A61K2800/436		823
A61K2800/437	11	Diffractive phenomena; Photonic arrays	CPCONLY	A61K2800/437		56
A61K2800/438	11	Thermochromatic; Photochromic; Phototropic	CPCONLY	A61K2800/438		257
A61K2800/45	10	Colour indicators, e.g. pH- or Redox indicators	CPCONLY	A61K2800/45		227
A61K2800/47	9	Magnetic materials; Paramagnetic compounds	CPCONLY	A61K2800/47		166
A61K2800/48	9	Thickener, Thickening system	CPCONLY	A61K2800/48		3543
A61K2800/49	9	Solubiliser, Solubilising system	CPCONLY	A61K2800/49		592
A61K2800/51	9	Chelating agents	CPCONLY	A61K2800/51		736
A61K2800/52	9	Stabilizers	CPCONLY	A61K2800/52		2493
A61K2800/522	10	Antioxidants; Radical scavengers	CPCONLY	A61K2800/522		7357
A61K2800/524	10	Preservatives	CPCONLY	A61K2800/524		3444
A61K2800/526	10	Corrosion inhibitors	CPCONLY	A61K2800/526		109
A61K2800/54	9	Polymers characterized by specific structures/properties	CPCONLY	A61K2800/54		789
A61K2800/542	10	characterized by the charge	CPCONLY	A61K2800/542		40
A61K2800/5422	11	nonionic	CPCONLY	A61K2800/5422		572
A61K2800/5424	11	anionic	CPCONLY	A61K2800/5424		741
A61K2800/5426	11	cationic	CPCONLY	A61K2800/5426		2121
A61K2800/5428	11	amphoteric or zwitterionic	CPCONLY	A61K2800/5428		403
A61K2800/544	10	Dendrimers, Hyperbranched polymers	CPCONLY	A61K2800/544		118
A61K2800/546	10	Swellable particulate polymers	CPCONLY	A61K2800/546		107
A61K2800/548	10	Associative polymers	CPCONLY	A61K2800/548		155
A61K2800/56	9	Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms	CPCONLY	A61K2800/56		2929
A61K2800/57	9	Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances	CPCONLY	A61K2800/57		962
A61K2800/58	9	Metal complex; Coordination compounds	CPCONLY	A61K2800/58		853
A61K2800/59	9	Mixtures	CPCONLY	A61K2800/59		1979
A61K2800/591	10	Mixtures of compounds not provided for by any of the codes A61K2800/592&#160;-&#160;A61K2800/596	CPCONLY	A61K2800/591		837
A61K2800/592	10	Mixtures of compounds complementing their respective functions	CPCONLY	A61K2800/592		6977
A61K2800/5922	11	At least two compounds being classified in the same subclass of A61K8/18	CPCONLY	A61K2800/5922		14664
A61K2800/594	10	Mixtures of polymers	CPCONLY	A61K2800/594		2145
A61K2800/596	10	Mixtures of surface active compounds	CPCONLY	A61K2800/596		3679
A61K2800/60	9	Particulates further characterized by their structure or composition	CPCONLY	A61K2800/60		63
A61K2800/61	10	Surface treated	CPCONLY	A61K2800/61		186
A61K2800/612	11	By organic compounds	CPCONLY	A61K2800/612		431
A61K2800/614	11	By macromolecular compounds	CPCONLY	A61K2800/614		229
A61K2800/62	11	Coated	CPCONLY	A61K2800/62		116
A61K2800/621	12	by inorganic compounds	CPCONLY	A61K2800/621		559
A61K2800/622	12	by organic compounds	CPCONLY	A61K2800/622		437
A61K2800/623	12	Coating mediated by organosilicone compounds	CPCONLY	A61K2800/623		252
A61K2800/624	12	by macromolecular compounds	CPCONLY	A61K2800/624		618
A61K2800/63	12	More than one coating	CPCONLY	A61K2800/63		228
A61K2800/65	10	Characterized by the composition of the particulate/core	CPCONLY	A61K2800/65		47
A61K2800/651	11	The particulate/core comprising inorganic material	CPCONLY	A61K2800/651		839
A61K2800/652	11	The particulate/core comprising organic material	CPCONLY	A61K2800/652		299
A61K2800/654	11	The particulate/core comprising macromolecular material	CPCONLY	A61K2800/654		599
A61K2800/70	8	Biological properties of the composition as a whole	CPCONLY	A61K2800/70		715
A61K2800/72	9	Hypo-allergenic	CPCONLY	A61K2800/72		1878
A61K2800/74	8	Biological properties of particular ingredients	CPCONLY	A61K2800/74		983
A61K2800/75	9	Anti-irritant	CPCONLY	A61K2800/75		2049
A61K2800/77	9	Perfumes having both deodorant and antibacterial properties	CPCONLY	A61K2800/77		159
A61K2800/78	9	Enzyme modulators, e.g. Enzyme agonists	CPCONLY	A61K2800/78		908
A61K2800/782	10	Enzyme inhibitors; Enzyme antagonists	CPCONLY	A61K2800/782		6790
A61K2800/80	8	Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof	CPCONLY	A61K2800/80		1037
A61K2800/805	9	Corresponding aspects not provided for by any of codes A61K2800/81&#160;-&#160;A61K2800/95	CPCONLY	A61K2800/805		8811
A61K2800/81	9	Preparation or application process involves irradiation	CPCONLY	A61K2800/81		1747
A61K2800/82	9	Preparation or application process involves sonication or ultrasonication	CPCONLY	A61K2800/82		3308
A61K2800/83	9	Electrophoresis; Electrodes; Electrolytic phenomena	CPCONLY	A61K2800/83		372
A61K2800/84	9	Products or compounds obtained by lyophilisation, freeze-drying	CPCONLY	A61K2800/84		2657
A61K2800/85	9	Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine	CPCONLY	A61K2800/85		7910
A61K2800/86	9	Products or compounds obtained by genetic engineering	CPCONLY	A61K2800/86		266
A61K2800/87	9	Application Devices; Containers; Packaging	CPCONLY	A61K2800/87		2939
A61K2800/872	10	Pencils; Crayons; Felt-tip pens	CPCONLY	A61K2800/872		254
A61K2800/874	10	Roll-on	CPCONLY	A61K2800/874		235
A61K2800/88	9	Two- or multipart kits	CPCONLY	A61K2800/88		2064
A61K2800/882	10	Mixing prior to application	CPCONLY	A61K2800/882		1512
A61K2800/884	10	Sequential application	CPCONLY	A61K2800/884		1589
A61K2800/91	9	Injection	CPCONLY	A61K2800/91		1129
A61K2800/92	9	Oral administration	CPCONLY	A61K2800/92		1700
A61K2800/94	9	Involves covalent bonding to the substrate	CPCONLY	A61K2800/94		227
A61K2800/95	9	Involves in-situ formation or cross-linking of polymers	CPCONLY	A61K2800/95		800
